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Approximately 40% of preterm births are preceded by microbial invasion of the intrauterine 
space, with ascent from the vagina being the most common pathway. Antimicrobial peptides 
(AMPs), in combination with mucin and other immune cells, constitute a barrier within the 
cervical canal which prevents ascending infection. I investigate whether overexpression of 
human beta-defensin 3 (HBD-3), a potent AMP, in the cervical mucosa prevents bacterial 
ascent from the vagina into the uterine cavity of pregnant mice.  
Methods 
Models of ascending infection and preterm birth 
Mice received E.coli (non-pathogenic K12 or pathogenic K1 with integrated luxABCDE operon) 
intra-vaginally at E16.5 and bacterial ascension was monitored by live whole body 
bioluminescence imaging.  
AAV gene therapy 
An adeno-associated virus vector (AAV8) containing the HBD-3 transgene was synthesised 
(AAV8-HBD3). AAV8-HBD3 or control vector AAV8-GFP control was administered intravaginally 
into E13.5 pregnant mice. This was followed by induction of ascending infection at E16.5 as 
described above. 
Results  
Following vaginal infection with E.coli K12, bioluminescence imaging showed bacterial ascent 
into the uterine cavity but this did not lead to preterm birth. Following vaginal infection with 
E.coli K1, bioluminescence showed bacterial ascent into the uterine cavity leading to 




 Following intravaginal infection with E.coli K12 or K1, there was significantly less uterine 
bioluminescence in the AAV8-HBD3 treated mice at 24 and 48 hours after infection compared 
with the AAV8-GFP controls, signifying reduced uterine bacterial ascent in the AAV8-HBD3 
treated mice. Although there was no increase in the gestation length in the E.coli K1 dams 
following AAV8-HBD3 treatment, there was an increase in the proportion of live pups at 
delivery compared with AAV8-GFP controls. 
Conclusion   
AAV-HBD3 may be a promising candidate for augmenting cervical innate immunity to prevent 
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Chapter 1 Introduction 
Summary 
Preterm birth is defined by the World Health Organization as delivery before 37 completed 
weeks of pregnancy. It is associated with serious neonatal morbidity and mortality, particularly 
for those infants born before 32 weeks gestation (Moore et al. 2012). 
Intrauterine infection accounts for at least 40% of cases of spontaneous preterm birth. The 
most common route of pathogen entry into the uterine cavity is believed to be ascent from 
the microbial diverse environment of the vagina. There are currently no treatments that 
significantly and consistently prevent preterm birth and so there is a serious need to develop 
novel preventative treatments.  
The cervix and its mucus plug play an important role in preventing ascending infection by 
providing a mechanical and immunological barrier that protects the uterine cavity from 
infectious insult. The plug contains numerous innate immune peptides known as antimicrobial 
peptides which contribute to its role in the prevention of infection. It is believed that a 
compromise in this specialised immune barrier confers an increased risk of infection-related 
preterm birth. I will investigate the novel hypothesis that expression of human antimicrobial 
peptides in the murine cervix using conventional virus-based gene transfer technology will 
prevent bacteria, which are capable of inducing preterm birth, from ascending the cervical 






Preterm birth is defined by the World Health Organization as delivery before 37 completed 
weeks of pregnancy (WHO 2015). It is associated with serious neonatal morbidity and 
mortality, particularly for those infants born before 32 weeks gestation (Moore et al. 2012). 
Preterm birth is the single largest direct cause of neonatal mortality in the United Kingdom and 
worldwide, being responsible for more than 1 million neonatal deaths globally (NICE 2015; 
Blencowe et al. 2013). There are 54,000 cases of preterm birth per year in England and Wales, 
which accounts for approximately 8% of all live births and a quarter of these are associated 
with preterm deliveries before 32 weeks gestation (NICE 2015). Worldwide, 15 million babies 
are born prematurely, representing a preterm birth rate of 11.1% (Blencowe et al. 2013; 
Blencowe et al. 2012).  
Despite extensive preterm birth research there has been no decline in preterm birth rates in 
the United Kingdom over the last ten years and these rates appear to be increasing in the 
developing world (NICE 2015; Blencowe et al. 2013).  
The Millennium Development Goal-4 (1990-2015) set out to reduce the mortality rate in 
children under 5 years old by at least two thirds. Unfortunately this goal was not achieved, 
with the slow decline in neonatal mortality being largely responsible for this; neonatal deaths 
account for greater than 42% of deaths in under 5 year olds (Lawn et al. 2010). Prematurity is 
the direct cause of approximately 30% of the 4 million neonatal deaths every year and acts as 
a risk factor for many other causes of neonatal death, such as infection (Blencowe et al. 2013).  
There is currently no effective treatment for the prevention of preterm birth (Iams et al. 2008). 
Even if we employed all of the five current interventions for preterm birth in high-income 
countries there would only be a 5.2% reduction in preterm birth rates (from 9.59% to 9.07% of 
livebirths) (Chang et al. 2013). Recent work from the March of Dimes preterm birth working 




research will be the most promising intervention to reduce preterm birth rates worldwide 
(Ferrero et al. 2016; Martin et al. 2017) (Figure 1.1.1). Interestingly the least promising 
intervention was found to be maximising or altering current preventative interventions. This 
highlights the serious necessity for research into the pathogenesis of preterm birth to enable 





Figure 1.1: The areas of intervention and their potential effect on reducing the rates of 
preterm birth. Research accounts for 59-74% of the potential reduction effect whilst Public 
health/Policy accounts for 14-39%. Altered clinical practice is the smallest intervention group 
to provide potential beneficial effects on PTB rates accounting for a 2-12% effect with the 
current knowledge levels. Adapted from (Martin et al. 2017) 
Epidemiology of Preterm Birth 
The incidence of preterm birth varies between countries, ranging from 5-13% of all live births, 
resulting in approximately 15 million premature deliveries every year (Koullali et al. 2016). 
Mortality and morbidity of babies born preterm decreases with increasing gestational age.  
Preterm birth is ranked 5th in the leading cause of disease burden over time in the 2015 Global 
burden of Disease study (GBD 2015 DALYs and HALE Collaborators et al. 2016). Children born 
prematurely are three times more likely to have vision problems and they are also at increased 
risk of hearing impairment (O’Connor & Fielder 2007; Marlow et al. 2005). Furthermore, they 




supplementary home oxygen (Greenough 2012; Bolton et al. 2012; Fawke et al. 2010). The 
cardiovascular consequences of prematurity have not been fully described although babies 
born extremely preterm (below 28 weeks gestation) are likely to be at increased risk of 
cardiovascular disease in the future (McEniery et al. 2011). Unsurprisingly, preterm birth leads 
to significant financial costs amounting to approximately £1 billion per year in England and 
Wales (Mangham et al. 2009).  
It is not only the child that is affected by prematurity, it can also have a huge impact on the 
mother and other family members. The mother, for example, has an increased risk of preterm 
birth in the future which could put even more of a financial and health burden on the family 
(Laughon et al. 2014). Furthermore, there is a high prevalence of post-traumatic stress disorder 
in mothers following preterm birth and this can influence their coping mechanisms and future 
mental health (Ghorbani et al. 2014; Misund et al. 2014). 
There are numerous risk factors associated with preterm birth (Table 1.1). The strongest 
predictor of preterm birth is a previous preterm birth or late miscarriage; these are associated 
with a 32% chance of a recurrent preterm birth (Laughon et al. 2014). BMI and low socio-
economic status are associated with poor pregnancy outcomes, including preterm birth 
(Thompson et al. 2006). Connective tissue disorders, such as rheumatoid arthritis and Ehler 
Danlos syndrome, are associated with an increased risk of preterm birth, as are uterine 
anomalies (Wallenius et al. 2015; Khander et al. 2017). A short interpregnancy interval, IVF and 
multiple pregnancy are all obstetric factors which are associated with preterm birth (Shachar 
et al. 2016; Kindinger et al. 2016; Pandey et al. 2012). 
Mid-trimester cervical shortening is strongly associated with premature delivery, with a 
cervical length below 25mm being highly predictive of preterm birth in both low and high risk 
women (Iams et al. 1996; Owen et al. 2001). Cervical length screening is common practice in 




routinely recommended due to its low sensitivity (van der Ven et al. 2015; Orzechowski et al. 
2014). 
Fetal fibronectin is a glycoprotein found in placental tissue, amniotic fluid and the extracellular 
matrix of the decidua basalis, and it is believed to be released in response to inflammatory or 
mechanical damage to the membranes or placenta (Honest et al. 2002). Fetal fibronectin 
testing has a role in predicting the risk of preterm birth in symptomatic women, having a high 
negative predictive value for delivery within two weeks (Abbott et al. 2013). Furthermore, it is 
useful as a screening tool in combination with cervical length measurements in asymptomatic 






 Risk factor Reference 
Maternal 
characteristic 
Extremes of BMI 
 
 
(Lynch et al. 2014; 




(Mei-Dan et al. 2015) 
 
 Black ethnicity 
 
 
(Schaaf et al. 2013) 
 
 Low socio-economic status 
 
 
(Thompson et al. 2006) 
 
Medical history Cervical surgery 
 
 
(Kyrgiou et al. 2014; 
Bevis & Biggio 2011) 
 Connective tissue disorders 
 
 
(Wallenius et al. 2015) 
 Uterine anomalies 
 
 
(Khander et al. 2017; 
Takami et al. 2014) 
Obstetric history Previous preterm birth 
 
 
(Khander et al. 2017; 
Takami et al. 2014) 
 Previous late miscarriage > 16 
weeks gestation 
 
(Khander et al. 2017) 
 Short interpregnancy interval 
 
 
(Shachar et al. 2016) 
Current pregnancy IVF 
 
 
(Sabban et al. 2017; 
Pandey et al. 2012) 
 Multiple pregnancy 
 
 
(Kindinger et al. 2016) 
 
 Short cervix 
 
 
(Hezelgrave et al. 2016) 
 
 
Table 1.1: The risk factors associated with preterm birth. Previous preterm birth is the 




Pathogenesis of Preterm Birth 
Preterm birth can be either spontaneous or iatrogenic (indicated early due to a maternal or 
fetal complication). Spontaneous preterm birth which includes preterm pre-labour rupture of 
membranes, accounts for approximately three quarters of preterm births in the UK, whilst the 
remaining quarter are classified as iatrogenic (Moutquin 2003).  
The pathogenesis of spontaneous preterm birth and preterm pre-labour rupture of 
membranes remains poorly understood. There is accumulating evidence that preterm birth is 
a complex syndrome which is attributable to multiple pathological processes. These processes 
include intrauterine infection, stress, vascular disorders and uterine over-distension (Romero 
2011). It is believed that these different pathophysiological processes lead to preterm labour 
by prematurely activating the common pathway of parturition. Intrauterine infection is the 
only known pathogenesis that has a definite causal link with spontaneous preterm birth 
(Minkoff 1983, Romero et al. 1988, Romero et al. 2001). Approximately 25-40% of cases of 
spontaneous preterm birth and preterm pre-labour rupture of membranes have been 
associated with infection and this number is thought to be even greater in cases of preterm 
birth occurring before 32 weeks gestation (Romero et al. 2001; Moore et al. 2012; Goldenberg 
et al. 2008; Goldenberg et al. 2000).  
Intrauterine infection as a cause for preterm birth 
There is a large body of evidence for the role of infection in preterm birth. As mentioned above, 
infection is associated with approximately 25-40% of cases of preterm birth, although this is 
likely to be an underestimate due to sample and culture selection bias (Goldenberg et al. 2000; 
Goldenberg et al. 2008). Histological chorioamnionitis, the hallmark of intrauterine infection, 
is found in around 66% of preterm births between 20 to 24 weeks and around 16% of preterm 




cases of histological chorioamnionitis using traditional culturing techniques. However, the 
advent of molecular techniques in microbiology using the 16S rRNA gene meant that we were 
able to detect bacteria in the uterine cavity (Jones et al. 2009). Interestingly, the majority of 
bacteria found to be associated with preterm birth are fastidious organisms that are 
notoriously difficult to culture. In clinical studies, the uterine cavity is thought to be largely 
sterile, minimal bacteria is detected in term elective caesarean section or indicated preterm 
deliveries (Jones et al. 2009). Bacteria is seen in both term and preterm fetal membranes 
following vaginal delivery. In preterm samples, however, there is increased prevalence, 
diversity and distribution of bacterial species.  
From an evolutionary perspective, infection-related preterm birth is likely to occur to improve 
the chance of maternal survival and reproductive fitness by allowing the mother to expel 
infected tissue. Evidence from animal models has shown that inoculation of the intrauterine 
cavity with live bacteria or bacterial toxins, such as lipopolysaccharide (LPS) leads to preterm 
birth, for example intrauterine LPS administration in mice (Migale et al. 2015; Rinaldi et al. 
2015) and trans-cervical E.coli inoculation in rabbits (Fidel et al. 2003). Furthermore, extra-
uterine systemic infections, such as malaria and pyelonephritis, are associated with preterm 
birth (Kalanda et al. 2006; Kaul et al. 1999). This is supported by evidence in rodent models 
where systemic administration of live bacteria or LPS cause preterm birth (Celik & Ayar 2002; 
Lee et al. 2003). 
The current understanding is that microbes invade the choriodecidual space, activating the 
decidua and the fetal membranes to produce inflammatory cytokines, including interleukin-1β 
(IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8) and tumour necrosis factor-α (TNF-α) 
(Goldenberg et al. 2000; Gonzalez et al. 2011). These cytokines recruit immune cells to the 
area, such as neutrophils and macrophages and then stimulate prostaglandin synthesis (which 
is responsible for inducing myometrial contractions). This inflammatory process also leads to 




cervix leading to cervical dilatation. Supporting evidence is shown in animal models of preterm 
birth where administering pro-inflammatory cytokines, such as IL-1β and TNF-α, into the 
uterine cavity are sufficient to cause premature labour (Sadowsky et al. 2006; Nadeau-Vallée 
et al. 2017).  
Ascending vaginal infection 
There are multiple potential routes by which bacteria can gain access into the intrauterine 
cavity; 
1) By ascending infection from the vagina via the cervix 
2) By haematogenous dissemination from the maternal blood via the placenta 
3) By retrograde seeding from the peritoneal cavity through the fallopian tubes 
4) By an invasive procedure, such as an amniocentesis or chorionic villus sampling 
Ascending vaginal infection is believed to be the most common pathway (Figure 1.2). The main 
supporting evidence for this pathway is based on the association between the bacterial species 
identified in the fetal membranes and placenta and those normally found in the lower genital 
tract by 16S ribosomal DNA PCR studies (Jones et al. 2009; Doyle et al. 2017). These species 
include Ureaplasma urealyticum, Ureaplasma parvum and Streptococcus agalactiae (also 
known as Group B Streptococcus). It has also been found that histological chorioamnionitis is 
more common and more severe at the site of membrane rupture, supporting an ascending 





Figure 1.2: Routes of entry of pathogens into the pregnant uterine cavity. By ascending 
infection from the vagina via the cervix (1), by haematogenous dissemination from the 
maternal blood via the placenta (2), by retrograde seeding from the peritoneal cavity through 
the fallopian tubes (3) or by an invasive procedure, such as an amniocentesis or chorionic villus 
sampling (4). Ascending vaginal infection is thought to be the most common route of entry.  
There are two theories describing how bacteria ascend into the uterine cavity (Figure 1.3): 
1. Bacteria ascend into the choriodecidual space where they replicate and cause 
inflammation followed by subsequent passage through the chorioamniotic 
membranes to reach the intraamniotic cavity (Grigsby et al. 2010; Adams Waldorf et 
al. 2011). 
2. Bacteria ascend to the decidua of the supracervical region, followed by subsequent 
passage through a distinct region of the chorioamniotic membranes to reach the 
intraamniotic cavity (Steel et al. 2005; Kim et al. 2009). Chorioamnionitis is thought to 





Figure 1.3: Ascending vaginal infection - two theories describing the trafficking of bacteria 
into the chorioamniotic membranes during microbial invasion of the amniotic cavity. (1) 
Widespread bacterial invasion along the choriodecidual and chorioamniotic planes prior to 
entering the amniotic cavity. (2) Initial intraamniotic entry of bacteria through a restricted 
supracervical region leading to intraamniotic invasion and subsequent bacterial movement 
into the amnion and chorion. 
 
It is unknown why some women are more at risk of developing ascending infection leading to 
subsequent preterm birth, but the interaction between cervical mucosal immunity and the 
diverse vaginal microbiome may play a key role. Bacterial vaginosis, a vaginal infection where 
normal lactobacillus-predominant vaginal flora is replaced with an overgrowth of anaerobic 
bacteria, has been associated with preterm birth (Hillier et al. 1995). Furthermore, certain 
gene-environment interactions are thought to confer an increased risk of preterm birth; 
polymorphism in the tumour necrosis factor promoter region and concurrent bacterial 
vaginosis (Macones et al. 2004). More recent evidence has shown that specific bacterial 




ascension and infection of the intrauterine cavity more likely (Randis et al. 2014). Furthermore, 
concurrent viral infection may alter cervical mucosal immunity and predispose to ascending 
vaginal infection (Racicot et al. 2013).  
It is also not clear what comes first in the mechanistic pathway of infection-related preterm 
labour; ascending infection or cervical dilatation. Ascending infection may lead to 
inflammatory changes in the cervix which result in cervical shortening and dilatation or 
alternatively the cervix may dilate initially and allow for pathogens to ascend into the uterine 
cavity. Preterm birth has been linked to cervical treatment for cervical intra-epithelial 
neoplasia and this risk appears to be proportional to the volume of cervical tissue removed 
(Castanon et al. 2014; Kyrgiou et al. 2014). The reduction in cervical epithelium may lead to an 
impairment in the mechanical and structural integrity of the cervix resulting in an increased 
risk of ascending vaginal infection or alternatively, the reduction in cervical epithelial surface 
area may cause an impairment in the host innate immune defence to combat ascending vaginal 
infection. In addition, cervical intra-epithelial neoplasia is caused by an inability to clear high-
risk human papilloma virus and it has been postulated that cervical human papilloma virus 
infection alone confers a risk of preterm birth (Reilly et al. 2012). This points towards an 
inherent impairment in cervical antimicrobial defence as the cause of preterm birth.  
The vaginal microbiome and preterm birth 
A healthy vaginal microbiome in pregnant and non-pregnant women is associated with low 
bacterial diversity and lactobacillus dominance. Lactobacillus species are thought to provide 
protection against pathobiont colonization through lactic acid excretion, hydrogen peroxide 
excretion and antimicrobial production of bacteriocins (Aroutcheva et al. 2001). An association 
between lactobacillus depletion and vaginal dysbiosis leading to poor pregnancy outcomes, 
such as preterm birth and late miscarriage, has long been reported (Hillier et al. 1995; Donders 




certain lactobacillus species, Lactobacillus iners (L.iners), at 16 weeks gestation is associated 
with increased rates of preterm birth instead of bacterial vaginosis (Petricevic et al. 2014; 
Kindinger et al. 2017), whilst a dominance of Lactobacillus crispatus is associated with a 
reduced risk of preterm birth (Kindinger et al. 2017). Interestingly, L.iners is often associated 
with bacterial vaginosis as its dominance in the vagina confers a less stable microbiota with a 
tendency to transition to a bacterial vaginosis-associated state (Verstraelen et al. 2009; 
Tamrakar et al. 2007). Older studies looking at the link between vaginal dysbiosis and preterm 
birth were unable to differentiate the lactobacillus species and so may have missed this 
important association (Hillier et al. 1995; Leitich et al. 2003). 
Lactobacillus species appear to have differing effects on the vaginal mucosa which may 
contribute to the mechanisms by which L.iners leads to preterm birth. These effects include 
host-bacterial metabolite interactions whereby L.iners produces more L-Lactic acid compared 
with L.crispatus which produces more D-lactic acid (Witkin et al. 2013). L-lactic acid has been 
shown to promote vaginal extracellular matrix metalloproteinase inducer, as well as matrix 
metalloproteinase-8 which may lead to subsequent cervical remodelling resulting in ascending 
infection and/or preterm birth. Furthermore, L.iners has been shown to induce pro-
inflammatory cytokines, such as IL-8, in human vaginal epithelial cells in vitro (Anahtar et al. 
2016). 
The morbidity and mortality of the premature infant 
Preterm birth is now the leading cause of death in infants under 5 years old (Liu et al. 2015) 
with the risk of mortality and the severity of preterm birth complications being inversely 
related to gestation at delivery (Moore et al. 2012). Prematurity is associated with 
complications in a number of organ systems including cognitive and neurological disability, 
such as cerebral palsy, respiratory conditions and gastrointestinal disease (Moore et al. 2012; 




As mentioned above, intrauterine infection and inflammation is commonly associated with 
preterm birth, particularly at the earlier gestations (Moore et al. 2012). Whilst some of the 
complications observed in babies born preterm relate to immaturity, there is substantial 
evidence that perinatal exposure to infection and inflammation leads to further damage. 
Bacteria and inflammatory mediators, such as cytokines, can reach the fetus directly by 
transplacental transmission or indirectly via ingestion from the amniotic fluid (Adams Waldorf 
& McAdams 2013). 
Neurodevelopmental consequences of prematurity include cerebral palsy, sensorineural 
hearing loss, blindness and severe intellectual disability (Chang 2015). Cerebral palsy is often 
seen in the setting of diffuse white matter injury and/or cystic periventricular leukomalacia. 
Prematurity has also been linked to neuropsychological conditions such as schizophrenia and 
autism (Meldrum et al. 2013; Meyer et al. 2011). The preterm brain is particularly susceptible 
to inflammation; any dysregulation in the normal production of cytokines appears to influence 
brain development. Pro-inflammatory cytokines either cause a direct insult to 
oligodendrocytes and neurons; there is evidence TNF-α is toxic to oligodendrocytes (Li et al. 
2008), or they cause secondary injury by activating microglia leading to local cytokine and free 
radical release (Burd et al. 2012). This is supported by clinical data in which placental infection 
and inflammation alone was found to be a predictor of diparetic cerebral palsy in the very 
preterm infant (Leviton et al. 2010). Interestingly, Elovitz et al., have reported evidence of fetal 
brain injury and subsequent long-term neurological sequelae in a mouse model of intrauterine 
inflammation even in the absence of preterm birth (Elovitz et al. 2011; Dada et al. 2014). 
Furthermore, fetuses of rabbits transcervically inoculated with E.coli have been shown to 
develop white matter brain injury, which is similar to the pathology we see clinically in preterm 




Current treatments for preterm birth 
In view of the clear link between intra-uterine infection and preterm delivery, the use of 
antibiotics has been one of the main focuses of preterm birth research. Clinical studies 
investigating the use of systemic antibiotics for preterm birth prevention has shown 
inconclusive results (Subramaniam et al. 2012). In particular, there is no evidence that 
antibiotics cause a delay to delivery in women with established preterm birth (Kenyon et al. 
2001; King & Flenady 2002). Furthermore, there is evidence that antibiotic use may be 
associated with an increased risk of cerebral palsy in the infant (Kenyon et al. 2008). It is likely 
that antibiotic use at this late stage may only mask the damaging inflammation which has 
already occurred and therefore lead to more severe pathology. This data has unsurprisingly 
resulted in a significant barrier to further research into antibiotic use in a clinical setting.  
The treatment of bacterial vaginosis (which has been linked to preterm birth) with antibiotics 
has not been found to significantly reduce the rates of preterm birth in a Cochrane review of 
21 trials (Brocklehurst et al. 2013). This is supported by data in which metronidazole treatment 
was not found to reduce preterm birth rates (and may even lead to higher rates) in women 
greater than 24 weeks gestation who were at high risk of preterm birth (Shennan et al. 2006). 
Following antibiotic treatment for bacterial vaginosis, the vaginal microbiota has been found 
to be predominately composed of the lactobacillus species, L.iners (Ferris et al. 2007). In view 
of the recent data linking a L.iners dominant vaginal microbiota to an increased risk of preterm 
birth it is possible that antibiotic treatment for bacterial vaginosis may be doing more harm 
than good (Kindinger et al. 2017). 
Cervical cerclage, the placement of a suture in the cervix, is commonly performed in women 
at high risk of preterm birth who have a reduced cervical length. There is evidence that it leads 
to a reduction in preterm birth in this group of women (Berghella et al. 2011) but this benefit 




mechanism is unknown it is believed to have a role in maintaining the integrity of the cervical 
barrier and mucus plug. There is, however, evidence that the type and the location of the 
cervical suture has an effect on the length of gestation (Kindinger et al. 2016; Cook et al. 2017).  
Progesterone has long been used as a preventative treatment for women at high risk of 
preterm birth, possibly due to its anti-inflammatory effects. The OPPTIMUM study, a large 
randomised controlled trial on vaginal progesterone use in women at high risk of preterm 
birth, showed no reduction in risk of preterm birth or improvement in neonatal outcomes (Su 
et al. 2014; Norman et al. 2016). However, a recent meta-analysis of vaginal progesterone in 
preterm birth, including data from OPPTIMUM, showed evidence of a reduced risk of preterm 
birth in a sub-group of high risk women who have a cervical length ≤ 25mm (Romero et al. 
2016). These studies highlight the need to develop novel preventative therapies for preterm 
birth. 
Animal models of infection-related preterm birth 
Animal models of infection-related preterm birth provide useful insight into the mechanisms 
that regulate infection, inflammation and preterm parturition. An ideal research model for 
preterm birth would have similar reproductive biology as a human, mimic what occurs clinically 
and have comparable fetal and neonatal development. The non-human primate would 
represent a near-ideal species in which to investigate preterm birth although their use is 
limited due to cost and ethical considerations. Nevertheless, the rhesus macaque has been 
used to model infection-related preterm birth by infiltration of group B streptococcus, as well 
as inflammatory cytokines, into the amniotic cavity and choriodecidual space (Grigsby et al. 
2010; Waldorf et al. 2011; Elst et al. 1991; Sadowsky et al. 2006).  
In the human and the non-human primate, systemic progesterone withdrawal does not seem 




rat and rabbit, term labour occurs after involution of the corpus luteum which results in 
progesterone withdrawal (Challis et al. 2000). This has been supported by evidence in which 
blocking progesterone using RU486 (a competitive progesterone receptor antagonist) induces 
preterm birth in rodents (Garfield et al. 1987; Dudley et al. 1996). This was initially thought to 
be a concern when using lower mammalian species as preterm birth models but it has since 
been shown that progesterone withdrawal is not an essential step in the preterm labour 
process following bacterial inoculation in mice (Hirsch & Muhle 2002). 
Rodents, mainly mice, have been used as models of infection-related preterm birth for many 
years. Large numbers can be used, they are relatively cheap to maintain and they have short 
breeding cycles making them a practical animal model for preterm birth research. 
Furthermore, more transgenic mouse models are available compared to other animal species 
so the specific genes and pathways involved in parturition can be interrogated. Systemic 
administration of LPS was initially used to induce preterm birth in mice (Lee et al. 2003; Kaga 
et al. 1996). These models tend to mimic the systemic extra-uterine infections, such as 
pyelonephritis or malaria, which are associated with preterm birth clinically. To model the 
localised intrauterine inflammatory process seen more commonly in human preterm birth, 
models were developed by administering intrauterine LPS (Migale et al. 2015; Elovitz et al. 
2003; Elovitz & Mrinalini 2005; Edey et al. 2016; Rinaldi et al. 2014). More recently a less 
invasive but equally efficient model has been developed which uses ultrasound, instead of 
laparotomy, to target the injection site (Rinaldi et al. 2015).  
The use of animal models to mimic the ascending vaginal infection in preterm birth is much 
less common. Intravaginal LPS administration in pregnant mice has been shown to cause 
cervical inflammation and remodelling (Gonzalez et al. 2011; Gonzalez et al. 2014). A murine 




developed (Randis et al. 2014). Furthermore, intravaginal application of E.coli (055) has been 
used to develop a model of preterm birth in mice (Akgul et al. 2014).  
Intravaginal application of a laboratory strain of E.coli-tagged with a red fluorescent protein 
and Ureaplasma urealyticum has been used to model ascending vaginal infection with the 
added benefit of being able to track bacterial ascent (Racicot et al. 2013). Interestingly, these 
bacteria were not able to ascend into the pregnant uterine cavity unless the cervix had prior 
exposure to viral infection. 
Bacteria that are commonly implicated in preterm birth clinically include the genital 
mycoplasmas, Streptococcus agalactiae (Group B streptococcus) and commensal species of 
the oral cavity such as Fusobacterium nucleatum (Witt et al. 2005; Nguyen et al. 2004; Kataoka 
et al. 2006; Feikin et al. 2001; DiGiulio et al. 2008; Han et al. 2009). Escherichia coli (E.coli) is 
commonly used in animal models of preterm birth, whether as live bacteria or as an E.coli 
strain of LPS endotoxin, however, it is not classically associated with preterm birth clinically. 
Although interestingly a recent systemic review of data published on the intraamniotic 
microbiome of women who delivered preterm found E.coli to be present in the amniotic fluid 
of 7% of women who delivered preterm, whilst a bacteria more commonly associated with 
preterm birth, Ureaplasma urealyticum, was only found in 11% (Mendz et al. 2013). 
Furthermore, E.coli is easily obtained and cultured so provides a convenient infectious agent 
for preterm birth modelling, as well as proving to be efficient in inducing premature delivery 
in mice. As with all animal models, they do not exactly mimic the same condition as humans 
but they provide an understandable and easily manipulated model that is consistent with the 
3Rs of animal research (nc3Rs 2014). 
The development of animal models of ascending vaginal infection is particularly important for 




preventative treatments which could be clinically translated into pregnancies at risk of 
delivering prematurely. 
The innate immune system 
The innate immune system compromises the rapid, non-specific and primitive part of the 
immune system (Figure 1.4). It provides the first line of host defence in all multicellular 
organisms and it results in swift immune responses as it does not rely on antigen recognition 
like the adaptive immune system. The innate immune system in humans includes the 
complement system, neutrophils, macrophages, cytokines, chemokines and the naturally 
occurring antimicrobial peptides (AMPs) (Tosi 2005). The main role of the innate immune 
system is the fast elimination of pathogens and the activation of a stereotypical inflammatory 
response. This system has evolved to recognise foreign pathogens by pathogen-recognition 
receptors which are found on the surface of epithelial cells, innate immune cells such as 
neutrophils and macrophages and are also found secreted into tissue fluids or the bloodstream 
(Janeway & Medzhitov 2002). These receptors bind to specific pathogen-associated molecular 
patterns found in groups of microorganisms. The main pathogen-recognition receptors 
involved in the innate immune system are the toll-like receptors. Toll-like receptor signalling 
leads to immune cell recruitment as well as the production and secretion of endogenous AMPs 














Figure 1.4: The innate immune system. The innate immune system is the rapid, non-specific 
and primitive part of the immune system. The innate immune system comprises of epithelial 
cell barriers. As well as producing substances such as, mucus which can trap pathogens, these 
cells can express antimicrobial peptides which have direct antimicrobial activity and specific 
immunomodulatory roles. The immune cells involved in innate immunology are the 
phagocytes; neutrophils, macrophages and dendritic cells. They can phagocytose invading 
pathogens and macrophages and dendritic cells specifically have a role in antigen presentation, 
linking the innate and acquired immune systems. Natural killer cells also have a role in innate 
immunity by non-specifically killing virus and tumour infected cells. The complement system is 
an important part of the immune system, being the major humoral defence mechanism by 





Natural antimicrobial peptides (AMPs) 
AMPs, as discussed above, are important effector molecules of the innate immune system. 
Over 1200 AMPs have been discovered so far with the common unifying function of killing 
microbes at physiological concentrations (Bevins et al. 1999). They are found abundantly in the 
host defence systems of all plants and animals (Borregaard et al. 2000). The majority of these 
peptides consist of 10-50 amino acid residues and their common features include a positive 
charge whilst maintaining a hydrophobic and amphipathic structure. It is thought that these 
features allow them to interact with the negatively charged phospholipid groups and 
hydrophobic fatty acid chains of microbial membranes to form lytic pores and therefore 
facilitate the subsequent release of cytosol contents (Latal et al. 1997). 
AMPs appear to play a key role in linking the innate and adaptive immune system firstly by 
activating immune cells such as dendritic cells, T lymphocytes and monocytes and secondly by 
inducing specific cytokine release (Yang et al. 1999; Biragyn 2011). There are two main types 
of AMPs in humans; defensins and cathelicidins; humans possess a single cathelicidin gene, 













 6 cysteine motifs 
with disulphide 




 6 cysteine motifs 
with disulphide 
bridges (C 1-5, 2-4, 
3-6) 
 
Source  Epithelial cells 
 Leucocytes 
 HNP 1-4; 
neutrophil 
granules 
 HD5-6; Paneth 
cells of small 
intestine 
 Epithelial cells 
Regulation  Constitutive and 
inducible 




 Broad spectrum  Broad spectrum  Broad spectrum 
 
Table 1.2: The main AMPs in humans are the cathelicidin and the defensins. This table 
describes the structure, types, locations and properties of these AMPs. The structural peptide 
images have been adapted from (Wang & Guangshun 2014). 
 
Defensins are widely distributed in epithelial cells and neutrophils. They are part of the 
cysteine rich beta-sheet peptide family which includes the two main subfamilies the α and β-
defensins. They share a common structure of six disulphide-linked cysteine bridges forming 
the characteristic β-sheet (Ganz 2003). They differ in the pattern of their cysteine pairings 
(Wiesner & Vilcinskas 2010). These small cationic peptides have a broad range of antimicrobial 
activity against a wide range of bacteria including gram negative bacteria, gram positive 
bacteria and fungi (Miyasaki & Lehrer 1998). Their main mechanism of antimicrobial killing is 




So far, 6 α-defensins have been discovered; human neutrophil peptides 1-4 (isolated from 
azurophilic granules in human neutrophils) and α-defensins 5 and 6 (found in intestinal paneth 
cells) (Wiesner & Vilcinskas 2010; Ghosh et al. 2002). The beta-defensins (HBD), on the other 
hand, are found at all mucosal surfaces, either constitutively or inducibly expressed. Their 
synthesis and release is regulated by bacteria, viruses and inflammatory cytokines. HBDs are 
highly conserved peptides which are thought to have evolved from a single ancestral beta-
defensin gene (Dhople et al. 2006). There are four human beta-defensins. HBD-1 is 
constitutively expressed in some tissues, whilst HBD-2, HBD-3 and HBD-4 are inducible, usually 
in response to a pro-inflammatory stimulus (Pazgier et al. 2006). Their charge-dependent 
microbial killing mechanism can occur at micromolar concentrations but this is inhibited under 
conditions of increased ionic strength.  
Cathelicidin is stored in secretory granules of neutrophils and macrophages, as well as in 
epithelial cells. Humans and mice possess a single cathelicidin gene, the CAMP gene, which 
produces the LL-37 and CRAMP proteins respectively. Exons 1 to 3 of the CAMP gene encode 
the signal precursor and the pro-sequence domain, whilst exon 4 encodes the mature 
antimicrobial peptide (Zanetti et al. 2000; Pestonjamasp et al. 2001). Cleavage of the inactive 
precursor by proteinase-3 or elastase to release the mature C-terminal antimicrobial peptide 
occurs upon degranulation of activated neutrophils (Panyutich et al. 1997; Sørensen et al. 
2001) however, the cleavage process in epithelial cells is less well understood (Pestonjamasp 
et al. 2001). 
The antimicrobial activity of cathelicidin is rapid and broad spectrum, effectively killing many 
common antibiotic-resistant strains of bacteria (Zanetti et al. 2002). The mechanism of 
microbial killing is, like defensins, through disruption of the microbe’s membrane integrity 




Human beta-defensin-3 (HBD-3) 
HBD-3 has potent antimicrobial activity against multiple bacteria, fungi and viruses (Table 1.3) 
and appears to be resistant to high salt environments (Harder et al. 2001). HBD-3 also has the 
potential to bind and neutralise LPS leading to anti-toxin properties (Lee et al. 2010). 
Importantly, it is able to inhibit HIV replication by acting as an endogenous CXCR-4 antagonist 
(Feng et al. 2006). 
In addition to its antimicrobial activities, it also has important immunomodulatory properties. 
It has a chemoattractant role which is mediated through its effector ligands for chemokine 
receptor CCR6 on T-lymphocytes and immature dendritic cells (Wu et al. 2003). This allows 
HBD-3 to link the innate and adaptive immune systems. There is, however, significant 
controversy as to whether HBD-3 exerts pro- or anti-inflammatory effects in vivo. It has been 
found to increase pro-inflammatory cytokines such as IL-6, IL-8 and IL-1β by dendritic cells and 
monocytes, as well as inhibiting the production of the anti-inflammatory cytokine IL-10 by 
monocytes (Tewary et al. 2013; Funderburg et al. 2011). Furthermore, recent evidence has 
supported this pro-inflammatory effect by showing that HBD-3 can cause an exacerbated IFN-
β response in human and mouse macrophages in response to the viral ligand mimic 
polyinosinic:polycytidylic acid (Semple et al. 2015).  
In contrast, HBD-3 has numerous anti-inflammatory effects. In addition to its ability to 
neutralise the LPS toxin by direct binding, it can also inhibit TNF-α and IL-6 in LPS stimulated 
cells (Semple et al. 2010; Bedran et al. 2014). The underlying mechanism has been shown to 
be the inhibition of pro-inflammatory gene transcription within TLR-4 stimulated cells (Semple 
et al. 2011). Furthermore, HBD-3 can attenuate pro-inflammatory cytokine responses to the 
oral pathogen Porphyromonas gingivalis in mucosal secretions (Pingel et al. 2008). In addition, 
HBD-3 and LL-37 appears to work synergistically to reduce inflammatory cytokine production 




Antimicrobial activity of HBD-3 
Escherichia coli (Hoover et al. 2003) 
Pseudomonas aeruginosa (Harder et al. 2001) 
Klebsiella pneumoniae (Sahly et al. 2006) 
Staphylococcus aureus (Hoover et al. 2003) 
Streptococcus pyogenes (Harder et al. 2001) 
Streptococcus pneumoniae (Scharf et al. 2012) 
Enterococcus faecium (Harder et al. 2001) 
Porphyromonas gingivalis (Shelburne et al. 2005) 
Staphylococcus carnosus (Hoover et al. 2003) 
Saccharomyces cerevisiae (Hoover et al. 2003) 
Candida albicans (Harder et al. 2001) 
Candida parapsilosis (Harder et al. 2001) 
Candida krusei (Harder et al. 2001) 
HIV-1 (Feng et al. 2006) 
Table 1.3: Antimicrobial activity of HBD-3. HBD-3 has broad spectrum antimicrobial activity; 
it is particularly microbicidal against gram negative bacteria. 
Cervical innate immunity in pregnancy 
The innate immune system of the female reproductive tract is a unique and specialized system 
that functions to support and protect the fetus as well as protecting against potential 
pathogens. The cervix has a particularly important role in pregnancy as it acts as the 
gatekeeper to the uterus by protecting the largely sterile decidua from the diverse microbial 
environment of the vagina. During pregnancy, the cervix produces a specialised cervical mucus 
plug which contributes to its important immuno-protective role. The cervical mucus plug is a 




which contributes to its structural and immunological properties is the mucinous 
glycoproteins. These mucins sterically inhibit the diffusion of larger molecules, such as bacteria 
and fungi, as well as providing ligands for cytokines and chemokines. Importantly, these mucins 
are negatively charged oligosaccharides which help to retain positively charged molecules, 
including the endogenously occurring AMPs (Becher et al. 2009). A number of AMPs have been 
found in the cervical mucus plug; secretory leucocyte protease inhibitor (SLPI), elafin, 
lysozyme, human neutrophil peptides 1-3 and human beta-defensin 1 (Hein et al. 2002; Hein 
et al. 2001; Stock et al. 2009). The cervical mucus plug appears to function as a structural and 
immunological barrier preventing ascending vaginal bacteria from gaining access into the 
uterine cavity. 
AMPs and preterm birth 
The role of cervical AMPs in the pathogenesis of preterm birth is not entirely clear. Bacterial 
vaginosis in pregnancy which has been linked to an increased risk of preterm birth is associated 
with low cervico-vaginal levels of elafin (Hillier et al. 1995; Stock et al. 2009). Furthermore, low 
levels of SLPI and elafin have also been found in the amniotic fluid and fetal membranes of 
woman with preterm pre-labour rupture of membranes (King et al. 2007). It is thought that 
these low AMP levels may reflect a reduced capacity of these women to respond to and to 
combat vaginal infection. Polymorphisms of the elafin gene have been identified which are 
associated with reduced elafin secretion, although this has not been investigated in women at 
risk of preterm birth (Tejera et al. 2009). Recent data has shown a reduction in cervical HBD-1 
and SLPI in women after cervical excision for cervical intra-epithelial neoplasia (Mitra et al. 
Society of Reproductive Investigation, 2016, unpublished data). Cervical excision for cervical 
intra-epithelial neoplasia, as mentioned previously, is a major risk factor for preterm birth and 




In contrast to this, SLPI and elafin have also been found to be raised in the cervico-vaginal fluid 
of women in the second trimester who subsequently develop cervical shortening and 
spontaneous preterm birth (Abbott et al. 2014). In addition, SLPI has been shown to act as a 
marker of impending delivery in normal term deliveries (Samejima et al. 2015). Increased 
expression of SLPI, elafin and human neutrophil peptide mRNA has been found in the cervical 
cells of women who were admitted in preterm labour (Itaoka et al. 2015; Xu et al. 2008; 
Lucovnik et al. 2011). It is likely that these women are responding to subclinical vaginal 
infection by increasing endogenous levels of cervical AMPs, so as to enhance their host defence 
mechanisms. This is in contrast to the increased levels being a cause of the premature 
parturition. In support of this, cathelicidin has been shown to be increased in cervico-vaginal 
fluid in women with bacterial vaginosis during pregnancy and have a protective role in 
resolving the dysbiosis (Frew et al. 2014). The fact that cathelicidin levels have been found to 
return to normal after bacterial vaginosis treatment would also support this protective role 
(Valore et al. 2006).  
Ureaplasma species, which colonize the vagina in some women, have been associated with 
preterm birth (Witt et al. 2005). Interestingly, it has been found that these bacterial species 
can manipulate host defence by downregulating AMP gene expression (Xiao et al. 2014).  
Gene therapy: novel therapeutic strategies for preterm birth 
The use of gene transfer therapy is increasingly considered to be a realistic treatment option 
for a variety of single gene defect disorders and there are successful clinical trials using gene 
therapy for the treatment of inherited immunodeficiency, Leber’s congenital amaurosis and 
haemophilia (Gaspar et al. 2011; Bainbridge et al. 2015; Russell et al. 2017; Nathwani et al. 
2014). In recent years, acquired diseases such as cardiovascular disease, cancer and infectious 
diseases have been the subject of most of the gene therapy research rather than inherited 




field (Ginn et al. 2013). Of most relevance to obstetrics research, is the development of a 
therapy for fetal growth restriction using adenoviral vector-delivered vascular endothelial 
growth factor to the maternal arteries during pregnancy ((Mehta et al. 2014), http://everrest-
fp7.eu/). This exciting advancement in gene therapy for fetal growth restriction has lead the 
way for the development of gene therapies for other pregnancy disorders. Furthermore, the 
above study has performed patient-led focus groups to discuss the acceptability of gene 
therapy for pregnancy disorders and overall this type of therapy was found to be generally 
favourable. 
Viral vector-based gene therapy 
Gene transfer can be achieved by viral and non-viral vectors. Viral vectors have been more 
successful up to now, due to their increased efficiency of gene delivery, and they have been 
used in all of the successful gene therapy clinical trials so far (Bainbridge et al. 2015; Nathwani 
et al. 2012). The most common viral vectors used are lentiviruses, adenoviruses and adeno-
associated viruses (AAV). Lentiviral vectors, a subclass of retroviruses, naturally integrate into 
both dividing and non-dividing cells as well as showing stable and long-term expression. 
Adenoviral vectors have high packaging capacity, are non-integrating and can deliver short-
term gene transfer however, a serious safety concern was raised after an adenoviral vector 
caused the death of a patient in the late 1990s. This was found to be caused by the adenoviral 
capsid leading to a cytokine storm which resulted in subsequent multi-organ failure. The 
majority of adenovirus research now focuses on its use as a targeted oncolytic agent, vascular 
disease and as a vaccine delivery vector, rather than as an intravenous treatment of genetic 
diseases (Appaiahgari & Vrati 2015; Bradshaw & Baker 2013; Mehta et al. 2014).  
AAV vectors, on the other hand, are becoming increasingly popular for the treatment of 
genetic disease due to their ability to produce safe and stable long term expression in vivo. 




ago (Rose et al. 1969; Rose et al. 1966). Their popularity is linked to their low immunogenicity 
and the fact that they predominantly remain as an non-integrating extrachromosomal episome 
in the majority of cells (Nakai et al. 2001). They have shown success in dozens of gene therapy 
clinical trials and they have been approved as a treatment for lipoprotein lipase deficiency in 
Europe (Wierzbicki & Viljoen 2013). 
Adeno-associated virus 
AAV was discovered in 1965 as contaminant DNA viral particles in adenoviral preparations 
(Atchison et al. 1965; Hoggan et al. 1966). It is a small, non-enveloped icosahedral virus with a 
diameter of approximately 25nm (Chapman 2006). It belongs to the Dependovirus genus of the 
family Paroviridae. They are considered to be naturally replication deficient due to the need 
for a helper virus, such as adenovirus or herpes virus, for replication and generation of virions 
(Samulski et al. 1982; Handa & Carter 1979). The life cycle of wild-type AAV is biphasic; lytic, 







Figure 1.5: Life cycle of wild-type AAV. Upon entry into the host cell nucleus, AAV can follow 
one of two pathways of its life cycle; the lytic or the latent. The lytic pathway occurs when 
there is co-infection with a helper virus, such as adenovirus. This results in genome replication, 
viral gene expression, packaging and release of virions. The latent pathway occurs in the 
absence of helper virus co-infection. Latency occurs by preferential integration of the virus 
genome into the AAVS1 locus on chromosome 19 (Kotin et al. 1990). Helper virus infection of 
an AAV latently infected cell can result in subsequent replication, packaging and release of AAV 
virions. 
 
The wild-type AAV genome consists of a linear single stranded DNA molecule of approximately 
4.7 kilobases which includes the viral rep and cap genes flanked by 145 nucleotide long 
inverted terminal repeats (ITRs) (Koczot et al. 1973; Rose et al. 1969) (Figure 1.6). The ITRs act 
as self-priming hairpins that enable genome replication (Bohenzky et al. 1988). The four rep 
proteins are essential for replication, transcription, integration and encapsidation (Trempe et 




a 60 subunit icosahedral with the help of an assembly activating protein (Naumer et al. 2012). 
As the ITRs contain the necessary cis-acting sequences, the viral coding sequences can be 
removed from the wildtype AAV genome and a DNA sequence of choice can be inserted 
between the flanking ITRs to develop a recombinant AAV (rAAV) gene delivery vector. 
Replication and assembly of virions is then achieved by addition of the AAV rep and cap 
proteins in trans and the adenoviral helper plasmid (Samulski et al. 1982).  
In rAAV transduced cells, vector genomes are predominantly maintained as concatenated 
episomes (Xiao et al. 1996), although they can undergo integration into the genome 
(Cunningham et al. 2008). At least 12 serotypes of AAV have been identified from humans and 
primates with variable cellular tropisms (Zincarelli et al. 2008). Several of these serotypes have 
been reported to bind to a primary cell surface receptor, such as heparan sulphate 
proteoglycan for AAV2 (Summerford & Samulski 1998), for initial attachment to the cell surface 
followed by the subsequent binding of a secondary receptor that enables viral internalization.  
Recently published work using a loss-of-function genetic screening approach has identified a 
universal AAV receptor that appears to be an essential receptor for multiple AAV serotypes, 
which is capable of endocytosing from the plasma membrane and trafficking to the trans-Golgi 
network  (Pillay et al. 2016). The different cellular tropisms of AAV serotypes are thought to 
result from unique interactions with this universal AAV receptor (Pillay et al. 2017). How this 
receptor fits in to our previous understanding of AAV attachment and entry into the host cell 
still needs to be clarified but it has huge potential to improve our understanding of the AAV-







Figure 1.6: AAV viral genome. Two ITRs flank the AAV ssDNA genome which encodes the rep 
and cap genes. The rep gene encodes the four non-structural rep proteins; Rep 78, Rep 68, 
Rep 52 and Rep 40. The cap gene encodes the three structural proteins; VP1, VP2 and VP3 
(adapted from (Drouin & Agbandje-McKenna 2013)). 
 
Clinical translation of AAV gene therapy 
As mentioned previously, AAV gene therapy has led to many successful clinical trials and is the 
first gene therapy vector to be approved by the European medicines agency for the treatment 
for lipoprotein lipase deficiency (Wierzbicki & Viljoen 2013; Nathwani et al. 2014; Bainbridge 
et al. 2015). rAAVs can infect dividing and non-dividing cells, and they have been shown to 




humans include gene silencing, insertional mutagenesis, phenotoxicity, immunotoxicity, 
horizontal and vertical transmission of delivered DNA. 
Gene silencing is thought to occur through mechanisms such as promoter methylation (Li & 
Dinauer 1998). Recent evidence has shown that inhibition of histone deacetylation and DNA 
methylation can improve gene expression (Kia et al. 2013). Insertional mutagenesis appears to 
be minimal after AAV transduction as the transferred genomes tend to persist in an episomal 
non-integrated form, but even if the AAV does integrate there have been no vector-induced 
malignancies reported in humans (Kaeppel et al. 2013; Schnepp et al. 2003; Li et al. 2011).  
AAV is often described as the least immunogenic of the commonly used viral vectors as the 
innate immune responses are considered to be minimal compared with other vectors, 
particularly adenoviral vectors (Zaiss et al. 2002). The innate immune signalling TLR9-MyD88 
pathway appears to be responsible for the immune response to AAV (Zhu et al. 2009). In some 
situations AAV can avoid innate immune responses by inefficiently activating TLRs or limiting 
antigen-presenting cell transduction, which can help to reduce cytotoxic T cell responses (Zaiss 
et al. 2002; Hensley & Amalfitano 2007; Jooss & Chirmule 2003; Zhang et al. 2000; Somanathan 
et al. 2010). There does appear to be a critical threshold by which AAV leads to CD8+ T cell 
priming resulting in immunotoxicity and how this threshold is reached is largely unknown, 
although the combination of capsid, transgene and inflammatory environment within the host 
tissue is thought to play an important role in this (Wu et al. 2014; Manno et al. 2006). There is 
accumulating evidence that the cytokine milieu of the host tissue can dictate T cell priming, for 
example, an anti-inflammatory environment can induce an immune tolerant environment by 
inducing T regulatory cells (Cao et al. 2007; Mingozzi et al. 2007).  Strategies to reduce T cell 
responses include reduction of vector doses and induction of transient immunosuppression 
with, for example, a short course of steroid treatment (Jiang et al. 2006; Mingozzi et al. 2013; 




The humoral immune response caused by pre-existing neutralising antibodies (70% of the 
human population are seropositive for AAV2 neutralising antibodies) can be problematic, 
leading to the inhibition of gene transfer (Boutin et al. 2010). There has been increasing 
interest in developing AAV variants from animals, such as AAVrh.10 from the rhesus macaque, 
as humans will ideally have no or minimal pre-existing neutralising antibodies to these AAV 
vectors (Thwaite et al. 2015; Sondhi et al. 2007). 
Horizontal transmission of donated DNA has often been of concern for gene therapy 
translation in situations where virus is more likely to be shed into the environment, such as the 
respiratory system. Preclinical studies demonstrate vector shed in bodily fluids after 
intravenous injection in the non-human primate is no longer infectious by 72 hours after 
injection (Favre et al. 2001). Germline vertical transmission of delivered DNA is also of concern, 
but a rabbit model has shown no evidence of germline transmission in male gametes following 
systemic AAV2 and AAV8 administration (Schuettrumpf et al. 2006; Favaro et al. 2009). 
Cervical gene therapy  
The main focus of cervical and vaginal targeted gene transfer research up to now has been in 
the prevention of infectious diseases. Adenoviral vectors encoding interferon-ϒ, IL-12 and 
MCP-1 cytokines have been used as an intravaginal treatment for vaginal candidiasis, 
unfortunately their use did not protect against candida vaginitis (Wozniak et al. 2005). 
Prevention of genital herpes simplex virus (HSV) infection using RNA interference strategies 
has showed promise, for example, the use of lipoplexes carrying small-interfering RNAs (siRNA) 
that target essential HSV-2 genes (Palliser et al. 2006) or the use of HSV-1 vectors carrying 
short-hairpin RNA (shRNA) that target HSV-2 DNA polymerase. Anti-HIV antibodies have been 
delivered using AAV vectors to human cervical and vaginal cells in vitro and also to the lower 




in vivo (Abdel-Motal et al. 2014; Abdel-Motal et al. 2011). A gene therapy approach has not 
been explored for preterm birth prevention.  
AMP gene therapy 
The many important functions of AMPs and their association with human disease point 
towards these peptides as a new therapeutic target. However, these peptides are very 
expensive to produce and purify chemically, and they are relatively unstable in vivo. Therefore, 
gene transfer of AMPs has been explored as a way of overcoming these potential problems for 
the treatment of infectious diseases and other immune disorders. In support of this, there is 
evidence that gene delivery of cathelicidin is significantly more effective than purified 
cathelicidin peptide in an infected burn model (Jacobsen et al. 2005).  
The antimicrobial activity of AMPs makes them useful as localised antibiotic treatments, 
especially in situations where there are multiple antibiotic resistances. HBD-2 gene therapy 
has been tested in a rodent urinary tract infection model and chronic otitis media model (Zhao 
et al. 2011; Woo et al. 2014). Natural venoms contain AMPs and it has been discovered that 
spider venom in particular contains several different types of AMPs (Vassilevski et al. 2009). 
Interestingly, plasmids containing 6 spider venom AMP genes were used to transduce HEK 
293T cells which resulted in strong anti-chlamydial affects (Lazarev et al. 2011).  
The defensins’ ability to influence the adaptive immune system means they have a potential 
role as immunomodulators in inflammatory disorders and cancer. HBD-2 transduced tumours 
demonstrated chemotactic activity of immature dendritic cells leading to significant inhibition 
in tumour growth (Li et al. 2014).  
β-defensins have been discovered to play a key role in wound repair; stimulating the migration 
and proliferation of keratinocytes in areas of skin damage (Supp et al. 2004; Niyonsaba et al. 




in a porcine diabetic wound model (Hirsch et al. 2009). This was found to reduce bacterial load 
within the wound and also improve re-epithelialisation leading to better wound closure.  
The use of cathelicidin in gene therapy, like defensins, has been mainly for its microbial killing 
properties. Diminished antimicrobial function of cathelicidins and defensins have been 
implicated in cystic fibrosis patients where it is thought that the abnormal salt environment of 
the cystic fibrosis airway reduces AMP function (Smith et al. 1996). To combat this, adenoviral 
vectors expressing the human cathelicidin gene have been used to transduce human bronchial 
xenografts from cystic fibrosis patients (Bals et al. 1999). This overexpression of cathelicidin 
was sufficient to restore bacterial killing in the airway fluid to that of normal controls. 
Furthermore, adenovirus expressing human cathelicidin was used in a mouse model of 
Pseudomonas aeruginosa lung infection (a common pathogen in cystic fibrosis lungs) which 
led to a significant reduction in bacterial load and airway inflammation (Bals et al. 1999).  
As well as its role in microbial killing, cathelicidin can bind and neutralise LPS (Cironei et al. 
2003). This enables it to reduce the systemic inflammatory response by inhibiting 
endotoxaemia. This important function has been utilised in a mouse model of LPS and E.coli 
sepsis in which an adenoviral vector encoding the cathelicidin gene improves sepsis survival 
rates (Bals et al. 1999). Cathelicidin’s role in immune modulation has also been utilised in a 
mouse model of ulcerative colitis (Tai et al. 2012). A plasmid containing the murine cathelicidin 
gene was intra-rectally applied to a dextran sulfate sodium-induced colitis mouse and this lead 
to a reversal in the elevated interleukin1-beta (IL1-β) and tumour necrosis factor-alpha (TNF-
α) levels, neutrophils and apoptotic cells seen in this model.  
Elafin is a serine elastase inhibitor AMP which is produced constitutively from epithelial cells 
(Pfundt et al., 1996). As well as its antimicrobial role, elafin is also able to attenuate 




et al. 2008). Adenoviral delivered elafin to inflamed endothelial cells resulted in reduced IL-8 
production and cytotoxicity (Henriksen et al. 2004).  
There is also the potential for synergistic antimicrobial function using gene therapy with a 
combination of multiple AMPs, particularly in view of the small size of the AMP genes. HBD-2 
in combination with cathelicidin can synergistically augment microbial killing in transduced 
human keratinocytes (Carretero et al. 2004). 
Bioluminescence imaging 
Bioluminescence imaging (BLI) is a powerful technology for studying cellular immune 
responses in vivo; light is emitted when luciferase enzymes catalyse their substrates. 
Bioluminescence imaging detects this light as a surrogate marker for protein expression using 
a comparatively inexpensive cooled charge-coupled device (CCCD) camera. Unlike 
conventional reporter gene methods which require analysis of large numbers of animal 
cohorts at different time points, BLI allows for continual analysis in the same cohort. This 
reduces the number of animals needed (in accordance with the 3Rs principle of the NCRs)  and 
also increases the fidelity of the data by reducing inter-animal variation (nc3Rs 2014). 
Continual BLI for pathogen colonization and treatment response is a well-established tool in 
infectious disease research (Suff & Waddington 2017). 
Bioluminescent pathogens 
Bioluminescent pathogens can be genetically engineered by transfer of the luxCDABE operon 
from bacteria such as Photorhabdus luminescens or Xenorhabdus luminescens which confers 
them with constitutive bioluminescence. The bacterial lux operon contain 5 genes; luxA and 
luxB encode the luciferase enzyme that oxidises a long-chain aldehyde and a reduced flavin 
mononucleotide to produce oxidised flavin, the reaction which emits light at 490nm, and the 




the aldehyde substrate required for the light-emitting reaction (Figure 1.7) (Baldwin et al. 
1984). The main advantage of the lux operon system is that the use of an exogenous substrate 
is unnecessary which reduces the problem of substrate bioavailability. 
 
Figure 1.7: The lux operon (luxCDABE) reaction emits light. luxA and luxB encode the 
luciferase enzyme that oxidises a long-chain aldehyde and a reduced flavin mononucleotide to 
produce oxidised flavin, the reaction which emits light at 490nm. luxC, luxD and luxE genes 
encode a multienzyme complex responsible for the regeneration of the aldehyde substrate 
required for the light-emitting reaction. FMH- flavin mononucleotide, FMNH2- reduced flavin 





Project hypothesis and aims 
Central to this thesis are the following hypotheses:   
(1) That the augmentation of endogenous antimicrobial peptides within the 
murine cervix using conventional virus-based gene transfer technology will prevent 
bacteria which are capable of inducing preterm birth from ascending the cervical 
canal and accessing the intrauterine space.  
(2) That reducing or preventing bacterial presence in the intrauterine space 
through increasing cervicovaginal AMP expression prolongs gestational length and 
improves the survival of the offspring.  
 
The specific aims are:  
1. To develop and characterise models of ascending vaginal infection and to assess the 
effect this has on pregnancy and pup survival.  
2. To determine the most effective viral vector (as well as optimising additional factors) 
to achieve successful gene transfer to the cervical epithelium of female mice.  
3. To design and produce a gene therapy AMP construct and use this to overexpress 
an AMP in murine cervical epithelium in vivo.  
4. To determine the effect of this AMP overexpression in the cervix on bacterial 
survival, motility and ascent into the uterus.  
5. To determine the effect of this AMP overexpression in the cervix on gestation, pup 




Chapter 2 Methods  
Developing and characterising the ascending infection model 
Bacterial culture: Escherichia coli K12 MG1655-luxCDABE 
Escherichia coli K12 MG1655-luxCDABE (E.coli K12) were kindly gifted from Dr Mark Tangney, 
University College Cork. E.coli K12 were inoculated in 10ml of Luria Bertani (LB) broth, 
supplemented with 300μg/ml Erythromycin. It was grown overnight at 37⁰C at 200rpm (0.6g). 
The following morning the culture was diluted to an OD600 of 0.1 in LB broth with erythromycin. 
This was grown for 2 to 3 hours at 37⁰C and 200rpm (0.6g) to mid-logarithmic phase. The 
bacteria were harvested when the OD600 was between 0.5 and 0.7. They were centrifuged for 
1 minute at 18000g and the pellet was washed twice with 10mM PB. The pellet (1x109 CFU) 
was then resuspended in 30μl of 10mM PB. CFU was determined by serial dilutions and plating 
on LB plus erythromycin agar plates. 
Bacterial culture: Escherichia coli K1 A192PP-luxABCDE 
Escherichia coli K1 A192PP-luxABCDE (E.coli K1) were kindly gifted from Professor Peter Taylor, 
University College London. E.coli K1 were inoculated in 10ml of LB broth, supplemented with 
50μg/ml Kanamycin. It was grown overnight at 37⁰C at 200rpm (0.6g). The following morning 
the culture was diluted down to an OD600 of 0.01 in LB broth and kanamycin. This was grown 
for 2 to 3 hours at 37⁰C and 200rpm (0.6g) to mid-logarithmic phase. The bacteria were 
harvested when the OD600 was between 0.5 and 0.7. They were centrifuged for 1 minute at 
18000g and the pellet was washed twice with 10mM PB. The pellet (1x109 CFU) was then 
diluted to 1x105 CFU in 10 mM PB and 20μl of this was aliquoted (approximately 2x102 CFU). 





SIM (Sulfide, Indole, Motility) medium agar was mixed into 100ml of ddH20 and placed into 
15ml Falcon® centrifuge tubes. Each tube was inoculated in the centre of the media to a depth 
of 2cm with 2-3 bacterial colonies using a sterile needle. They were incubated at 37⁰C 
overnight. The following day the bacterial motility was assessed. A positive motility test is 
indicated by a diffuse zone of bacterial growth spreading from the central inoculation zone. 
Ascending vaginal infection 
The mice used in this study were supplied by Charles River. All animal experiments conducted 
were in agreement with the Home Office guidelines and institutional guidelines at University 
College London and under project licence held by Dr Simon Waddington (PPL 70/8030). The 
mice strains used include CD-1, BALB-C, C57BL/6 and C57BL/6N-Tyrc-Brd (albino BL/6). 
Adult female mice (6-8 weeks old) received 20µl bacteria (preparation described above) intra-
vaginally using a sterile 200μl pipette tip under anaesthesia (isoflurane in 100% oxygen with a 
flow rate of 2L/min). This was followed by 10μl of F127 pluronic gel intravaginally (Sigma 
Aldrich, UK) and quinine powder to the introitus (Boughter et al. 2005), to deter the mice from 
cleaning the bacterial suspension. To obtain pregnant mice, stock animals were time mated 
and the following morning was described as embryonic day 0.5 (E0.5). Pregnant dams received 
bacterial suspensions on either E14.5, E15.5 or E16.5. 
Whole body bioluminescence imaging  
Mice were anaesthetised with isoflurane (in 100% oxygen with a flow rate of 2L/min) and 
bioluminescent images were captured using an IVIS imaging system (IVIS Lumina II, 
PerkinElmer, USA) at different time points. To measure photon radiance quantitatively, regions 




as photons per second per centimetre squared per steradian (photons/second-cm2/sr) using 
Living Image software (Perkin Elmer, Coventry, UK). 
Transformation of competent bacterial cells  
ccdB or One Shot Stbl3TM chemically competent E.coli cells were thawed on ice prior to each 
transformation. 10pg to 100ng of DNA was added to each 50µl vial, gently mixed and incubated 
on ice for 30 minutes. The cells were heat shocked for 45 seconds at 42°C. The cells were placed 
on ice for 2 minutes, after which 250µl of SOC media was added and the cells shaken at 200rpm 
(0.6g), 37°C for 1 hour. The cells were spread on LB agar plates containing ampicillin 
(100µg/mL) or kanamycin (50µg/mL). The plates were incubated over night at 37°C, after 
which colonies were selected by using a sterile 10µl pipette tip and grown overnight in LB broth 
(plus antibiotic) at 200rpm (0.6g) and 37°C. Plasmid DNA was prepared using Qiagen Mini-prep 
kits following the manufacturer’s instructions. Larger volumes of plasmid DNA were prepared 
using Qiagen Maxi-prep kits following the manufacturer’s instructions. For long term storage, 
bacterial cultures were stored at -80°C in a 1:3 ratio of glycerol. 
Plasmid DNA concentrations were measured using a FluoStar Omega LVIS plate 
spectrophotometer (BMG Labtech, Buckinghamshire, UK) by measuring the ratio of the 
absorbance of light at wavelength 260nm and 280nm. 
Cell culture 
Cell lines End1/E6E7 and human embryonic kidney (HEK) 293T cells were obtained from the 
America Tissue Culture Collection (Manassas, VA, USA). End1/E6E7 were maintained in 
Keratinocyte Serum Free medium, supplemented with 0.1ng/ml human recombinant 
epidermal growth factor, 0.05mg/ml bovine pituitary extract and calcium chloride 44.1mg/ml 
at 37⁰C in 5% CO2. HEK 293T cells were maintained in DMEM, supplemented with 10% fetal 




Production of lentiviral vectors 
Lentiviral plasmids were gifted from Dr Stephen Howe, UCL and Dr Juliette Delhove, St 
George’s University. To generate the lentiviral plasmid with the NF-KB response element, a 
Gateway® cloning system (Life Technologies, Glasgow, UK) was used by Dr Delhove. The 
lentiviral backbone which was used contained a minimal promoter upstream of the NF-KB 
response element, followed by a 3xFLAG, FLuc (firefly luciferase), and 2A-eGFP (enhanced GFP) 
(Buckley et al. 2015) (Figure 2.1). 
To produce a second generation lentivirus a three plasmid system was used (Demaison et al. 
2002) (Figure 2.2). Envelope plasmids VSV-G (pMD.G2; Vesicular Somatitis Virus glycoprotein) 
and the packaging plasmid pCMVΔR8.74 containing the gag and pol genes were used (kindly 
gifted from Dr Stephen Howe, UCL). The packaging plasmid allows the lentivirus carrying the 
transgene to integrate into the host genome. The envelope and the packaging plasmids were 
produced in large scale by Aldevron (North Dakota, USA). 
 
 
Figure 2.1: An example of a lentiviral plasmid with the NF-κB response element. The plasmid 




2.1.8.1.  Lentiviral transfection 
Lentiviral preparations were made using three plasmids with the standard second generation 
lentivirus system (Figure 2.2).  
 
Figure 2.2: Lentivirus preparation using the standard second generation lentiviral system. 
2.1.8.2.  Titration of lentiviral vector 
The lentiviral vector was titrated using the p24 antigen ELISA kit. Lentiviral vectors were 
diluted; 1:1 x 106, 1:5 x 106 and 1:1 x 107 and added to the antibody coated wells. Standards 




was then read at 450nm and the quantity of p24 antigen was calculated. Viral titre was then 
expressed as genomic copies; GC/ml. 
Production of AAV 8 viral vectors  
The AAV viral vector is produced following the three plasmid transient transfection protocol 
described below (Binny & Nathwani 2012) (Figure 2.3). The three plasmids include the helper, 
the packaging and the genome plasmids. Genome plasmids were provided by Vector Biolabs 
and Aldevron (USA). The helper plasmid, pHGTI, contains the key adenoviral genes to support 
efficient AAV replication and packaging (Streck et al. 2005). The packaging plasmid expresses 
the two AAV genes rep and cap. These genes are not flanked by ITRs so they cannot be 
packaged into new AAV capsids. The genome plasmid contains the promoter and transgene of 
choice flanked by ITRs. This will be packaged into the AAV vector. All viral vectors used in this 
study are pseudotyped; an AAV 6 or AAV 8 capsid containing a ssDNA genome consisting of 
the chosen promoter and transgene flanked by ITRs derived from AAV 2. For NF-KB biosensor 
experiments a AAV 8 serotype vector containing a minimal promoter upstream of the NF-KB 
response element, followed by a FLuc (firefly luciferase) and 2A-eGFP (enhanced GFP) 





2.1.9.1.  AAV 8: Three plasmid AAV transfection 
The AAV vector is produced following the three plasmid transient transfection protocol 

















2.1.9.2.  AAV purification with HPLC (High Performance Liquid Chromatography) 
AAV particles were purified by affinity chromatography using an ÄKTA HPLC system (GE 
Healthcare UK Ltd, Buckinghamshire, UK) with a sepharose (GE Healthcare UK Ltd, 
Buckinghamshire, UK) packed column (Generon, Maidenhead, UK).  
All the HPLC fluid lines were washed with filtered 20% ethanol followed by PBS (pH 7.5) 
through line A and 50mM of Glycine (pH 2.7) through line B. After which the Sepharose column 
was attached and equilibrated with PBS using a flow rate of 1mL/min. The prepared AAV 
supernatant and cell lysates were then run through the Sepharose column. After this, PBS was 
run through the column to remove the unbound protein and DNA. To elute the viral particles 
from the column, 50mM of Glycine (pH 2.7) was run through Line B. The elution fractions were 
collected in 1mL FACS tubes with 30µl of 1M Tris (pH 8.8) to neutralise the glycine. The 
fractions containing virus were identified by the peaks in absorbance at 260nm and 280nm. 
The viral fractions were then collated and injected into a 10KDa dialysis cassette. This was left 
spinning overnight in PBS to neutralise the acidic pH.  
2.1.9.3.  AAV concentration 
Amicon Centrifugal 100KDa filter was initially primed with 5ml PBS. This was centrifuged for 5 
minutes at 3000g at 4°C. The PBS was discarded and the collected AAV virus was added to the 
filter and again centrifuged for 5 minutes at 3000g at 4°C. The concentrated virus in the Amicon 
ultra membrane was removed and placed in a 1.5mL micro-centrifuge tube. The membrane 
was washed with 200µl of PBS to collect further virus remaining on the filter. The concentrated 
virus was sterilised using a 1.5mL micro-centrifuge tube with a 0.22µm filter. The virus was 





2.1.9.4.  AAV batch validation 
A coomassie gel was performed to detect the three structural viral capsids: VP1, VP2 and VP3. 
A NuPAGE pre-cast gel was placed into a gel tank with MOPS buffer. 20μL of concentrated virus 
was mixed with 20μL of Laemlli loading buffer and heated for 5 minutes at 95°C. This was 
loaded onto the gel with a 5μL prestained protein ladder. The gel was run at 125 volts for 
approximately 30 minutes. The gel was placed into the Coomassie blue dye, protected with 
aluminium foil and shaken on a platform shaker for 2 hours. The Coomassie dye was removed 
and destain solution was placed on the gel for a further 2 hours on a platform shaker. The gel 
was visualised using white light (Bench top UV trans-illuminator, UVP BioDoc-It2 Imaging 
system, Cambridge, UK) to detect the three structural proteins. 
2.1.9.5.  Denaturing alkaline gel electrophoresis to titre viral DNA  
The alkaline electrophoresis buffer, power pack and electrophoresis gel tank were placed into 
the fridge to cool them down to 4°C. The alkaline gel was prepared with 0.8g agarose and 98ml 
ddH20. Once cooled below 50 °C, 2ml 50x alkaline electrophoresis buffer was added and the 
gel was left to set in a gel tray. 25μl of concentrated AAV, as well as serial dilutions in PBS, were 
then added to 8.5 μl of alkaline sample loading buffer. The samples were cooled down on ice 
and loaded onto the gel, alongside a 5µl Hyperladder. The gel was then run at 20 volts 
overnight at 4°C. The following day, the gel was placed into 0.1M Tris and shaken for 1 hour 
on a platform shaker. It was transferred into 4x Gelred in 0.1M sodium chloride and was shaken 
for 2 hours covered in aluminium foil. The gel was rinsed briefly in ddH20 and the image 
captured using a UV transilluminator. The gel image was analysed in Image J, where the viral 





Injection of AAV and lentiviral vectors and bioluminescence imaging 
after intravenous and intracranial injections 
For intravenous injections, postpartum day 0 female neonates were intravenously injected 
with 10μl of 1x1012 viral vector genomic copies/ml. For neonatal intracranial injection, 
unilateral intracranial injections of 2.5 μl of 1x1012 viral vector were performed on postpartum 
day 0 neonates. For in utero fetal intracranial injections, a mid-line laparotomy was performed 
on pregnant mice at embryonic day 15.5 under isoflurane anaesthesia (procedures performed 
by Dr Simon Waddington). A subcutaneous injection of morphine (5mg/kg) and bupivacaine 
(2mg/kg) was given for analgesia. Uterine horns were exteriorized and kept moist with a sterile 
PBS swab. Intracranial injections of the fetuses were performed and then the uterine horns 
were replaced into the abdomen and the peritoneum and skin were sutured in two layers. 
Mice recovered in a heated chamber and were then singly housed with regular monitoring. 
For bioluminescent imaging mice were anesthetised with isoflurane and received an 
intraperitoneal injection of 10-300µl (volume dependent on the stage of development of mice) 
of 15mg/mL of D-luciferin. Mice were left for 5 minutes before they were imaged using the 
IVIS machine as mentioned previously (section 2.1.5.   
Protein extraction 
Extracted tissues were frozen in 100μl of lysis buffer (Reporter gene assay lysis buffer, Roche, 
Burgess Hill, UK). Samples were defrosted and homogenised with a hand-held homogenizer 
(Proscientific, Oxford, CT, USA). They were centrifuged for three minutes to separate cell debris 





Protein assays were performed using the Pierce BCA Protein Assay Kit (Thermo-Scientific, 
Glasgow, UK). Samples were loaded alongside BSA standards, described in the manufacturer’s 
protocol. The samples were loaded into a 96 well plate and 200µl of BCA protein assay reagent 
(1 part BCA reagent B to 50 part BCA reagent A) was added to each sample, including the 
standards. The plate was incubated at 37°C for 30 minutes and absorbance was then read at 
562nm using a FluoStar Omega microplate reader. Results were analysed in MARS data 
analysis data software. 
Cytokine ELISAs: IL1-β, IL-6 and TNF-α 
Samples were processed using the R&D systems ELISA kit according to manufacturer’s 
protocols. Samples and antibodies were diluted with reagent diluent (1% BSA in PBS, pH 7.4). 
For the IL-1β standards; the lower and upper limits of detection were 15.6pg/ml and 
1000pg/ml, respectively. For the Il-6 standards; For the TNF-α standards; 31.3pg/ml and 
2000pg/ml, respectively. The plate was read at absorbance 450nm using the FluoStar Omega 
microplate reader. Results were analysed in MARS data analysis data software.  
Inflammation and neutrophil influx immunohistochemistry and 
quantification 
2.1.14.1.  Tissue processing and sectioning of organs 
Mice were anaesthetised using isoflurane. Sacrifice perfusion was performed by incising the 
right atrium and injecting 10mL of sterile PBS into the left ventricle. Tissues were removed and 
stored in 4% PFA for 48 hours, then transferred to 30% sucrose at 4°C until microtome 




hours, followed by removal of the skull and a further 48 hours in fresh 4% PFA prior to transfer 
into 30% sucrose.  
The samples were frozen in blocks of embedding matrix OCT and then mounted onto the 
microtome platform (Thermo-fisher, Glasgow, UK). Transverse sections were cut at 10-40μm 
(depending on the organ) and stored in TBSAF at 4°C. 
For processing of embryos and placentas, tissues were removed and stored in 10% neutral-
buffered Formalin solution (Sigma-Aldrich, Dorset, UK) for 48 hours followed by storage at 4°C 
in 70% ethanol. Tissue was then paraffin-embedded and sectioned at 5μm. 
2.1.14.2.  Immunohistochemistry 
Representative sections of the organ were selected, mounted onto double-coated chrome 
gelatin Superfrost slides (VWR, Leicestershire, UK) and left to dry for two hours. The slides 
were placed in 4% PFA for 10 minutes followed by washing three times in TBS. They were 
treated with 30% H2O2 in 1xTBS, to block endogenous peroxidase activity, for 30 minutes at 
room temperatures. The slides were washed again and the edge painted with a DAKO pen to 
contain the antibody solutions. The slides were blocked with 15% serum (animal specificity 
dependent on the secondary antibody) in 0.1% TBS-T for 30 minutes at room temperature. 
This was followed by incubation in primary antibody (in 10% serum in 0.1% TBS-T) overnight 
at 4°C. The slides were washed again three times and secondary antibody in 10% serum in 0.1% 
TBS-T was added. This incubation period was for 2 hours at room temperature. Following this 
the slides were incubated for a further 2 hours in ABC Vectastain (Vector Labs, Peterborough, 
UK). Slides were transferred into DAB solution (0.05% 3.3’-diaminobenzidine (DAB) in TBS with 
30% H2O2 and left for 2 to 3 minutes. The reaction was stopped by transferring the slides to a 
cuvette containing ice-cold TBS. The slides were allowed to air dry and were dehydrated for 15 
minutes in 100% ethanol. The slides were then placed into Histoclear for 30 minutes, followed 




2.1.14.3.  Immunofluorescence staining 
A similar protocol was followed for immunofluorescence, sections were mounted onto double-
coated chrome-gelatin Superfrost slides (VWR, Leicestershire, UK) and then left to dry. 
Sections were fixed in 4% PFA for ten minutes followed by washing three times in TBS. The 
slides were blocked with 15% serum (animal specificity dependent on the secondary antibody) 
in 0.1% TBS-T for 30 minutes at room temperature. This was followed by incubation in primary 
antibody (in 10% serum in 0.1% TBS-T) overnight at 4°C. The slides were washed again three 
times and secondary antibody in 10% serum in 0.1% TBS-T was added. After the secondary 
antibody was incubated for 2 hours away from direct light, DAPI was prepared in TBS using a 
1:5000 concentration. The sections were incubated with DAPI for 2 to 3 minutes and then 
washed in TBS. The sections were allowed to dry away from direct sunlight and then cover-
slipped using Fluoromount-G. Sections were stored in 4°C. 
For paraffin embedded slides, slides were placed in Histoclear for 10 minutes and then 
rehydrated in 100% ethanol for 10 mins, 95% ethanol for 5 mins and 75% ethanol for 5 mins. 
Antigen retrieval was then performed by boiling the slides in citrate buffer for 20 minutes 
followed by washing in 1xTBS. The remaining steps then followed the above protocol from the 
blocking step. 
2.1.14.4.  Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labelling (TUNEL) assay 
Brain sections were selected and mounted on to double-coated gelatin-chrome Superfrost-
plus glass slides (VWR) and left to dry overnight. When dry, slides were placed in histology slide 
cuvettes and covered with 50 ml 4% PFA, left for 5 min, and washed with 0.1M PB. Methanol 
with 10% H2O2 was poured in the cuvettes and left for 15 minutes at room temperature. After 
this incubation, slides were transferred to clean cuvettes and covered in 0.1M PB. TUNEL 
staining solution was prepared on ice. Incubation was allowed for 2.5 hours at room 




This was followed by incubation in Vectastain ABC solution (1:1000 in 0.1M PB, Vector 
Laboratories) for 1 hour at room temperature. A 3,3'-diaminobenzidine Cobalt-Nickel solution 
was made and filtered with a 0.2 μm filtered aspirator and poured in designated cuvettes. 
Slides were washed three times in 10 mM PB and transferred to the DAB cuvettes, where 
reaction was timed and monitored under the microscope (for approximately 5 min). Slides 
were washed in 10 mM PB and left to dry overnight for subsequent coverslipping. The next 
day, sections were dehydrated for 5-10 min in absolute ethanol, cleared in a Histoclear for 10-
15 min and immediately coverslipped using DPX mounting medium. 
2.1.14.5.  Neutrophil influx quantification 
The uterine horn sections were visualised using a x5 objective lens and the epithelium and sub-
epithelial stromal areas were identified (Figure 2.4). 5 random fields of view were selected 
using a x40 objective lens. The numbers of neutrophils were counted per area. 5 sections were 
counted per mouse and the number of neutrophils counted per area averaged per mouse.  
2.1.14.6.  Intestinal villus height 
A random section of jejunum-ileum was selected per mouse using a x40 objective lens. Villus 
height was measured from the basal layer of the submucosa to the ending of the villus. 5 villi 
were counted in each section and the height was averaged per mouse.  
2.1.14.7.  ICAM-1 and CD-68 immunohistochemistry thresholding 
The uterine horn or brain sections were visualised using a x5 objective lens and the desired 
area was identified (Figure 2.4 & Figure 2.5). 5 random fields of view were selected using a x40 












Figure 2.5: P6 left hemisphere of the brain on a coronal section with specific brain regions 
identified. A=Cortex, B=Hippocampus, C=Thalamus, D=Striatum 
 
 
Figure 2.4: Anatomical diagram of the murine uterus and a transverse section of the uterine 




Inflammatory cytokine mRNA expression 
2.1.15.1.  Tissue collection 
Pregnant mice were sacrificed by cervical dislocation 18 hours after intravaginal E.coli infection 
(see section 2.1.1, 2.1.2 and 2.1.4). Uterus, placenta and fetal membranes were collected and 
stored in RNAlater (Sigma Aldrich, Dorset, UK) at -80°c for quantitative PCR (qPCR) analysis.  
2.1.15.2.  RNA extraction 
Total RNA was extracted from the uterus, fetal membranes, and placental tissue, using the 
RNeasy mini kit (Qiagen, Crawley, UK) as per the manufacturer's guidelines. Tissue was initially 
homogenized in RNA lysis buffer using a sterile needle and syringe. RNA was then quantiﬁed 
using the FluoStar Omega LVis reader followed by storage at -80°C. 
2.1.15.3.  cDNA synthesis 
10µl of RNA was reverse transcribed with the High Capacity cDNA Reverse Transcription kit 
(Applied Biosystems, Life Technologies Ltd., Paisley, UK). 10µl RNA was added to a 96 well 
microplate with 10µl RT mastermix in each well (Table 2.1). The plate was sealed, centrifuged 
brieﬂy to eliminate air bubbles and then transferred to the thermal cycler on ice (Table 2.2). 






Reverse Transcription Mastermix x1 Amount per 20 µl 
reaction (µl) 
10X RT buffer 2.0 
25X dNTP buffer 0.8 
10X random primers 2.0 
Multiscribe reverse transcriptase 1.0 
RNAse inhibitor 1.0 
Nuclease free H20 3.2 
Table 2.1: Reverse Transcription mastermix 
T°C 25 37 85 4 
Time (min) 10 120 5  
Table 2.2: Reverse transcription cycling conditions 
2.1.15.4.  Quantitative polymerase chain reaction (qPCR) 
Primer sets were obtained from Life Technologies based on validated primers (see appendix) 
(Edey et al. 2016). Quantitative PCR was performed in the presence of SYBR green using the 
KAPA biosystems SYBR® fast qPCR kit (Sigma Aldrich) (Table 2.3 and Table 2.4).  
qPCR Mastermix x1 Amount/µl 
2X RT KAPA Fast SYBR mastermix 10.0 
Forward primer (20µM) 0.4 
Reverse primer (20µM) 0.4 
Rox light 0.4 
Nuclease free H20 6.8 
cDNA 2.0 






T°C Time  Cycles 
95 3 min 1 
95 15 s  
60 20 s 40 
72 20 s*  
Table 2.4: qPCR cycling conditions. 
 *data acquisition from green channel 
Standard curve ampliﬁcations (for PCR reaction efﬁciency) were determined for each primer 












Figure 2.6: Example of standard curve amplification for GAPDH. 










Target gene expression was normalized for RNA loading by using GAPDH, and the expression 
in each sample was calculated relative to a calibrator sample, using the 2−ΔΔCt method of 
analysis. All qPCR analyses were performed on an Applied Biosystems Quant Studio 3 
instrument (Applied Biosystems, Life Technologies Ltd., Paisley, UK). 
 
Cervical epithelium transduction in vivo 
In vivo viral marker studies  
2.2.1.1.  Viral vectors 
The following vectors were obtained for in vivo experiments: 
Viral vector Company 
AAV2/6 CMV-GFP Vector Core, University of Pennsylvania, 
USA 
AAV2/8 CMV-GFP Vector Core, University of Pennsylvania, 
USA 
AAV2/6 CMV-Luciferase Vector Biolabs, Malvern, USA 
 
AAV2/8 CMV-Luciferase Vector Core, University of Pennsylvania, 
USA and Vector Biolabs, Malvern, USA 
Recombinant adenovirus CMV-Luciferase Vector Core, University of Pennsylvania, 
USA 





2.2.1.2.  Injection of viral vectors in vivo 
Adult (6-8 weeks old) female C57BL/6N-Tyrc-Brd mice were anaesthetised with isoflurane. 10μl 
of virus (diluted in PBS if necessary) to a concentration of 1x1012 genomic copies/mL was 
administered intravaginally using a 200μl sterile pipette tip. This was either applied in 
combination or plugged with 20μl of F127 thermosensitive pluronic gel or AK12 
thermosensitive pluronic gel. The pluronic gel was allowed to harden, which takes 
approximately 2 to 3 minutes before removing the mouse from the anaesthetic.  
Ex-vivo luminometry 
Tissue samples were lysed with 500µl of 1x Lysis buffer (Promega) followed by 
homogenisation. The homogenates were centrifuged for 10 minutes at 18000g and the 
supernatants collected. Each sample was loaded on to a white 96 well plate. 1.5mM of 
luciferase (Promega) was added at a 1:1 volume ratio to the sample. FluoStar Omega 
microplate reader (BMG labtech) was used to read the luminescence and the results were 
analysed using MARS data analysis data software (BMG labtech). 
Immunohistochemistry and Immunofluorescence 
Samples were prepared as described above in section 2.1.14.1, except that transverse sections 
of the vagina, cervix and uterus were obtained and cut at 40μm. The protocol used is described 
in section 2.1.14.2 and 2.1.14.3. Antibody dilutions detailed in Appendix 10.3.   
GFP ELISA 
Primary antibody (monoclonal anti-GFP antibody) was diluted 1:10000 in bicarbonate buffer. 
100μl was added to each well of a 96-well plate and incubated at 4°C overnight. The plate was 
washed 3 times. 300μl of block solution was added to each well and incubated at 37°C for 1 




was added to the wells in duplicate followed by incubation at 37°C for 1 hour. The plate was 
washed three times and then a biotin conjugated secondary antibody (polyclonal anti-GFP 
antibody) diluted 1:500 in block solution was added to each well. This was incubated for 1 hour 
at 37°C followed by 3 washes. Streptavidin-HRP diluted 1:20000 in block solution was added 
to each well and incubated at 37°C for 1 hour. The plate was washed 3 times and then TMB 
substrate solution was added and incubated for 10 minutes at room temperature away from 
direct light. A stop solution of 2.5M H2SO4 was added and the plate was read at an absorbance 
of 450nm using the FluoStar Omega microplate reader. The results were analysed in MARS 
data analysis data software.  
Designing and developing AMP viral vectors 
Designing a HBD-3 construct 
A bicistronic AAV plasmid was designed containing the human-beta defensin 3 transgene 
(defb103) and the enhanced GFP transgene under the control of separate CMV promoters 
(Figure 2.7). The plasmid was made by Vector Biolabs (Malvern, USA). See the appendix for the 
plasmid map (Appendix 10.5). 




Plasmid transient transfections  
1x105 cells were seeded per well in DMEM supplemented with 10% FCS and incubated 
overnight at 37°C and 5% CO2. A transfection mixture containing; 250µl of serum free OptiMEM 
media, 1µg of plasmid containing transgene and 1. 5µl of 40µM PEI per well was prepared. This 
was mixed and incubated for 20 minutes at room temperature. The media was removed from 
the cells and they were washed in serum free OptiMEM media. 250μl of transfection mix was 
added per well and left to incubate for 4 hours at 37°C and 5% CO2. After this incubation time, 
the transfection mix was removed and replaced with 500ml of DMEM supplemented with 10% 
FCS. The cells were incubated for 72 hours until protein extraction. 
Supernatant and cell lysate AMP extraction 
Supernatants and cell lysates were placed in 20% acetic acid overnight at 4°C. The following 
day the samples were centrifuged at 18000g for 10 minutes. The cell debris was discarded and 
the resulting supernatants placed into micro-centrifuge tubes. These samples were lyophilized 
overnight and the extracted protein was resuspended in 10mM acetic acid.  
AAV production 
The AAV 2/8 viral vector containing the HBD-3 and GFP transgenes was produced as described 
above (section 2.1.9.  ) and also made by Vector Biolabs (Malvern, UK). The AAV 2/6 viral vector 
containing the HBD-3 and GFP transgenes was made by Vector Biolabs (Malvern, UK). 
AMP protein detection and quantification 
2.3.5.1.  AMP western blotting 
The samples were added to 2.5µl of 4x SDS buffer, 2µl of Dithiothreitol (DTT) and the total 
volume made up to 12µl with dH20. The protein samples were heat shocked at 100°C for 5 




UK) was placed into a western blot tank containing MOPS buffer, where 10µl of the samples 
were loaded. 5µl of a Precision plus protein all blue ladder was also loaded. The gel was then 
run for 30 minutes at 300V. The gel was transferred on to a pre-prepared PVDF membrane 
(Trans-Blot turbo pack: BioRad, UK) and placed into a transfer chamber for 3 minutes. The 
membrane was incubated in a blocking buffer (5% milk powder in 0.01% PBS-T) for 1 hour. This 
was followed by 3 washes in PBS-T. The membrane was then incubated with primary antibody 
(anti-rabbit HBD-3: 1:1000 concentration) in 1% milk in PBST on a roller shaker overnight at 
4°C. The membrane was washed the following morning and then incubated with the secondary 
HRP-conjugated antibody in 1% milk in PBS-T for 1 hour on a roller shaker. After further 
washes, the membrane was added to Chemiluminescence solution for 3 minutes followed by 
visualisation on a BioRad ChemiDoc imager.  
2.3.5.2.  AMP ELISAs 
Samples were processed using the Peprotech HBD3 ELISA kit according to manufacturer’s 
protocol. Samples and antibodies were diluted with reagent diluent (1% BSA in PBS, pH 7.4). 
For the HBD-3 standards; the lower and upper limits of detection were 63pg/ml and 
4000pg/ml, respectively. The plate was read at an absorbance of 405nm using the FluoStar 
Omega microplate reader. The results were analysed in MARS data analysis data software.  
AMP functional killing assays 
E.coli K12 was grown to mid-logarithmic phase and diluted to 1x105 CFU/ml. The bacteria were 
centrifuged at 14000g for 3 minutes. The pellet was washed once in 10mM PB followed by 
further centrifugation and then re-suspended in 10mM phosphate buffer. In a 96 well plate, 
90μl of the resuspended bacteria was mixed with 10μl recombinant HBD-3 protein, prepared 
supernatant, extracted cell lysate samples or vaginal lavage. The plate was incubated for 30 




Serial dilutions were then plated and placed at 37°C overnight. CFU were counted the following 
morning. 
In vitro killing assays were performed by inoculating transfected cell media with 100μl of 1x105 
CFU/ml E.coli-K12 at 72 hours after plasmid transfection. This was placed at 37°C and 5% CO2 
for 2 hours. Bioluminescence was determined prior to inoculation and then at 2 hours after 
inoculation using the FluoStar Omega microplate reader. The results were analysed in MARS 
data analysis data software. The fold change in bioluminescence was used as a measure of 
bacterial viability. 
Microbiome studies using next generation sequencing 
Culture-independent profiling of bacterial communities relies on the amplification and 
sequencing of the universal prokaryotic 16S ribosomal RNA (rRNA) gene. The rRNA gene is 
1500bp long and contains nine hypervariable regions interspersed between conserved regions 
(Figure 2.8). This study uses the V3-V4 hypervariable region for sequencing. Next generation 
sequencing can generate 1x107 sequences from a single sample and so allow for an extensive 
description of microbial DNA. It involves amplification of a PCR library with barcoded primers, 
followed by clean up and normalisation steps and then subsequent sequencing on a MiSeq™ 
(Illumina, Cambridge, UK). After sequencing, downstream bioinformatics is necessary to 
demultiplex samples, cluster sequences to operational taxonomic units (OTUs), quality filter 
and analyse data. The Quantitative Insights into Microbial Ecology (QIIME) software platform 




Figure 2.8: 16S rRNA gene with 9 hypervariable regions interspersed between conserved 
regions (blue). 
Vaginal lavage 
Vaginal lavage samples were obtained by administering 100µl of sterile PBS into the vagina of 
the mouse and pipetting in and out 10 times. Samples were put into a sterile Eppendorf and 
snap frozen in dry ice, followed by storage in -80°C. 
DNA extraction of vaginal lavage samples 
DNA extraction was performed using a QIAmp DNA mini kit (Qiagen, Manchester, UK) 
according to manufacturer’s guidelines. Pipettes and AE buffer were placed under the UV light 
for 20 minutes prior to extraction in the dedicated microbiome extraction area. 20µl of 
proteinase K followed by 100µl sample was added to a lysis matrix B tube (MP biomedicals, 
Santa Ana, US). 200µl of AL-buffer was added and mixed by vortexing for 15 seconds. The 
samples were incubated at 56°C for 10 minutes. Bead beating at 50 oscillations for 1 minute 
was then performed using a Tissue-Lyser LT (Qiagen, Manchester, UK). Samples were 
centrifuged at 6600g for 1 minute and then 200µl of 70% ethanol was added followed by 
mixing by inversion. The contents are then applied to the column provided in the kit and 
centrifuged at 6600g for 1 minute. The column was placed in a new collection tube and 500µl 
of AW1 buffer was added followed by centrifuging at 6600g for 1 minute. The column was 
subsequently placed in a new collection tube and 500 µl of AW2 buffer was added followed by 
centrifuging at 6600g for 3 minutes. The column was next placed into a sterile Eppendorf and 




quantified using the Qubit DNA high sensitivity assay kit and Qubit 2.0 machine (Thermo Fisher 
Scientific, UK), followed by freezing at -80°C. 
Broad range 16S rRNA gene qPCR  
Broad range 16S rRNA gene qPCR was performed to confirm gene expression and to determine 
DNA inhibition. The qPCR mastermix was prepared using POWER SYBR® Green master mix 
(Applied Biosystems, Cheshire, UK) (Table 2.5). Primers are detailed in 10.4.  DNA samples were 
run as neat, 1/10 and 1/100 dilution to check for DNA inhibition. qPCR was performed on a 
Biorad CFX96 Touch™ Real-Time PCR Detection System (Biorad, Watford, UK) with the 
following cycling conditions (Table 2.6). 
qPCR Mastermix x1 Amount per 20 µl 
reaction (µl) 
POWER SYBR Green Master Mix 12.5 
Forward primer (0.7pmol/µl) 0.9 
Reverse primer (0.24pmol/µl) 0.3 
Nuclease free H20 9.3 
Cdna 2.0 
Table 2.5: 16S rRNA gene qPCR mastermix 
 
T°C Time  Cycles 
95 10 min 1 
95 15 s  
60 30 s* 45 
Table 2.6: 16S rRNA gene qPCR cycling conditions. 




Next generation sequencing  
2.4.4.1.  V3-V4 16s rRNA gene amplicon PCR 
The mastermix without the DNA template and primers was made up and 42.5µl was added to 
each well of a 96-well plate (Table 2.7). Barcoded forward and reverse primers were added 
(see 10.4.  ), making sure to change tips between wells. DNA template was added before briefly 
spinning the plate and running in the PCR machine (Biorad T100 Thermal cycler) (Table 2.8). 
Amplicon PCR Mastermix x1 Amount per 50 µl 
reaction (µl) 
10x PCR buffer 5.0 
Forward primer (0.5µM) with barcode 
attached-different for every samples 
1.25 
Reverse primer (0.5µM) with barcode 
attached-different for every sample 
1.25 
dNTP mix 1 
Taq DNA polymerase 0.25 
Nuclease free H20 36.25 
Cdna 5.0 
Table 2.7: Amplicon PCR mastermix 
T°C Time  Cycles 
95 3 min 1 
95 30 s  
50 30 s 30 
72 30 s  
72 10 min 1 




2.4.4.2.  PCR clean-up 
35µl of AMPure beads (Beckman Coulter, High Wycombe, UK) was added to each well 
containing PCR products. Once mixed, this was incubated for 5 minutes at room temperature. 
The plate was then placed onto a magnetic stand (Beckman Coulter, High Wycombe, UK) for 2 
minutes or until the supernatant becomes clear. The supernatant is removed and then the 
beads were washed twice in 200µl of 80% ethanol. The plate was then removed from the 
magnetic stand and 50µl of AE buffer was added to each well and mixed. After a 2-minute 
incubation period, the plate was then placed back onto the magnetic stand for 2 minutes or 
until the supernatant becomes clear. The supernatant with the PCR clean product was 
removed and transferred to a new 96 well plate and was stored for 1 week at -20°C. 
2.4.4.3.  Next generation sequencing  
The DNA from the above step was quantified using a Qubit DNA high sensitivity assay kit and 
Qubit 2.0 machine (Thermo Fisher Scientific, UK). The DNA concentration in each well was 
normalised to the lowest concentration sample. The DNA was then pooled including negative 
DNA extraction controls. This library was diluted to 0.4nM after quantification using the Qubit 
2.0, standard curve qPCR and an Agilent high sensitivity DNA kit with the Agilent 2200 
Tapestation instrument (Agilent genomics, Santa Clara, US) (Figure 2.9). The library was 
subsequently loaded onto the MiSeq™ sequencer (Illumina, Cambridge, UK) as per 
manufacturer’s guidelines using the 500 cycle V2 MiSeq™ reagent kit (Illumina) with the 





Figure 2.9: DNA quantification using the Agilent Tapestation method. The 571 peak represents 
the bacterial DNA library using the V3-V4 barcoded primers.  
Cervical AMP gene therapy in ascending vaginal infection and preterm birth 
models 
Adult female mice (6-8 weeks) C57BL/6N-Tyrc-Brd were mated overnight with stud males. The 
day a copulatory plug was observed was designated embryonic Day 0.5. Intravaginal AMP gene 
therapy (1x1012 genomic copies/ml) was injected on embryonic day 13.5 using a sterile 200µl 
pipette followed by application of AK12 pluronic gel (Polyvivo, US). 72 hours later, intravaginal 
injection of bioluminescent E.coli was performed, followed by daily bioluminescence imaging 
(Figure 2.10). Following injections, mice were placed in individual cages and continuously 
monitored with individual closed circuit television cameras and a digital video recorder. Time 
to delivery was recorded and defined as the number of hours from the time of injection to 










Data are expressed as means ± standard deviation. Data were checked for normality using the 
Shapiro-Wilk normality test. Data that was normally distributed was analysed with unpaired t-
tests, one-way ANOVA and two-way repeated measure ANOVA with Bonferroni post hoc tests. 
Non-parametric data was analysed with Mann-Whitney rank tests and Kruskal-Wallis tests with 
Dunn’s post hoc tests. All statistical analyses were performed with GraphPad Prism software 
version 7.0 (GraphPad, San Diego, CA). P < 0.05 was considered statistically significant. Next 
generation sequencing data was kindly analysed by Dr Grace Logan using QIIME software.  
Figure 2.10: Schematic representation of AMP gene therapy experiments. Vector is 
administered on E13.5, followed by intravaginal bacterial administration 72 hours later on 




Chapter 3 Developing a mouse model of 
ascending vaginal infection and preterm 
birth 
Summary  
Mouse models of disease in pregnancy are important research tools as mice are relatively 
inexpensive, have short gestation periods (19-21 days) and there is considerable homology 
between the human and mouse genomes and gene function. As ascending vaginal infection is 
believed to be an important factor in many cases of spontaneous preterm birth, it is imperative 
to create a mouse model capable of mimicking this infection. This type of model would enable 
testing of a cervically-targeted therapy for preterm birth prevention. It is also important that 
we consider the principles of the 3Rs (replacement, reduction and refinement) as a framework 
when developing these mouse models. With this in mind, I tested the hypothesis that with an 
appropriate mode of administration, choice of bacteria and mouse strain, a repeatable model 
of bacterial ascending vaginal infection could be established in pregnant mice.  
In this chapter I describe the development of an ascending infection model system using 
bioluminescent E.coli (K12 and K1 strain) in non-pregnant and more relevantly pregnant mice, 
that enabled the tracking of bacterial ascent without the need to sacrifice animals at multiple 
time points. E.coli K12 is a non-pathogenic laboratory strain of E.coli that is commonly used in 
molecular biology and is not known to cause disease. E.coli K1, on the other hand, is a 
pathogenic stain which is known to cause neonatal sepsis and meningitis in humans (Simonsen 




E.coli K1 resulted in premature delivery in approximately 60% of dams within 48 hours of 
administration. These model systems enabled the interrogation of the mechanisms leading to 
premature delivery as well as providing a useful model to test preventative therapies for 
preterm birth. 
Bioluminescent E.coli strains K12 and K1 show constitutive expression of the 
lux operon 
E.coli K12 and K1 bacteria were diluted in LB broth (plus appropriate antibiotic) and grown at 
37°C and 200rpm. Strains were assessed for absorbance (OD600) and bioluminescence at 30-
minute intervals. Both E.coli K12 and K1 produce a bioluminescent signal over the growth cycle 
























Figure 3.1: Characterization of E.coli K12 and E.coli K1 growth. (A) Growth of E.coli k12 and 
E.coli K1 in LB broth at 37°C and 200rpm, over time. There is an increase in OD600 absorbance 
over time. (B) Bioluminescent signal from E.coli K12 and E.coli K1 during the growth cycle. 
Bioluminescent signal correlates with the growth phase (as determined by absorbance), 






































Bioluminescent E.coli strains K12 and K1 are motile 
Bioluminescent E.coli (K12 and K1) was assessed for normal motility patterns using specialised 
motility media (SIM media) to confirm its potential for ascension into the uterine cavity. After 
24 hours incubation at 37°C, there was a diffuse spread in bacteria from the central inoculation 
in the motility agar medium, confirming that this strain of bacteria is motile (Figure 3.2). 
 
 
Figure 3.2: E.coli K1 and K12 are motile. Bacterial bioluminescence at inoculation (left) and 
24h after inoculation (right). There is bacterial growth and movement to the outer edges of 









The C57BL/6N-Tyrc-Brd mouse strain is best for modelling ascending vaginal 
infection 
Initial experiments were performed using bioluminescent E.coli K12 in CD1 outbred mice. 
Bacterial luminescence could only be detected transiently in CD1 mice which had received 









Figure 3.3: CD1 mice do not show ascending infection 24 hours after E.coli K12 vaginal 
administration. These are representative images at the time of E.coli K12 intravaginal 
administration and after 24 hours in CD1 mice. There was no obvious E.coli K12 




Other studies which assessed bacterial infection in the vagina and cervix used the C57BL/6 
strain of mouse (Gupta et al. 2014). Therefore, ascending vaginal infection with E.coli K12 was 
compared with three different mouse strains (CD-1, BALB/c and C57BL/6) and a spontaneous 
albino mutant of the C57BL/6 strain (C57BL/6N-Tyrc-Brd) (Figure 3.4). The C57BL/6N-Tyrc-Brd 
strain was identified as a potential candidate because as it has been reported that there is at 
least a 10-fold quenching of bioluminescent signal from mice with black fur (Campbell et al. 
2014). There was significantly increased bacterial infection seen in C57BL/6N-Tyrc-Brd mice 
compared to CD-1 mice at the 6, 18 and 24 hour time points (P=0.0049, P=0.0024 and 
P=0.0007, respectively) and compared to BALB/c mice at the 18 and 24 hour time points 
(P=0.0063 and P=0.0002, respectively) (Figure 3.4C). This trend was also seen in the C57BL/6 
mice but was only significant at 24 hours (compared with CD-1 mice; P=0.0011, and compared 












Figure 3.4: The C57BL/6N-Tyrc-Brd mouse strain is best for modelling ascending vaginal 
infection. (A) Representative images of E.coli K12 infection 24 hours after administration, 
showing increased bioluminescent signal in C57BL/6N-Tyrc-Brd mice. (B) E.coli K12 
bioluminescence over time in different mouse strains. (C) E.coli K12 bioluminescence at 
different time points. There is increased bioluminescent signal in the C57BL/6N-Tyrc-Brd mice at 
all time points. n=3, data log10 transformed and analysed with a two-way repeated measures 
ANOVA with post hoc Bonferroni test,*P<0.05, **P<0.01, ***P˂0.001, ****P˂0.0001 




































































































Bacteria ascend into the non-pregnant uterine cavity 
Non-pregnant mice were culled and their reproductive tracts were imaged at 6, 18, 24 and 48 
hours after receiving intravaginal injection of E.coli K12 (Figure 3.5). Bacteria were detected in 
the upper vagina and cervix at 6 hours, ascending the uterine horns at 18 to 24 hours and 
diminished by 48 hours. 
 
  
Figure 3.5: Bacteria traverse the cervical barrier of the non-pregnant uterus by 6 hours and 
then ascend to the top of the uterine horns by 24 hours. Representative images of the time 
course of ascending bacterial infection in the non-pregnant reproductive tract following 




Local inflammatory studies in non-pregnant mice 
In the majority of spontaneous preterm birth cases, there is no obvious overwhelming 
infection in the mother and it is only during retrospective pathological examination of the 
placenta and fetal membranes that we see evidence of chorioamnionitis and funisitis (Wu et 
al. 2009). There is now strong evidence that the initiation of labour, term and preterm, is 
associated with an increased production of pro-inflammatory cytokines and an influx of 
neutrophils and macrophages in the cervix, uterus and fetal membranes (Rinaldi et al. 2014). 
Therefore, I hypothesised that these inflammatory markers would be elevated in the uterus of 
the mice after ascending bacterial infection. 
Pro-inflammatory cytokines are not increased in the uterus of infected 
mice 
The pro-inflammatory cytokine profile of the cervix and uterus was characterized by 
quantifying TNF-α and IL-1β cytokines. These cytokines are typically produced in response to 
bacterial infection. There was a non-significant increase in uterine IL-1β and TNF-α in the 





















Figure 3.6: There is a non-significant increase in TNF-α and IL-1β in uterine homogenates 24 
hours after intravaginal E.coli K12 administration. (A) Uterine IL-1β protein expression 24 hour 
after intravaginal E.coli K12 infection. (B) Uterine TNF-α expression 24 hour after intravaginal 
E.coli K12 infection. n=15, E.coli K12-infected; n=10, PBS controls; data not normally distributed
therefore analysed with a one-tailed Mann-Whitney rank test, P=0.16. 
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There is an influx of neutrophils into the uterine horns of infected mice 
To determine whether intravaginal E.coli-K12 infection resulted in neutrophil influx into the 
uterine tissues, anti-Ly-6g immunohistochemistry was performed on uterine horn samples 
collected 24 hours after intravaginal infection (Figure 3.7A). There was a significant increase in 
neutrophil influx in the E.coli K12 infected uterine horns, compared to the control horns 























Figure 3.7: There is an increase in neutrophils in the sub-epithelial stroma of the uterine 
horns 24 hours following intravaginal E.coli K12. (A) Representative images of neutrophil 
localization using immunohistochemical staining of Ly-6g with haematoxylin counterstain. 
Brown coloration depicts DAB-positive cells. (B) There is an increase in sub-epithelial stroma 
neutrophil counts in the E.coli K12-infected group compared with uninfected controls. n=3; 
unpaired t-test, **P˂0.005.   























ICAM-1 Immunohistochemistry is upregulated in the uterine horns of 
infected mice 
ICAM-1 is a cell surface glycoprotein that is a ligand for the leucocyte adhesion protein-1. It is 
present at low concentrations on leucocytes and endothelial cells and facilitates the migration 
of leucocytes from the blood into tissues. Pro-inflammatory cytokines, such as IL-1β and TNF-
α greatly increase the concentration of these proteins to allow for increased migration of these 
cells into infected and inflamed tissues. I hypothesised that intravaginal E.coli-K12 would 
increase ICAM-1 expression in the uterus 24 hours after administration. ICAM-1 
immunohistochemistry was performed on uterine tissue 24 hours after intravaginal E.coli K12 
administration and showed ICAM-1 upregulation compared with uninfected PBS controls 














Figure 3.8 ICAM-1 is upregulated in the uterine horns 24 hours following intravaginal E.coli 
K12. (A) Representative images of neutrophil localization using immunohistochemical staining 
of ICAM-1. Brown coloration depicts DAB-positive cells. (B) There is increased ICAM-1 
upregulation in the uterine horns 24 hours after intravaginal administration E.coli K12. n=3; 
unpaired t-test, ****P˂0.0001.  
A 
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Ascending vaginal bacterial infection is possible in pregnant mice using 
bioluminescent E.coli K12 
To mimic the type of infection that is believed to occur in cases of spontaneous preterm birth, 
intravaginal infection with bioluminescent E.coli K12 was performed in pregnant mice. Mice 
received E.coli K12 on embryonic day 16.5 as described above (Figure 3.9). Embryonic day 16.5 
was initially chosen as the day of bacterial administration based on previously published work 
(Rinaldi et al. 2014; Rinaldi et al. 2015; Edey et al. 2016). Pregnant mice were visualised at the 
time of injection and then at 6 hours after injection, followed by daily imaging. Bacteria were 
seen in the upper vagina after administration as would be expected (Figure 3.10A). 6 hours 
after bacterial administration, bacteria were seen in the left uterine horn. This is followed by 
bacteria being present throughout the uterine cavity at 24 and 48 hours after bacterial 
administration (Figure 3.10A). After delivery (P0) the bacteria begin to clear until they are not 
visible at 96 hours after bacterial administration. The pups were born with no evidence of 





Figure 3.9: Mice were injected with bioluminescent E.coli K12 on E16.5 using a sterile pipette 
(20µl of 1x109 CFU) and bacterial movement was then assessed by daily in vivo 
bioluminescence imaging. Mice were also filmed using a continuous closed-circuit television 













Figure 3.10: E.coli K12 ascends into the pregnant uterine cavity over 24 hours but does not 
infect pups. (A) Pregnant mice were administered intravaginal E.coli K12 on embryonic day 16.5. 
At 0h (the time of injection) bacteria are visible in the vagina. By 6 hours after injection bacteria 
is seen ascending into the uterine cavity. At 24 hours, embryonic day 17.5, the bacteria is visible 
in both uterine horns and this bacterial load increases by 48 hours, embryonic day 18.5. The 
following day, the pups were born and there is now minimal bacteria seen in the uterus or 
vagina (P0). On postpartum day 1 (P1) the bacteria have been cleared. * indicates the day of 
birth (P0) 24 hours later; on embryonic day 17.5, bacteria have ascended into the uterine horns.
Bacteria clears by the second postpartum day. (B) There is no E.coli K12 present in pups born to 




Pregnant mice intravaginally infected with E.coli K12 do not deliver 
prematurely or have reduced litter sizes 
An ideal model of ascending vaginal bacterial infection in pregnant mice would also result in 
premature delivery. Therefore, delivery timings were determined in infected pregnant mice 
compared with controls injected with PBS. There was no difference in time to delivery between 
these two groups (P=0.35) (Figure 3.11A). To explore this ascending infection model further, 
intravaginal administration of E.coli K12 was performed at different gestational ages; 
embryonic day 14.5 and embryonic day 15.5. There was no obvious difference in bacterial 
ascent into the uterine cavity with bioluminescence imaging. In support of this, there was no 
difference in time to delivery between these administration gestations and PBS controls 
(P=0.39 and P=0.19, respectively) (Figure 3.11B & Figure 3.11C). In view of this, the E16.5 time 
point was used for bacterial administration in subsequent experiments. The litter size was 
determined in E.coli K12 infected dams compared to PBS controls. There was no difference in 














                                        
 
Figure 3.11: Pregnant mice intravaginally infected with E.coli K12 do not deliver prematurely 
or have reduced litter sizes. (A) Delivery time after intravaginal E.coli K12 infection at 
embryonic day 16.5. n=5; data log transformed, unpaired t-test, P=0.35. (B) Delivery time after 
intravaginal E.coli K12 infection at embryonic day 15.5. n=3, infected group; n=5, uninfected 
control group; data log transformed, unpaired t-test, P=0.19. (C) Delivery time after 
intravaginal E.coli K12 infection at embryonic day 14.5. n=5; data log transformed, unpaired t-
test, P=0.39. (D) The litter size between E.coli K12 infected dams and uninfected control dams, 


































































E.coli is detected in the placenta from pups of E.coli K12 infected dams 
Embryos were removed from the dam 48 hours after E.coli K12 intravaginal administration. 
The embryos were imaged with their membranes, placenta and cord intact. Bacteria was 
detected in the placenta but not in the embryo (Figure 3.12). E.coli immunofluorescence 
staining revealed E.coli bacterial presence on the maternal and fetal sides of the placenta, as 






Figure 3.12: E.coli is detected in the placenta of pups from E.coli K12 infected dams. 










Figure 3.13: E.coli is detected in the placenta of pups from E.coli K12 infected dams. 
Representative images of anti-E.coli immunofluorescence staining of E.coli K12 infected 
placentas and uninfected controls (10x magnification). E.coli is present on the maternal and 
fetal sides of the placenta and at the placental origin of the umbilical cord. E.coli - green 







Pathogenic bioluminescent E.coli K1 ascends into the pregnant uterine 
cavity and causes preterm birth 
As E.coli K12 did not induce preterm delivery in pregnant mice, the effects of a more 
pathogenic strain of E.coli, E.coli K1, were examined. E.coli K1 is responsible for causing 
neonatal meningitis and sepsis in humans and is dependent on vertical transmission from the 
mother (Ba-Thein et al. 2002; Witcomb et al. 2015). Bioluminescent E.coli K1 was intravaginally 
administered into pregnant mice on embryonic day 16.5 as described above (Figure 3.9). 
Different bacterial counts were administered to determine the effect on bacterial ascent and 
time to delivery (2x102 and 2x103). Intravaginal administration of E.coli K1 lead to ascending 
infection in the uterine cavity by 24 hours after injection (Figure 3.14A & Figure 3.14B). The 
higher bacterial count lead to increased bacteria in the uterine cavity, however, these dams 
had much higher rates of systemic infection post-partum requiring the animal to be culled 
(4/10 with 2x103CFU versus 2/10 with 2x102CFU, n=10 dams). Therefore, 2x102 CFU of E.coli K1 
was used for intravaginal administration in subsequent experiments. Intravaginal E.coli K1 
(lower dose; 2x102CFU) resulted in premature delivery compared with PBS controls (time to 
delivery; 49 hours ± 9.9 hours vs. 66 hours ± 6.3 hours, P=0.0007) (Figure 3.14C). Furthermore, 
there was a reduction in the proportion of pups born alive in the E.coli K1 infected group 



















































Figure 3.14: E.coli K1 ascends into the pregnant uterine cavity over 24 hours and leads to 
preterm birth and a reduced proportion of pups born alive. Representative images of E.coli K1 
ascending into the uterine cavity of pregnant mice. (A) 2x102 CFU (low dose) of E.coli K1. (B) 
2x103 (high dose) CFU OF E.coli K1. The higher bacterial count (2x103) leads to increased bacterial 
bioluminescence in the uterine cavity but increased rates of postpartum systemic infection. (C) 
E.coli K1 infected dams (lower dose; 2x102 CFU) deliver earlier than PBS controls. Time to 
delivery after bacterial administration; 49 hours ± 9.9 hours in E.coli K1 dams vs. 66 hours ± 6.3 
hours in PBS controls. n=8, data log transformed, unpaired t test, *** P=0.0007. (D) E.coli K1 
infected dams (lower dose; 2x102 CFU) have a lower proportion of pups born alive. The 
proportion of pups born alive are 0.64 ± 0.4 in E.coli K1 infected dams versus 0.98 ± 0.05 in PBS 





E.coli K1 was detected in the placenta, fetal membranes and amniotic fluid 
18 hours after bacterial administration 
Dams were sacrificed 18 hours after intravaginal administration of E.coli K1, the intact uterine 
horns were imaged ex vivo and bacteria were detected within the uterine cavity (Figure 3.15A). 
On closer inspection, bacteria were detected in the placenta, membranes and amniotic fluid 
surrounding the fetus (Figure 3.15C). The placenta and fetal membranes were highly 
bioluminescent, whilst the amniotic fluid appeared less bioluminescent suggesting that the 
bacteria may infect the placenta and membranes first and then traverse the membranes to 
reach the amniotic fluid (Figure 3.15B).  
E.coli was detected on both sides of the placenta and appeared to be present in the giant cell 
layer on the maternal side and the chorionic plate on the fetal side (Figure 3.16). It appeared 
that the bacteria were invading from both sides of the placenta as they are clearly present on 


















































Figure 3.15 : E.coli K1 was detected in the placenta, fetal membranes and amniotic fluid 18 
hours after bacterial administration. (A) Representative ex-vivo image of the uterus 18 hours 
after intravaginal E.coli K1 administration. (B) Ex vivo bacterial bioluminescent signal from the 
fetal membranes, placenta and amniotic fluid 18 hours after intravaginal E.coli K1. The placenta 
and fetal membranes are highly bioluminescent, whilst the amniotic fluid is less bioluminescent. 
n=15 from >3 dams. (C) Representative image of a fetus within its sac and separated into 
membrane, placenta and fetus 18 hours after infection. Bacteria is detected in the placenta, 






Bacteria is detected in the fetus by 24 hours after administration 
Dams were sacrificed 24 hours after intravaginal administration of E.coli K1, the fetuses were 
imaged. Bacteria was detected within the fetus by this time point (Figure 3.17). Bacteria 






Figure 3.17: Bacteria is detected in the fetus 24 hours after intravaginal administration of 
E.coli K1. Representative image of a fetus 24 hours after maternal intravaginal E.coli K1.  
 Figure 3.16: E.coli is detected on both side of the placenta following E.coli K1 administration.
Representative image of E.coli immunofluorescence of an E.coli K1 infected placenta. (A) H&E 
stained placenta showing the different placental regions. (B) Anti-E.coli antibody 









Figure 3.18: E.coli is present in the respiratory and gastrointestinal tract of the infected fetus 
24 hours after intravaginal administration of E.coli K1 to the pregnant dam. (A) 
Representative images of anti-E.coli immunohistochemistry of the lung and small intestine of 
E.coli K1 infected fetuses and uninfected controls (10x magnification). Brown 
discoloration/arrows depicts DAB positive cells. (B) Representative images of anti-E.coli 





Bacteria is seen in the small intestine and lungs on whole fetus anti-E.coli 
immunohistochemistry (Figure 3.18A). Bacteria is specifically seen throughout the 
gastrointestinal and respiratory tracts using immunofluorescence staining (Figure 3.18B). 
 
Intravaginal administration of E.coli K1 and E.coli K12 leads to an 
upregulation of inflammatory cytokine mRNA expression in the uteroplacental 
tissues 
mRNA expression of inflammatory cytokines of the uteroplacental tissues (uterine 
myometrium, fetal membranes and placenta) were determined in the pregnant mice 18 hours 
following intravaginal administration of E.coli K1, E.coli K12 or PBS (Figure 3.19). 
There was significant upregulation of Il1b, Cxcl2 and Cxcr2 expression in the E.coli K1 uteri 
compared with uninfected PBS controls (P˂0.0001, P˂0.0001 and P=0.0003 respectively). 
There was also upregulation of Il1b and Cxcl2 in the E.coli K12 uteri compared with uninfected 
PBS controls (P=0.0007 and P=0.004) (Figure 3.19A).  
There was upregulation of Il1b and Cxcl2 expression in E.coli K1 fetal membranes compared 
with uninfected PBS controls (P˂0.0001 and P=0.014, respectively). There were no significant 
differences in inflammatory cytokine mRNA expression between the E.coli K12 fetal 
membranes and the uninfected PBS controls (Figure 3.19B).  
In the placenta, there was upregulation of Il1b, Il6 and Cxcl1 expression in the E.coli K1 
placentas compared with uninfected PBS controls (P˂0.0001, P=0.02 and P=0.0006 
respectively). There was an upregulation of Tnfa, Il6 and Cxcl1 expression in the E.coli K12 
placentas compared with uninfected PBS controls (P=0.03, P=0.02 and P=0.0079 respectively 






















































































Figure 3.19: Uterine, fetal membrane and placental inflammatory cytokines are 
upregulated after intravaginal administration of E.coli K1 and E.coli K12. (A) Uterine 
inflammatory cytokine relative mRNA expression. n=3. (B) Fetal membrane 
inflammatory cytokine relative mRNA expression. n=8, E.coli K1 group; n=6, E.coli K12 
and PBS uninfected group. (C) Placental inflammatory cytokine relative mRNA 
expression. n=8, E.coli K1 group; n=6, E.coli K12 and PBS uninfected group (from > 3 
dams). Data are shown as relative mRNA expression to GAPDH (2-ΔCT), data not 
normally distributed therefore log transformed prior to analysis with a two-way 
ANOVA and post-hoc Bonferroni test, *P˂0.05, **P˂0.005, *** P˂0.001, 
****P˂0.0001.  
  










































To interrogate the mechanisms behind preterm parturition following intravaginal E.coli K1, I 
determined the fold change differences of inflammatory cytokine expression between this 
group and the E.coli K12 group (which does not lead to premature delivery) (Figure 3.20). Cxcl1 
and Cxcl2 expression was significantly increased in E.coli K1 uteri compared with E.coli K12 
uteri (Cxcl1 32.8 fold, P=0.0024 and Cxcl2 16.3 fold, P=0.0174). There was an increase in CXCR-
2 expression but this is not significant (Cxcr2 9.6 fold, P=0.06). Looking at the fetal membranes 
and placental tissues, there was a significant increase in Il1b (fetal membranes 16.5 fold, 
P=0.0011 and placenta 13.9 fold, P=0.0013). 
 
 Uterine tissues Fetal membranes Placental tissues 
Il1b 2.2 16.5** 13.9** 
Tnfa 2.3 -2.2 -2.6 
Il6 3.6 -2.5 2 
Cxcl1 32.8** -1.9 -1.39 
Cxcl2 16.4* 2.4 1.26 
Cxcr2 9.6 -5.6 1.11 
 
Figure 3.20: Fold change in inflammatory cytokine mRNA expression of E.coli K1 tissues 
compared with E.coli K12 tissues. Data shown as fold change in mRNA expression (2-ΔΔCT), 





Increased neutrophil influx into the uterus 18 hours after intravaginal E.coli 
K1 
Neutrophils were localised within the uterine decidua 18 hours after administration of E.coli 
K1, E.coli K12 or PBS (Figure 3.21). There appeared to be increased numbers of neutrophils in 
the E.coli K1 infected uteri, although neutrophil counts were not quantified. 
 
 
Figure 3.21: There is increased neutrophil influx into the uterus 18 hours after intravaginal 
E.coli K1. Representative images of neutrophil localization in the uterine decidua 18 hours after 
intravaginal administration of E.coli K1, E.coli K12 or PBS uninfected controls (x10 
magnification). Anti-ly6G immunohistochemistry with haematoxylin counterstain, brown 
coloration depicts DAB positive cells. 





This chapter describes the development of an ascending vaginal infection and preterm birth 
model in the pregnant mouse.  
An ascending infection model of preterm birth  
Preterm birth mouse models are invaluable in understanding the mechanisms behind 
inflammation, bacterial infection and preterm birth and in investigating novel therapeutic 
approaches for the prevention of preterm birth. Successful preterm birth mouse models using 
local delivery of bacteria, bacterial products or inflammatory mediators have been developed 
(Table 3.1). These models have provided insight into the pathogenesis of preterm birth, for 
example, by discovering the important role of activator terminator-1 protein in mediating 
infection-related preterm birth (MacIntyre et al. 2014). These models have also recapitulated 
the process of ascending vaginal infection (Akgul et al. 2014; Racicot et al. 2013; Vornhagen et 
al. 2016). The models developed here complement the existing models and add to knowledge 
in the field. This model is less invasive than laparotomy models and also allows for cervical 
targeted therapies to be studied. The use of bioluminescent pathogens confers several 
advantages to this model; the ability to track pathogens longitudinally within the same cohort 
of mice, the ability to improve our understanding of how pathogens infiltrate the uterine cavity 
and the ability to use bioluminescence imaging to test response to novel therapies by tracking 
bacterial colonization and ascent. This model also supports two of the 3Rs of animal research, 
reduction and refinement; reducing the number of animals needed and the minimally-invasive 






The mouse strain, C57BL/6N-Tyrc-Brd, is best for modelling ascending vaginal infection using 
bioluminescent E.coli 
The C57BL/6N-Tyrc-Brd (albino form of BL6) mouse strain was found to be the most efficient and 
reproducible strain for modelling ascending infection determined by in vivo bioluminescence 
(Figure 3.4). The C57BL/6 strain is often used in mice models of infection, including other 
models of ascending vaginal infection in the literature, because it has been found to have 
increased susceptibility to bacterial infection (Backstrom et al. 1992; Campbell et al. 2014) 
(Table 3.1). It is thought that the strain possesses a mild immunosuppressed phenotype as a 
result of a deficiency of cathepsin E, which has a role in antigen processing in immune cells and 
in the regulation of toll-like receptor expression (Tulone et al. 2007; Tsukuba et al. 2006).  
Cervical viral infection is not required for bacteria to ascend into the uterine cavity 
Other studies show that the pregnant murine cervix requires priming with viral infection to 
allow for bacterial ascent of U.urealyticum into the uterine cavity (Racicot et al. 2013). 
Interestingly, they found that this was not the case in the non-pregnant cervix, which allowed 
free movement of E.coli into the uterine horns without viral priming. They showed that cervical 
viral infection during pregnancy decreased the amount of TLRs, cytokines and antimicrobial 
peptides in the cervix and essentially reduces the antimicrobial capacity of the mucus plug 
allowing bacteria to breach the cervical barrier. Here we show that viral priming is not required 
for ascending vaginal infection with E.coli in pregnant mice (of note, mice were tested for 
murine parvovirus and found to be negative). This is consistent with data reporting the use of 
intravaginal E.coli 0:55 in pregnant mice to induce preterm birth (Akgul, et al. 2014). In the 
model described here, I applied quinine powder topically to the vagina after bacterial 
administration to prevent mice from cleaning the administered bacteria (as quinine is an 
aversive tastant to mice (Boughter et al. 2005). Interestingly, quinolone antimalarials (the 




3) and toll-like receptor 9 (TLR-9) signalling (Kužnik et al. 2011; Cui et al. 2013). TLR-9 
recognises CpG dinucleotides, common in bacterial and some viral nucleic acids and has a role 
in activating antigen-presenting dendritic cells thus, linking the innate and acquired immune 
responses (Wagner 2002). Whilst TLR-3 recognises dsRNA, a common product of viral 
replication, and so has an important role in host defence against viruses (Sen & Sarkar 2005). 
TLR-3 and TLR-9 have been found to be expressed in cervical mucosal epithelial cells and have 
a role in regulating  proinflammatory cytokines and antiviral immune responses in the lower 
reproductive tract (Andersen et al. 2006). Racicot et al., showed decreased expression of TLRs 
in the cervix, including TLR-3 and TLR-9, following systemic murine herpes infection and this 
contributed to the reduced antimicrobial capacity of the cervix allowing ascending bacterial 
infection to occur (Racicot et al. 2013). Therefore, it is possible that the use of quinine in this 
model is acting in a similar way. However, in contrast to Racicot et al., in this study there 
appears to be much less variation in bacterial colonization and ascent in pregnant mice 
compared with non-pregnant mice, although a direct comparison was not performed. I 
speculate that the mechanism is likely to be more simple, such as vaginal anatomical variation 
between pregnant and non-pregnant mice, as I found bacterial application into the posterior 
fornix of a pregnant mouse vagina much easier. 
Non-pathogenic E.coli K12 versus pathogenic E.coli K1 ascending infection 
Intravaginal administration of E.coli K12 does not induce premature parturition (Figure 3.11). 
The bioluminescent E.coli K12 used in this study is the common molecular biology strain 
MG1655. It is integrated with the luxABCDE operon from the plasmid p16Slux; a single copy of 
the lux operon is present in the 16s rDNA site in the chromosome of the E.coli (Cronin et al. 
2012). This site-specific integration means that there is no interference in the behaviour of the 
bacteria. The mature LPS of this E.coli K12 strain is known to lack the O antigen as a result of 




pathogenic by making it less resistant to hostile environments and less likely to colonize hosts 
and cause disease (Browning et al. 2013). Therefore, it is not surprising that it does not induce 
the inflammatory response necessary to induce premature delivery in pregnant mice. In 
support of this, there is evidence that different virulent E.coli LPS serotypes used to induce 
preterm birth in pregnant mice elicit differing TLR-4 mediated inflammatory responses which 
result in varying premature delivery timings (Migale et al. 2015).  
In this model, E.coli K12 is only detected on placental tissue in vivo (Figure 3.12). This is 
interesting as this bioluminescent strain was originally developed for tumour research using 
the bacteria’s ability to naturally home to tumours following systemic administration (Cronin 
et al. 2016; Cronin et al. 2012; Murphy et al. 2017). It is thought that the tumour-specific nature 
of bacterial growth is due to tumours having regions of hypoxia, increased vascularity, local 
immune suppression and growth factor, such as VEGF, availability. Placentas share many of 
the same properties as tumours so it is unsurprising that E.coli K12 are attracted to this organ 
in vivo. The bacteria do not appear to invade the placental tissue and are seen as clusters on 
the outer edges of maternal decidual side and fetal side of the placenta. This is consistent with 
the non-invasive nature of this strain and is also seen in tumours where the injected bacteria 
grow in the stromal region of the tumour external to the tumour cells (Cronin et al. 2012).  
The K1 strain of E.coli is the leading cause of neonatal sepsis and meningitis (Bonacorsi & 
Bingen 2005). This study uses the E.coli 018:K1 A192PP strain with the luxCDABE transposon 
integrated by mini-Tn5 mutagenesis (Witcomb et al. 2015). Intravaginal administration of this 
bacteria leads to premature delivery in approximately 50% of pregnant mice within 48 hours 
(Figure 3.14). This is consistent with data produced from other PTB models using intravaginal 
live bacteria administration; E.coli 055:B5 - 50% of dams deliver within 48 hours (Akgul, et al. 
2014), GBS – 25-50% of dams deliver within 72 hours (Vornhagen et al. 2016; Randis et al. 





The movement of bacteria into the uterine cavity following vaginal ascent 
There is conflicting evidence as to where vaginal pathogens ascend to once they have breached 
the cervical barrier; some believe bacteria invade the chorioamniotic and choriodecidual 
spaces prior to entering the amniotic cavity, whilst others believe that bacteria traverse the 
fetal membranes through a restricted supracervical region and directly enter the amniotic 
cavity first (Grigsby et al. 2010; Goldenberg et al. 2000). Clinical data supporting direct amniotic 
cavity invasion has shown that 16S rRNA gene copy number in the amnion was significantly 
greater than in the chorion (Kim et al. 2009). In addition to this, in some women with 
chorioamnionitis there was bacteria identified in the amniotic cavity but not in the 
chorioamniotic membranes. However, more recent evidence has shown that in a quarter of 
women with preterm chorioamnionitis there was no evidence of intra-amniotic bacterial 
invasion or inflammation (Oh et al. 2017). The use of bioluminescent E.coli in these models 
enabled me to longitudinally track the bacterial movement over time. E.coli K1 was initially 
seen within the cervical canal by approximately 6 hours after intravaginal infection, followed 
by subsequent detection within the placenta and fetal membranes by 18 hours. Bacteria was 
also present in the amniotic fluid at this time but this has significantly less bioluminescent 
signal than in the placenta or membranes (Figure 3.15). Therefore, this indicates that the 
bacteria are likely to reach the choriodecidual space first where they replicate and then spread 
to the placenta and membranes eventually traversing the fetal membranes to colonize the 
amniotic cavity. This is further supported by the fact that bacteria are subsequently detected 
within the fetal respiratory and gastrointestinal tract 24 hours after vaginal administration by 
ingestion and inhalation from the amniotic fluid. It has been shown that this bacteria takes up 




movement of bacteria into the amniotic cavity occurring after choriodecidual invasion  
(Witcomb et al. 2015) (Figure 3.17). 
Pro-inflammatory cytokine gene upregulation in uteroplacental tissues  
Intravaginal E.coli K1 leads to an upregulation of a number of inflammatory genes in the 
uteroplacental tissues that are commonly associated with preterm parturition (Goldenberg et 
al. 2000; Rinaldi et al. 2015; Edey et al. 2016; Migale et al. 2015) (Figure 3.19). Il1b appears to 
be an important mediator of preterm labour in all of the uteroplacental tissues infected by 
E.coli K1. This is supported by studies in which IL-1β has been used to induce premature 
delivery in mice, followed by subsequent inhibition of its receptor to prevent premature labour 
(Sadowsky et al. 2006; Nadeau-vallée et al. 2017). Furthermore, Il-1β has been shown to 
increase prostaglandin F2-α receptor mRNA expression, a gene involved in uterine contractility 
during labour, in myometrial cells (Zaragoza et al. 2006).   
Interestingly, the expression of the chemokines Cxcl1, Cxcl2 and the chemokine receptor Cxcr2 
are increased in the preterm E.coli K1 group compared with the non-preterm E.coli K12 group 
(Figure 3.20). This is consistent with data from preterm birth models where LPS is administered 
intrauterine (Rinaldi et al. 2014; Diamond et al. 2007; Pirianov et al. 2009). The expression of 
these chemokines CXCL-1 and CXCL-2, as well as CXCL-5 and CXCL-8 have been shown to be 
upregulated in the human myometrium during labour (Bollopragada et al. 2009; Hamilton et 
al. 2013). The CXC chemokines, via their interaction with the neutrophil expressed CXCR-1 and 
CXCR-2 receptors, mediate the extravasation of neutrophils into the myometrium. This data is 
supported by the large neutrophil influx seen in the decidua of E.coli K1 dams 24 hours after 
administration of intravaginal bacteria (Figure 3.17). Neutrophil influx into gestational tissue 
has been associated with term and preterm labour (Osman et al. 2003; Shynlova et al. 2013). 
This is supported by a study in which administration of a broad-spectrum chemokine inhibitor 




upregulation of IL-1β, IL-6, IL-12, CXCL-1 and CXCL-2 (Shynlova et al. 2014). Recent data, 
however, has shown that depletion of neutrophils in preterm birth mouse models has no effect 
on premature parturition (Rinaldi et al. 2014; Filipovich et al. 2015). Interestingly, it was found 
that neutrophil-depleted mice delivered earlier than controls following intrauterine LPS, 
suggesting that neutrophil influx may be involved in ameliorating the inflammatory response 
and thus have a positive effect on inflammation-associated preterm birth. Of note, these 
studies used LPS or killed E.coli as the infectious agent and so the inflammatory response 
leading to premature parturition associated with live E.coli, as in this model, may be different. 
Furthermore, in this study uteroplacental tissue sampling was performed at 18 hours after 
E.coli injection, consistent with previous intrauterine LPS studies, but this model takes longer 
to cause premature delivery (approximately 12-24 hours). This may explain why other pro-
inflammatory cytokines known to be upregulated in LPS-induced PTB, such as IL-6 and TNF-α, 
are not found to be upregulated in this study.  
Cervical inflammation and remodelling in this model  
An interesting model of preterm birth which utilises intravaginal administration LPS has been 
developed (Gonzalez. et al. 2014; Gonzalez et al. 2011). It appears to rely on inflammatory 
changes at the cervical level which lead to subsequent cervical remodelling as a mechanism 
for premature delivery. Complement activation and macrophage infiltration was found to have 
a role in cervical remodelling (Gonzalez et al. 2011). Although the cervix was not specifically 
assessed in this study, (data in Results Chapter 6; Figure 6.8 shows no evidence of cervical 
neutrophil or macrophage infiltration in E.coli K12 mice) it may be interesting to determine the 
effects of E.coli K1 ascending vaginal infection on cervical remodelling in further studies.  
Conclusion 
In conclusion I show that bioluminescent E.coli can be used to model ascending vaginal 




the mechanisms behind preterm parturition as well as providing a novel means of testing 







Table 3.1: Mouse models of infection and inflammation associated preterm birth.  Models with systemic routes of infectious agent administration are not included. 
Embryonic day has been modified for comparison (E0.5 describes the day the vaginal plug is observed). 
Route of 
administration 









Intrauterine  Reliably causes 
premature delivery 
 Useful for testing 
systemic or uterine 
treatment 
 Useful for assessing 
mechanisms of labour 
and preterm labour 
LPS (E.coli 
O111:B4) 
20µg CD-1 Laparotomy; 









Edey et al. 
2016; Rinaldi 
et al. 2014) 
LPS (E.coli 
O55:B5) 
250µg CD-1 Laparotomy; 










IL-1β  1µg CD-1 Laparotomy; 






vallée et al. 
2017; 
Nadeau-
Vallée et al. 
2015) 





injection in the 
midsection of the 
right uterine horn 
between 2 
gestational sacs 




















20µg C57Bl/6 Direct injection 
into intra- uterine 




E16.5  Ultrasound 
guided – less 
invasive  
 As reliable in 
causing PTB as 
laparotomy 
model 







20µg CD-1 Laparotomy; 











(Migale et al. 
2015) 
Intracervical  Mimics microbial 
breaching of the 
cervical barrier 





E13.5  (Reznikov et 
al. 1999) 
Intravaginal  Mimics what is 
thought to occur in 
human preterm birth 
 Less reliable inducer 
of PTB  (Rinaldi et al. 
2015) 
 Enables vaginal or 
cervical-targeted 
treatment to be 
assessed 
U.urealyticum 104 CFU C57BL/6 Intravaginal 
administration 







 Gestation at 
delivery not 
assessed – may 



























108 CFU C57BL/6 Intravaginal 
administration, 
followed by 
inversion of mice 
for 5 minutes 
E15.5  (Vornhagen 




250µg C57BL/6 Intravaginal 
administration 











  Group B 
streptococcus 
106 CFU C57BL/6 Intravaginal 
administration 
mixed with 10% 
gelatin  
E13.5  All dams culled 
on E17.5  
 PTB outcome: 
delivery prior to 
E17.5 





Chapter 4 Neonatal effects following 
maternal ascending vaginal infection 
Summary  
Preterm birth is associated with serious morbidity in the premature infants. These include 
neurological impairment such as cerebral palsy, learning difficulties, respiratory disease and 
gastrointestinal complications (Goldenberg et al. 2008; Back 2017). These infants are also at 
increased risk of chronic disease later in life such as obesity, diabetes and schizophrenia (Meyer 
et al. 2011; Rubens et al. 2014).  
As discussed earlier, preterm birth is associated with inflammation and infection in at least 40% 
of cases (Goldenberg et al. 2000). The presence of an inflammatory in utero environment can 
lead to fetal inflammatory response syndrome (FIRS) resulting in subsequent fetal injury. 
Bacteria or inflammatory mediators are thought to reach the fetus either indirectly through 
placental transmission or directly through the amniotic fluid (Adams Waldorf & McAdams 2013).  
This chapter explores the outcomes of neonates born to dams following intravaginal 
administration of the non-pathogenic E.coli K12 and the pathogenic E.coli K1. I hypothesise that 
pups from E.coli K1 infected dams will show evidence of brain and intestinal inflammation, 
representing models of preterm brain injury and necrotising enterocolitis. 
Interestingly I found evidence of brain inflammation and cell death in pups born from E.coli K1 




Half of all the pups born alive from dams infected with E.coli K1 survive the first 
week of birth 
64% of pups are born alive from E.coli K1 infected dams (Figure 31D). Of these surviving pups, 
48.6% survive to 7 days of life, compared with 100% of pups from E.coli K12 infected dams and 
uninfected dams (Figure 4.1A). There is no bacterial bioluminescent signal detected in pups from 
E.coli K12 infected dams (Figure 4.1B).  The pups from E.coli K1, however, have evidence of E.coli 
K1 colonisation in utero within 24-48 hours after bacterial administration (Figure 3.17). After 
birth, bacterial bioluminescent signal from the E.coli K1 pups decreases over the first week of 
life (Figure 4.1C and Figure 4.1D). This is consistent with reduced bacterial colonisation and 
infection over time due to the death of infected pups. By 14 days of life, the pups that have 






















































































Figure 4.1: Half of all the pups born alive from dams infected with E.coli K1 survive the first 
week of birth. (A) Survival of neonates from E.coli K1 and E.coli K12 infected dams.  Of the pups 
born alive, approximately 48.6% survived to postnatal day 6 compared with 100% of pups in the 
E.coli K12 group and the uninfected control group. n=25-35 pups from n=6 dams; log rank test 
****P˂0.0001. (B) Representative images of E.coli K12 pups on the day of birth (P0). There is no 
bioluminescent E.coli K12 detected in pups born to E.coli K12 infected dams. (C) Representative 
images of bacterial bioluminescence in E.coli K1 postnatal day 1 pups (top row) and 
subsequently on postnatal day 6 (bottom row). (D) Bacterial colonization of neonates from E.coli 
K1 infected dams. Bacteria was detected in the pups at birth and bacterial bioluminescence 
levels reduced slowly over the first week. n=4-7 pups from 2 infected dams; pup numbers 
decrease over 7 days.   
 
Pathogenic E.coli K1 
Pro-inflammatory cytokines increase in the brain of neonates from E.coli K1 
infected dams 
Brains were harvested on the day of birth from E.coli K1 infected pups and uninfected controls 
for cytokine protein analysis. There was a significant increase in IL-1β, IL-6 and TNF-α in the 
brains of E.coli K1 infected pups compared with uninfected controls (P=0.0004, P=0.03 and 



























































Figure 4.2: Inflammatory cytokines are increased in the brains of neonates born to E.coli K1 
infected dams and uninfected dams. Brains were collected on the day of birth. Brain cytokine 
expression from neonates born to E.coli K1 infected dams and uninfected dams: (A) IL-1β. (B)
TNF-α. (C) IL-6. n=5 in the E.coli K1 group, n=9 in the uninfected group, from >3 dams, unpaired 
t-test, data not normally distributed for TNF-α cytokine results therefore analysed with Mann 




There is evidence of brain inflammation in the brain of 7 day old pups from 
E.coli K1 infected dams 
Brains were harvested from postnatal day 6 pups from E.coli K1 infected dams and uninfected 
controls for TUNEL assay and CD68 immunohistochemistry (to assess microglial activation). 
There was evidence of apoptosis in the cortex, thalamus and striatum of E.coli K1 infected pups 
(P˂0.0001, P=0.0043 and P˂0.0001 respectively) (Figure 4.3A). Furthermore, there was 
increased microglial activation in the cortex of E.coli K1 infected pups compared to controls 
(P=0.0013) (Figure 4.3B & Figure 4.3C). 
 




















































Figure 4.3: There is evidence of brain inflammation in pups born to E.coli K1 infected dams and 
uninfected dams. (A) Quantification of TUNEL positive cells in the cortex, thalamus and striatum 
in the neonates from E.coli K1 infected dams on postnatal day 6 compared with uninfected 
controls. n=3; two-way ANOVA (overall P value 0.01) with post hoc Bonferroni test, **P˂0.01, 
****P˂0.0001. (B) CD68 quantification in specific brain regions of pups born to E.coli K1 infected 
dams and uninfected dams. n=3 from 3 separate dams; two-way ANOVA (overall P value 0.07) 
with post hoc Bonferroni test, **P=0.005. (C) Representative images of CD68 












There was no difference in intestinal villus height between E.coli K1 infected 
pups and controls 
The small intestines were harvested from postnatal day 6 pups from E.coli K1 infected dams and 
uninfected controls to assess for villi shortening, associated with intestinal inflammation. There 
is no difference in villus height between the E.coli K1 and the uninfected group (P=0.4) (Figure 
4.4). 
  




















Figure 4.4: There is no difference in intestinal villus height between E.coli K1 infected and 
control pups. (A) Representative images of H&E stained small intestine (jejunum-ileum) on 
postnatal day 6 from E.coli K1 infected pups and uninfected pups (x5 magnification). (B) Villus 
height of E.coli K1 infected small intestine compared with uninfected controls. There is no 






Non-pathogenic E.coli K12 
Inflammatory cytokines are not increased in the brains of neonates born to 
E.coli K12 infected dams and uninfected dams. 
There was no difference in IL-1β and IL-6 in the brains of E.coli K12 infected pups compared with 
uninfected controls (P=0.4 and P=0.29 respectively), however there was a small increase in TNF-
















































































Figure 4.5: Inflammatory cytokines are not increased in the brains of neonates born to E.coli
K12 infected dams and uninfected dams. Brains were collected on the day of birth. (A) Brain 
IL-1β protein expression of neonates born to E.coli K12 infected dams and uninfected dams. (B)
Brain TNF-α protein expression of neonates born to E.coli K12 infected dams and uninfected 
dams. (C) Brain IL-6 protein expression of neonates born to E.coli K1 infected dams and 
uninfected dams. n=5 in the E.coli K1 group, n=9 in the uninfected group, from >3 dams, 
unpaired t-test, data not normally distributed for IL-1β and TNF-α cytokine results therefore 




There was evidence of brain inflammation in 7 day old pups from E.coli K12 
infected dams 
Brains were harvested from postnatal day 6 pups from E.coli K12 infected dams and uninfected 
controls for TUNEL assay and CD68 immunohistochemistry. There is evidence of apoptosis in the 
cortex, thalamus and striatum of E.coli K12 infected pups compared with uninfected controls 
(P˂0.0001 and P˂0.0001 respectively) (Figure 4.6A). There is increased microglial activation in 
the hippocampus and striatum of E.coli K12 infected pups compared to controls (P=0.02 and 










Figure 4.6: There is evidence of brain inflammation in 7 day old pups from E.coli K12 infected 
dams. (A) TUNEL quantification in specific brain regions of pups born to E.coli K12 infected dams 
and uninfected dams. n=3 from separate dams; two-way ANOVA (overall P=0.01) with post hoc 
Bonferroni test, ****P˂0.0001. (B) CD68 quantification in specific brain regions of pups born to 
E.coli K1 infected dams and uninfected dams. n=3 from separate dams; two-way ANOVA (overall 























































Preterm birth is the most common cause of infant mortality worldwide with at least 40% of 
preterm births being associated with inflammation. Moreover, chorioamnionitis is an 
independent risk factor for neonatal brain injury including neurodevelopmental impairment, 
such as cerebral palsy, and cognitive deficits (Lee et al. 2015). In this chapter, I show that these 
models may also be used to model and study brain inflammation and injury in pups as a result 
of intra-uterine inflammation and prematurity. Numerous mouse models of perinatal brain 
inflammation and injury have been developed (summarised in Table 4.1) and despite the 
differences between brain development in mice and humans, for example delayed myelination 
in rodents, they can offer insights into specific pathogenic mechanisms that lead to preterm 
brain injury (Semple et al. 2013). 
Pro-inflammatory cytokines in the brain 
The brains of E.coli K1 infected pups show increased pro-inflammatory cytokine levels; IL-1β, IL6 
and TNF-α at birth (Figure 4.2). This data is consistent with the brain inflammatory cytokine gene 
profile in a intrauterine LPS model of preterm birth (Burd et al. 2010). Brain IL-1β expression, in 
particular, was found to be significantly increased, similar to the data shown here. These pro-
inflammatory cytokines are implicated in fetal inflammatory response syndrome and in 
particular, their presence in the amniotic fluid clinically is associated with subsequent cerebral 
palsy and bronchopulmonary dysplasia (Yoon et al. 1997a; Yoon et al. 1997b).  
Intra-uterine inflammation, prematurity and brain injury 
Whilst some of the neurological complications observed in babies born preterm relate to 
immaturity, there is substantial evidence that perinatal exposure to infection and inflammation 
leads to damage to the developing brain (Paton et al. 2017; Elovitz et al. 2011; Migale et al. 2015; 




dams, that do not deliver preterm, show evidence of neuroinflammation (Figure 4.6). 
Interestingly, in clinical studies, placental inflammation alone has been found to be a predictor 
of brain injury (Leviton et al. 2010). In the E.coli K12 model, there is upregulation of mRNA 
expression of TNF-α, IL-6 and CXCL-1 in the placenta 18 hours after administration followed by 
a small increase in TNF-α levels in the brains of the delivered pups 48 hours later. Consistent 
with this, Elovitz et al. showed that intrauterine administration of LPS, at an insufficient dose to 
cause preterm birth, resulted in increased pro-inflammatory cytokine expression in the fetal 
brains as well as reduced neuronal arborization in primary neuronal culture of these brains 
(Elovitz et al. 2011).  
Placental inflammation and brain injury 
The TUNEL and microglial data from the E.coli K1 and E.coli K12 pups was surprising as I expected 
that E.coli K1 would have had increased inflammatory effects in the brain (i.e. increased 
microglial activation and apoptotic cells), however they both induced very similar effects (Figure 
4.3 & Figure 4.6). A possible explanation for this is that the more sick or the very preterm pups 
from E.coli K1 dams, that would have had more neuroinflammation, actually died or had to be 
culled prior to brain harvesting for these analyses and so we are seeing a cohort of “healthier” 
pups.  
If this is the case, it would suggest that the inflammatory effects seen with these brain analyses 
is caused by bacterial presence in the uterus, regardless of whether the bacteria are pathogenic, 
rather than direct systemic or CNS bacterial infection (as we know that E.coli K12 does not infect 
the pups, Figure 3.12). It is known that systemic inflammation can cause rapid derogatory effects 
on the central nervous system before any peripheral organ dysfunction and even in the absence 
of direct bacterial invasion (Helderman et al. 2010). Placental inflammation, as mentioned 
previously, is a strong predictor for subsequent brain injury (Leviton et al. 2010). Of interest, the 




placenta, it could predict subsequent neonatal brain lesions and long-term diparetic cerebral 
palsy (Leviton et al. 2010). How intrauterine inflammation leads to fetal brain injury 
inflammation is poorly understood but many animal studies have shown that, regardless of the 
type of pathogen used, inflammatory cytokines are likely to be the link between preterm birth 
and brain injury (Bell & Hallenbeck 2002; Bell et al. 2004; Nadeau-vallée et al. 2017).  The 
neurodevelopmental process can be affected by any imbalance in the expression of cytokines 
within the fetal brain (Meyer et al. 2009). It is believed that these cytokines can reach the fetus 
by transplacental passage leading to a fetal inflammatory response syndrome (FIRS). IL-6, a pro-
inflammatory cytokine expressed by leucocytes, is known to transfer freely across the placenta 
in an ex vivo human model and raised serum levels in the fetus is the hallmark of FIRS (Young et 
al. 2002; Zaretsky et al. 2004). Interestingly, placental gene expression of IL-6 was similarly raised 
in both the E.coli K1 and E.coli K12 groups in this study and may represent the link between 
intrauterine inflammation and brain inflammation that we see. 
As mentioned above, activated microglia are seen in the brains of both E.coli K1 and E.coli K12 
exposed pups. They show an increased trend of expression in all the four brain regions assessed; 
cortex, hippocampus, striatum and thalamus for both strains, although they are only 
significantly increased in the cortex of E.coli K1 pups and the hippocampus and striatum of E.coli 
K12 pups. The probable mechanism of brain injury is a combination of direct injury of 
oligodendrocytes and neurons from pro-inflammatory cytokines (either via transplacental 
passage or secondary from FIRS) and indirect injury as a result of microglial activation by pro-
inflammatory cytokines, for example, IL-1β has been shown to activate hippocampal microglia 
in rats ex vivo (Burd et al. 2012; Vogt et al. 2008; Hailer et al. 2005). Activated microglia confer 
injury by further release of pro-inflammatory cytokines and excitatory metabolites such as, 
glutamate, which can be cytotoxic or by the release of oxidative free radicals (Dommergues et 
al. 2003; Li et al. 2005; Vargas et al. 2005). In an intrauterine LPS rabbit model, microglial 




as well as a significant motor deficit phenotype (Saadani-Makki et al. 2008; Kannan et al. 2007). 
Microglial activation has been found to be associated with autism and may contribute to the 
high incidence of autistic spectrum disorder amongst premature children (Vargas et al. 2005; 
Zerrate et al. 2007; Lyall et al. 2017). 
There was evidence of cellular apoptosis in all regions of the brain assessed in E.coli K1 and E.coli 
K12 infected brains. This is supported by data in which increased apoptosis was seen in the 
cortex and periventricular regions of neonatal rats exposed to intracervical LPS in utero (Bell & 
Hallenbeck 2002). For future studies, it would be interesting to determine the cells which 
undergo apoptosis as there is evidence that TNF-α signalling may have a role in LPS-induced 
microglial toxicity to pre-oligodendrocytes in rat brains (Li et al. 2008; Kim et al. 2011). 
Intestinal colonization of E.coli K1 
E.coli K1 is known to cause neonatal sepsis and meningitis in humans. The particular strain 
utilised in this study is currently being used to study patterns of E.coli K1 colonization and 
invasion in neonatal rats (Witcomb et al. 2015). E.coli K1 has been shown to cause lethal 
systemic infection in neonatal rats by translocation from the GI tract lumen into the bloodstream 
(Dalgakiran et al. 2014). The susceptibility to E.coli K1 gastrointestinal colonization is age-
dependent with neonates infected at the early gestation P2 (rather than P9) being more 
susceptible (Witcomb et al. 2015). This is thought to be because of a poorly developed intestinal 
mucus barrier at this age and reduced α-defensin expression from Paneth cells (Birchenough et 
al. 2017; Birchenough et al. 2013). The data shown in the previous chapter complements this 
work, showing that gastrointestinal E.coli K1 colonization also occurs in the majority of fetal mice 
following maternal intravaginal infection and supports the concept that colonization and 
subsequent systemic infection occurs as a result of an immature mucus barrier (Figure 3.17).  
Necrotizing enterocolitis (NEC) is seen commonly in premature infants and although its aetiology 




hypoxia/ischaemia appear to play a role (Lin et al. 2008; Hunter et al. 2008). Villous atrophy is a 
common histological feature of NEC and is used to describe NEC in experimental models 
(Niinikoski et al. 2004; Yurttutan et al. 2014). Maternal administration of E.coli K1 did not induce 
villous atrophy in the pups in this chapter (Figure 4.4). As mentioned earlier, the cohort of pups 
that survived to one week of life may not have exhibited any intestinal disease as they were the 
“healthier pups” (that were possibly less infected with bacteria). Alternatively, prematurity and 
GI tract bacterial colonization may not be enough to induce villous atrophy or a NEC-like 
phenotype as other factors such as hypoxia/ischaemia may also need to be present. 
The work in this chapter has several limitations. We measured cytokine levels in the whole brain 
which may not reflect the cytokine environment of different parts of the brain. Furthermore, 
cytokines have very short half-lives and so analysis on the day of birth may not be an accurate 
representation of the inflammatory response. The sample sizes were small (pups from 3 
dams/group) for the one week analyses and this work did not take into account how premature 
the pups were in the E.coli K1 group. For future studies, I would like to assess the brain further 
by studying other regions including the external capsule, corpus callosum and the periventricular 
regions. These regions incorporate the white matter, which is commonly associated with the 
brain injury seen in premature babies, for example periventricular leukomalacia (Yoon et al. 
1996; Yoon et al. 2003). I would also like to perform more thorough analysis of neuropathology 
(using Nissl, TUNEL, myelin basic protein immunohistochemistry), neuroinflammation (using 
Iba-1/CD68, GFAP immunohistochemistry) and oligodendrocyte maturation (using Olig2 and O4 
immunohistochemistry). 
In conclusion, this chapter demonstrates that intrauterine inflammation, regardless of whether 
it induces preterm birth in mice, can induce acute inflammation in the brain and possibly lead 


















E9.5  Reduced hippocampal 
and cortical thickness 
 Cerebellar pathology 
 Deficits in behavioural 
tests; pre-pulse 
inhibition, acoustic reflex 
and social interaction 
(Shi et al. 




Intrauterine LPS E15.5  Reduced MAP2 and 
dendrites in primary 
cortical neuronal 
cultures 
 Increased brain cytokine 
mRNA expression 
 Hypomyelination 




Burd et al. 
2009; Burd 
et al. 2010; 
Leitner et 
al. 2014; 
Wang et al. 
2007) 
Intrauterine LPS E17.5  Reduced dendrites in 
primary cortical neuronal 
cultures 
 Microglial activation 
 Increased brain cytokine 
mRNA expression 
 Brain injury improved 
with mesenchymal stem 
cell treatment 
 
(Lei et al. 
2015) 
Intravenous Poly I:C E9.5 or 17.5  Deficits in behavioural 
tests; open field, 
perseverative behaviour 
 Grey matter injury 
(Meyer et 
al. 2006) 
Intrauterine IL-1β E16.5  Increased brain cytokine 
mRNA expression 
 Degeneration and 
atrophy of brain 
 Visual evoked potential 
abnormalities 
(Nadeau-





Chapter 5 Gene delivery to the murine cervix 
Summary 
The previous chapters describe the development of ascending models of vaginal infection and 
preterm birth. In this chapter, I move on to assessing if gene delivery to the murine cervix is a 
plausible therapeutic system that could be used to develop a topical therapy for preterm birth 
which may be tested on the models described in the previous chapters.   
Gene transfer can be achieved by viral and non-viral vectors. Viral vectors have been more 
successful up to now as gene delivery vectors and have been used in numerous clinical trials 
(Bainbridge et al. 2015b; Nathwani et al. 2012). The most common viral vectors used are derived 
from lentiviruses, adenoviruses and adeno-associated viruses (AAV). AAV vectors have, 
however, been used to transduce human vaginal and cervical epithelial cells in vitro and they 
have successfully been used to transduce the lower reproductive tract of the rhesus macaque 
(Abdel-Motal et al. 2011; Abdel-Motal et al. 2014). However, delivering genes to the cervical 
epithelium in mice has not been done before. 
This chapter tests the hypothesis that murine cervical epithelium can be transduced by topically 
applied viral vectors. The optimal gene delivery system is assessed using different viral vectors 
as well as examining administration methods to improve gene delivery to the cervical mucosa. 
In contrast to the human cervix, the entirety of the murine cervix comprises stratified squamous 
epithelium (Leppi 1964). Although little is known about the mouse cervix, we do know that one 
layer of the 28-layer human vaginal and ectocervical stratified squamous epithelium sheds every 
four hours (Anderson et al. 2014). Therefore, thermosensitive hydrogels were assessed as a 




I show that viral vectors can transduce murine cervical epithelium in vivo leading to transient 
cervical protein expression lasting for up to 14 days. Thermosensitive hydrogels were found to 





In vivo transduction of the vagina and cervix is possible using viral vectors 
Initial studies were carried out to determine if it was possible to transduce the upper vagina and 
cervix of the mouse by topical delivery of different viral vectors encoding a firefly luciferase 
marker gene driven by a CMV promoter. The three different viral vectors used were; AAV 8, 
adenovirus serotype 5 and VSV-g pseudotyped lentivirus (Figure 5.1A). This data showed that 
there was evidence that it was possible to transiently express the luciferase enzyme using all the 
viral vectors tested. However, expression was variable and appeared to diminish by one-week 







Figure 5.1: In vivo transduction of the vagina and cervix is possible using viral vectors; AAV, 
adenovirus and lentivirus. (A) Representative images of cervico-vaginal luciferase expression 
comparing the three different viral vectors at 72 hours after intravaginal application. (B) 






































Luciferase expression is restricted to the vagina and cervix 
In mice treated with recombinant adenovirus serotype 5 delivering the luciferase gene, ex-vivo 
luminometry was performed on the vagina, cervix, uterus and liver at 72 hours after 
administration to confirm localisation of expression and to assess for viral spread into the uterus 
or liver (Figure 5.2). Ex vivo bioluminescent signal from the vagina and cervix 72 hours after 
transduction show no obvious expression in the uterine cavity (Figure 5.2A). Using ex vivo 
luminometry there was significant luciferase expression in the upper vagina and cervix 























Figure 5.2: Luciferase expression is restricted to the vagina and cervix following transduction 
with Ad5 CMV-Luciferase.  (A) Representative images of bioluminescence from the vagina, cervix 
and uterus 72 hours after transduction with Ad5 CMV-Luciferase (the cervix and vagina are 
detached from the uterus at the level of the uterine body just above the cervical canal). (B) Ex-
vivo luminometry of luciferase expression in different organs 72 hours after intravaginal 
application of Ad5 CMV-Luciferase. n=3, data analysed with a two-way ANOVA with post-hoc 
bonferroni test ****P˂0.0001. 
B 




























AAV 6 and AAV 8 can transduce cervical epithelium in vitro and in vivo 
AAV, rather than adenovirus or lentivirus, was chosen for the ensuing studies due to its relatively 
low immunogenicity, episomal-nature, thermostability and success in numerous clinical trials 
(Mingozzi et al. 2014; Gruntman et al. 2015; Schnepp et al. 2003). The most efficient application 
method for cervical epithelium transduction was determined. Numerous AAV serotypes have 
been identified with different cellular tropisms (Zincarelli et al. 2008). The two AAV serotypes 
assessed in this study were AAV 6 and AAV 8; this was based on studies in which AAV 6 was 
found to be most efficient serotype for transduction of human vaginal and cervical cell lines in 
vitro (Abdel-Motal et al. 2011) whilst AAV 8 has been successful in numerous clinical trials for 
Haemophilia (Nathwani et al. 2014) and is, therefore, clinically validated.  
AAV 6 - and AAV 8- CMV luciferase vectors were used to transduce human endocervical cells 
(End1 E6/7) in vitro followed by luminometry 72 hours after transduction. There was a significant 
increase in transduction of AAV 6 at an MOI of 50, compared to AAV8 (P=0.02), however, other 








Figure 5.3: Luciferase expression in endocervical cells 72 hours after transduction with AAV 
























In vivo experiments were subsequently performed by intracervical application of AAV 6- and 
AAV 8- CMV GFP in a diestrus (MPA-treated) female mouse. Mice were subcutaneously injected 
with medroxyprogesterone-acetate (2.5mg) 7 days prior to injection to ensure all mice were in 
the diestrus stage of the estrous cycle. This was performed to reduce variation amongst the mice 
as AAV transduction has been shown to be effected by hormones (Davidoff et al. 2003). To 
confirm that mice were in the diestrus stage, I performed a smear prior to viral vector application 
(Figure 5.4A).  
 There was no significant difference in the cervical expression of GFP for AAV6 or AAV8 serotypes 
(p=0.35) (Figure 5.4B), although AAV6 showed a tendency for higher expression. Nevertheless 
AAV 8 was used for the remaining experiments in this study as cervical expression was more 
consistent with this serotype (AAV 8; mean 63.1 SD±31, AAV 6; mean 158.2 SD±245.6). From a 
clinical translation point of view, AAV 8 also has lower prevalence of neutralising antibodies in 



























Figure 5.4: There is no difference in the cervical GFP expression between the AAV6 and AAV8 
serotypes. (A) Murine diestrus vaginal smear; representative image of a H&E stained vaginal 
smear showing the predominant cells to be polymorphonuclear leucocytes with a few larger 
epithelial cells. (B) Cervical GFP expression with ELISA for comparison of AAV 6 and AAV 8 











Thermosensitive gels can improve protein expression 
The use of thermo-sensitive gels to improve the efficiency of gene transfer to the mouse cervix 
was determined in the following experiments.  
GFP expression appears increased when using AK12 pluronic gel 
Intravaginal application of an AAV 8 viral vector encoding GFP (driven by a CMV promoter) was 
used for the following experiments. GFP expression comparing the use of AK12 pluronic gel with 
virus alone was assessed initially by direct fluorescence imaging. There appear to be more GFP 
expression following application of virus mixed with an AK12 pluronic gel compared to virus 








Figure 5.5: GFP expression appears increased when the AAV8-GFP viral vector is 
administered with an AK12 pluronic gel compared with AAV8-GFP viral vector alone. Direct 
GFP fluorescence imaging comparing a mixture of viral vector and pluronic gel AK12 (top) with 




Pluronic gels appeared to increase cervical GFP expression when 
administered in a mixture with the viral vector 
Two different types of pluronic gel were tested; AK12 and F-127 pluronic gels. AK12 forms a gel 
at 20-25⁰C, whilst F-127 works at 37⁰C. GFP expression was compared following administration 
of AAV8-GFP combined with either of these two pluronic gels as well as a no gel control (Figure 
5.6). There was a trend showing an increase in GFP expression when the viral vector was 
administered in a mixture with a pluronic gel (F-127 or AK12) compared with no pluronic gel, 
although this was not significant (P=0.42). 
 




















Figure 5.6: GFP expression was increased when the viral vector was administered in a 
mixture with pluronic gels (either F127 or AK12) compared with no gel although this was 
not statistically significant. Cervical GFP expression 72 hours after application of AAV 8 CMV-
GFP; comparison between F-127 gel, AK12 gel and no gel. n=7 in the F-127 and AK12 groups, 
n=3 in the control group; data not normally distributed therefore analysed with a Kruskal-




Whilst carrying out the above experiments, GFP expression was found to be expressed along the 
whole length of the vaginal mucosa rather than, as would be ideal, targeting the epithelium of 
the upper vagina and cervix. Therefore, a plug method was developed in which viral vector was 
applied alone to the cervix and then the pluronic gel was used as a plug at the vaginal introitus 
so that the vector remained in place. I chose the AK12 gel for further experiments as its gelling 
temperature of 20-25°C means that it formed a gel much quicker than the F127 gel (which works 
best at 37°C) and it seemed more appropriate for a plug that would be exposed to the outside 
environment at the vaginal introitus. Using the AK12 gel in a plugging method, there was a 
significant increase in cervical GFP expression, compared to the original mix method (P=0.0195) 
(Figure 5.7). Furthermore, this method significantly increased cervical GFP expression compared 
with vector alone (P=0.0244) (Figure 5.7).   




















Figure 5.7: The AK12 AAV plug method significantly increased cervical GFP expression. 
Cervical GFP expression comparing AK12 pluronic gel plug, AK12 pluronic gel mix method 
and vector alone. n=4 in AK12 mix group, n=3 in AK12 plug and control group; data analysed 





Luciferase expression occurs after 24 hours in vivo and begins to diminish 
after 120 hours  
Based on the above data, AAV 8 containing a luciferase gene driven by a CMV promoter was 
intravaginally administered using the AK12 plug method to determine time course of expression. 
Bioluminescence was detected at the earliest time point of assessment, 24 hours after injection, 
with peak signal occurring between 72 and 96 hours (Figure 5.8). Bioluminescent signal starts to 
diminish 120 hours after viral application and returns to background levels by 14 days after 
injection. 
 
Figure 5.8: Luciferase expression from the lower reproductive tract occurs after 24 hours 
following vector administration and begins to diminish by 120 hours. Time course of luciferase 








































GFP is expressed in the vaginal and cervical epithelium 
GFP immunohistochemistry was performed to determine cellular location of GFP expression. 
GFP was detected in the epithelial cells, with most of the expression seen in the top epithelial 
cell layers (Figure 5.9). There appears to be some evidence of basal layer expression.  
 
Figure 5.9: GFP is expressed in the upper vaginal and cervical epithelium. Representative 
images of GFP immunohistochemistry of transverse sections of the cervical and upper vaginal 
epithelium 72 hours following; AAV 8-GFP (top) or PBS (bottom) administration. Brown 
colouration depicts DAB-positive cells. Black arrow depicts basal epithelial cell layer. VL=vaginal 









GFP immunofluorescence was performed to further assess expression. Using a cytokeratin 
antibody for co-localisation, GFP expression was only found in cytokeratin positive cells 




Figure 5.10: GFP co-localises with cytokeratin in the cervix, confirming that GFP expression is 
confined to the epithelial cell layers. Representative images of cytokeratin and GFP 
immunofluorescence staining of transverse sections of the cervical epithelium 72 hours 
following; AAV8-GFP (top) or PBS (bottom) administration. Red fluorescence represents 






This chapter explores the use of viral vectors to deliver genes to murine cervical epithelium in 
vivo.  I find that it is possible to transduce the cervix and upper vagina using different types of 
viral vectors (Figure 5.1). Although no experiment comparing the transduction efficiency, 
localisation of expression and time course of expression between the different viral vectors was 
performed, initial data using viral vector transfer of the luciferase transgene shows direct 
expression after intravaginal administration of the three main viral vectors; a lentivirus (VSV-g), 
an adenovirus (rAd5) and an AAV (serotype 8) using bioluminescent imaging. There was no 
evidence of local vector spread into the uterine cavity or systemic spread into the liver on ex 
vivo luminometry (Figure 5.2). AAV was chosen as the viral vector for the remaining experiments 
in this thesis because of its immunogenicity profile and track record in preclinical research and 
clinical trials.  
AAV serotypes and cervical gene delivery 
Thirteen naturally occurring AAV serotypes of human and simian origin have been described so 
far (Zinn & Vandenberghe 2014).  The multiple AAV serotypes are differentiated by their capsid 
proteins which appear to determine their cellular tropism (Zincarelli et al. 2008). The mechanism 
behind cellular tropism is still, however, poorly understood although it is becoming clear that 
AAV interaction with cell surface receptors is the first step to successful transduction.  The recent 
discovery of a multi-serotype AAV receptor using genome wide screening is beginning to shed 
light on these mechanisms (Pillay et al. 2016). They have shown that different serotypes have 
evolved distinctive interactions with the receptor, for example AAV 8 requires interaction with 
both PKD-1 (polycystic kidney domain) and PKD-2 domains of the receptor for successful 
transduction, which may help to confer tropism. Furthermore cell infectivity and transduction is 
believed to be dictated by the ability of the capsid protein to attach to cell surface glycans as 




the best characterised (Kern et al. 2003). Cellular tropism is thought to be mediated in part by 
the differential glycan receptor usage for cell surface attachment (Pillay & Carette 2017).  
AAV 6 has been found to have the best transduction efficiency in vitro in human endocervical 
and vaginal cells; in primary cells as well as in purchased cell lines (Abdel-Motal et al. 2011; 
Abdel-Motal et al. 2014). This was confirmed in my experiment comparing the luciferase 
expression from AAV 6 and AAV 8 transduced endocervical cells (Figure 5.3). Although luciferase 
expression from the AAV 8 transduced cells was much higher in my experiments than previously 
published, it was only significantly different from AAV 6 transduced cells at the highest MOI. In 
vivo, AAV 6 and AAV 8 transduction was comparable and importantly AAV8 transduction 
appeared less variable between mice (Figure 5.4). Apart from the use of AAV 6 in the rhesus 
macaque, there is no published animal data looking at other AAV serotypes in vaginal or cervical 
gene transfer in vivo. In the mouse, research describing viral vector gene transfer to other organs 
with stratified squamous epithelium, such as the cornea, has been published (Hippert et al. 
2012). The cornea consists of an anterior stratified squamous epithelial cell layer, then a thick 
collagenous stromal centre with an endothelial cuboidal monolayer base. Interestingly after 
intrastromal injections of numerous AAV vectors delivering GFP (AAV 1,2,5,8), AAV 8 was found 
to be the most efficient at transducing the corneal squamous epithelium in mice as well as in 
human corneas ex vivo (Hippert et al. 2012; Sharma et al. 2010; Vance et al. 2016).  
Thermosensitive pluronic gels  
Thermosensitive pluronic gels have been developed for numerous functions, including vaginal 
drug delivery (Tuǧcu-Demiröz et al. 2013; Ghahremankhani et al. 2008; Jeong et al. 2000). More 
specifically as a viral vector delivery system, the F127 gel has been used to deliver VEGF with an 
adenoviral vector to the uterine circulation as a treatment for fetal growth restriction (Mehta et 
al. 2014; Mehta et al. 2016). The benefits of these gels are that they are biodegradable, low in 




body temperature. The F127 polymer becomes a gel at body temperature (37⁰C) whilst the AK12 
polymer gels at room temperature (20-25⁰C).  The use of AK12 and F127 gels in a mixture with 
the viral vector appeared to improve cervical viral vector transduction, although this was not 
significant and possibly because of the small sample size (Figure 5.6). Using a gel plugging 
method with the AK12 gel, however, there was a significant increase in cervical GFP expression 
(Figure 5.7).  No studies have specifically compared these two gels for vaginal use, F127 gel has 
been compared with hydroxylpropyl-methylcellulose gel preparations for vaginal oxybutynin 
delivery (Tuǧcu-Demiröz et al. 2013). Hydroxypropyl-methylcellulose preparations were found 
to show better muco-adhesive properties in a rabbit vaginal delivery model and therefore may 
be useful as a comparative gel and also perhaps as an additive to the AK12 or F-127 pluronic gels 
to prolong epithelial exposure time. 
Location of protein expression  
I show that the location of GFP expression following AAV8-GFP transduction is predominantly in 
the top epithelial cell layers of the upper vagina and cervical epithelium (Figure 5.9). Co-
localisation immunofluorescence staining with a pan-cytokeratin antibody confirms that 
expression is confined to the epithelial cell layers (Figure 5.10). The basal layer of the epithelium 
consists of epithelial stem cells and so transduction of this layer would lead to long term 
expression. There is no evidence of significant basal layer transduction seen on 
immunofluorescent staining, consistent with the time course of expression data. In this 
experiment luciferase expression diminishes in all mice 14 days after application suggesting 
complete shedding of the transduced upper epithelial cell layers.  Intravaginal administration of 
AAV 6 CMV-GFP in the rhesus macaque did, however, result in some basal layer transduction 
confirmed by p63 co-localisation (p63 is a transcription factor confined to the basal epithelial 
cells) (Abdel-Motal et al. 2014).  Although in these experiments the vaginal and ectocervical 




layer transduction. As the ultimate aim for the viral vectors in this study is to deliver genes to 
the cervix during pregnancy, short term expression would be most appropriate for clinical 
translation. 
Promoters for cervical gene delivery 
The human cytomegalovirus major immediate-early promoter/enhancer (CMV promoter) was 
chosen as the promoter for these experiments and the remaining experiments in my thesis. I 
chose this promoter as it is a strong and common promoter which leads to high transduction 
rates in most cells (Boshart et al. 1985). Transcriptional silencing, is the main concern with this 
promoter, although this is unlikely to be a problem in this situation, as mentioned above, 
expression is transient (Kong et al. 2009; Brooks et al. 2004; Prösch et al. 1996). However, for 
future translational applications cervical cell-targeted promoters should be assessed to reduce 
the risk of ectopic expression. This has been explored in normal endometrial cells but not in 
endocervical and ectocervical cells, although a secretory leucocyte protease inhibitor promoter 
could be considered (Othman et al. 2016; Itaoka et al. 2015). 
In conclusion, AAV viral vectors can be used to successfully deliver genes to the cervical 
epithelium and the optimal application method was determined with the use of thermosensitive 




Chapter 6 The effects of overexpressing 
antimicrobial peptide, human beta defensin-
3, on the murine cervix 
Summary 
In the previous chapter I describe the development of an efficient gene transfer system for the 
delivery of genes to the murine cervical epithelium. In this chapter, I use that system to deliver 
a human antimicrobial peptide gene to the cervix and explore the effects of this gene on cervical 
mucosal immunity in the mouse. 
During pregnancy, the cervix produces a specialised mucus plug which is believed to play a role 
in preventing pathogens from ascending into the uterine cavity. This plug is a large structure 
that fills the cervical canal during pregnancy and predominantly consists of mucins, negatively 
charged mucinous glycoproteins. Mucins provide the structural framework of the mucus plug 
and their immune properties include inhibition of bacterial diffusion, inhibition of viral 
replication and retention of positively charged molecules, such as antimicrobial peptides 
(Carlstedt et al. 1983; Habte et al. 2008). The mucus plug has been shown to have a high 
concentration of antimicrobial peptides; secreted from the surrounding endocervical cells and 
neutrophils (Hein et al. 2002; Hein et al. 2001; Becher et al. 2009). 
The pathogenesis of infection-related preterm birth is still unknown. Accumulating evidence 
points towards immune dysfunction within the cervix; whether this is as a result of reduced 




neoplasia or whether this is due to an inherent dysfunction in cervical mucosal immunity is yet 
to be clarified (Castanon et al. 2014; Stock et al. 2016; Kindinger et al. 2017; Kyrgiou et al. 2014). 
This chapter tests the hypothesis that overexpressing an antimicrobial peptide in the cervix 
would result in a “super” mucus plug capable of preventing bacterial ascent into the uterine 
cavity in vivo. HBD-3 was chosen as the antimicrobial peptide of choice because of its potent 
antimicrobial activity, particularly to bacteria implicated in preterm birth, and its relative 
resistance to high salt environments found in bodily fluids, such as cervical mucus (Harder et al. 
2001; Xiao et al. 2014).   
I find that it is possible to express human beta-defensin 3 in the murine cervix in vivo. 
Interestingly, HBD-3 expression appears to have immunomodulation properties in vivo resulting 
in an influx of neutrophils to the cervical epithelium. I assessed the effect of HBD-3 
overexpression on the vaginal microbiota of the mouse and found no significant changes in the 
microbial composition compared to untreated mice. 
Transient transfection of HEK 293-T cells with pAAV-HBD3 leads to GFP 
expression 
A bicistronic AAV plasmid containing the HBD-3 gene and a GFP marker gene under 
transcriptional control of separate CMV promoters was designed and made by Vector Biolabs 
(USA) (designated AAV-HBD3 for the rest of the chapter) (Appendix Figure 10.1).  Transient 
transfections of the AAV-HBD3 plasmid were performed on HEK 293-T cells and cells were 
imaged with a fluorescence microscope to detect GFP expression. GFP expression was detected 









Figure 6.1: There was GFP expression 24 hours after transient transfection with the AAV HBD-
3 plasmid. GFP expression in HEK293-T cells was visualised 24 hours after transfection. 
 
HBD-3 peptide is expressed in vitro 
To determine HBD-3 expression, cell supernatants and cell lysates were collected 72 hours 
after transfection and assessed using ELISAs. 
HBD-3 is overexpressed in the supernatants and cell lysates of HEK 293-T 
transfected cells  
HBD-3 was quantified in the cell supernatants and cell lysates. There was a significant increase 
in HBD-3 expression in the supernatants (p=0.0001) and the cell lysates (p=0.007) (Figure 6.2A 



















Figure 6.2: HBD-3 is overexpressed in the supernatants and cell lysates of HEK 293-T 
transfected cells. (A) Cell supernatant HBD-3 quantification 72 hours after transient transfection 
of AAV-HBD3 plasmid in HEK 293T cells. (B) Cell lysate HBD-3 quantification 72 hours after 
transient transfection of AAV HBD-3 plasmid in HEK 293-T cells. n=4; data analysed with an 











































Recombinant HBD-3 can kill E.coli K12 
Killing assays using recombinant HBD-3 were performed using bioluminescent E.coli K12 bacteria 
(Figure 6.3). The anti-E.coli K12 activity of recombinant HBD-3 increases with increasing peptide 
concentration. 
 
Figure 6.3: E.coli K12 kill increases with increased concentration of recombinant HBD-3. Total 
colony count on control plates with media alone was considered as 0%. 
 
HBD-3 functions in vitro 
Killing assays performed with the AAV transfected supernatants showed a significant reduction 
in absolute CFU numbers compared to control supernatants (P=0.0003) (Figure 6.4A).  The 
percentage of E.coli K12 CFUs killed by undiluted AAV supernatants was 41.25% (data not shown 
here). Serial dilutions of HBD-3 (from AAV-HBD3 supernatants) were performed, based on levels 
of HBD-3 determined by ELISA, and a dose response of HBD-3 kill was performed (Figure 6.4B). 
There was a reduction in the absolute number of E.coli K12 CFUs with each fold dilution, except 
at the 5ng/ml concentration.  

































Figure 6.4: HBD3 from AAV-HBD3 transduced cell supernatants have antibacterial activity 
against E.coli K12. (A) Killing assay; absolute number of E.coli K12 CFUs following treatment with 
AAV HBD-3 supernatants and control supernatants. (B) Dose response of E.coli K12 kill (x values 
log2 transformed). HBD-3 was serially diluted from AAV-HBD-3 transduced after concentration 
was determined by ELISA. (C) Fold change in bioluminescence following E.coli K12 infection of 
AAV HBD-3 transfected cells. n=3, performed in triplicate; data analysed with an unpaired t-test, 
*P˂0.05, ***P˂0.001 (A,C). 



















































As the E.coli K12 strain of bacteria used for killing assays is bioluminescent, luminometry was 
performed to determine the fold change in bioluminescence after infection of AAV-HBD3 
transfected cells and control cells. There was no change in bioluminescent signal from the AAV 
HBD-3 transfected cells suggesting no bacterial growth, compared with a fold increase of 1.6 in 
bioluminescent signal in untransduced cells (P=0.03) (Figure 6.4C)  
 
HBD-3 can be expressed in vivo following intravaginal application of AAV 8 HBD-
3 
HBD-3 expression was localised using HBD-3 immunofluorescence staining.  Mature HBD-3 
peptide was expressed in the upper layers of the vaginal and cervical epithelium of transduced 
mice (Figure 6.5). HBD-3 and GFP expression co-localised as expected and expression was 
confined to the upper epithelial cell layers, consistent with experiments in the previous chapter. 













Figure 6.5: HBD-3 and GFP expression colocalised to the upper epithelial cell layers of the cervix and upper vagina of AAV HBD-3 transduced 
mice. Co-localisation immunofluorescence staining of cervix and upper vagina of AAV HBD-3 transduced mice. Organs were harvested 72 hours 




HBD-3 is secreted into the vagina in vivo 
Vaginal lavages were taken from mice 96 hours after transduction with AAV HBD-3 and from 
untransduced controls. There were increased levels of HBD-3 detected in vaginal lavages of AAV 


















Figure 6.6: HBD-3 was detected in the vaginal lavage of AAV HBD-3 transduced mice. Vaginal 
lavages were taken from mice 96 hours after transduction with AAV HBD-3 and from 











Vaginal lavages from AAV HBD-3 transduced mice do not kill E.coli K12 or E.coli 
K1 ex vivo 
Vaginal lavages were taken from mice 96-120 hours after transduction with AAV-HBD3, AAV-
GFP and PBS. Unexpectedly, there was no difference in the E.coli K12 and E.coli K1 killing 











Figure 6.7: Vaginal lavages from AAV HBD-3 transduced mice do not kill E.coli K12 or E.coli K1 
ex vivo. (A) E.coli K12 killing assays were performed with vaginal lavage from AAV8 HBD-3, AAV8 
GFP and untransduced mice. There is no difference between the three groups. (B) E.coli K1 killing 
assays performed with vaginal lavage from AAV8 HBD-3, AAV8 GFP and untransduced mice. 
There is no difference between the three groups. n=5; data not normally distributed therefore 
analysed with a Kruskal-Wallis test with post hoc Dunn’s test. 


































AAV HBD-3 induces an influx of neutrophils into the cervical epithelium within 
72 hours after transduction 
Cervices were harvested 72 hours after administration of AAV HBD-3, AAV GFP, E.coli K12 and 
PBS. They were stained for anti-Ly6g, a neutrophil surface marker, to determine neutrophil 
influx into the cervical epithelium and sub-epithelial stroma. There was an increase in 
neutrophils into the cervical epithelium 72 hours after AAV8 HBD-3 administration, compared 
with AAV8 GFP (P=0.0077), E.coli K12 (P=0.0074) and PBS (P=0.016) (Figure 6.8A). There was no 
difference in the number of neutrophils in the cervical stromal layer between the four groups 
(Figure 6.8B).  
Macrophage influx, determined by CD68 immunohistochemistry, was also assessed but 
expression was minimal (≤ 1/section) in the cervix of all the groups so the data was not analysed. 

















Figure 6.8: AAV HBD-3 induces an influx of neutrophils into the cervical epithelium within 72 
hours after transduction. (A) Neutrophil influx into the cervical epithelium. There is an increase 
in neutrophils seen in the cervical epithelium 72 hours after administration of AAV HBD-3. (B) 
Neutrophil influx into the cervical sub-epithelial stroma. There is no difference in neutrophils 
seen in the cervical sub-epithelial stroma between the groups. n=3; data analysed with a one 


















































































There is a non-significant reduction in Defb14 mRNA expression in cervices 
transduced by AAV HBD-3 
qPCR was performed on cDNA obtained from cervices of AAV HBD-3 administered mice and AAV 
GFP administered control mice to detect inflammatory cytokine gene expression, as well as 
mouse β-defensin 14 gene (Defb14) which is the mouse orthologue of HBD-3 (Figure 6.9).  
There is a non-significant trend of reduced expression of Defb14 (4.2-fold), Il1b (2.5-fold) and 
Tnfa (1.7-fold) in AAV HBD-3 cervices, compared with controls. There was a non-significant trend 
of increased expression of Il6 (1.96-fold) in AAV HBD-3 cervices, compared with controls. 
 
Vector transduction is confined to the vagina and cervix in pregnant mice 
Copy numbers of the HBD-3 gene were determined in the cervix of pregnant mice 96 hours after 
transduction with AAV HBD-3 (mean=3570 GC/µg cDNA). Negligible levels (below the limit of 
detection) were found in the uterus, placenta, ovaries, liver, spleen and fetal organs of AAV HBD-






















Figure 6.9: There is a non-significant reduction in Defb14 mRNA expression in cervices 
transduced by AAV HBD-3. (A) Relative mRNA expression was determined in AAV HBD3 and 
AAV GFP cervices. n=6; data shown as 2-ΔCT data and analysed by two-way ANOVA with post hoc 
Bonferroni tests (B) Fold change in mRNA expression from AAV HBD-3 cervices compared with 
AAV GFP cervices. There is a non-significant reduction in defb14 (4.2-fold), Il1b (2.5-fold) and 
Tnfa (1.7-fold) expression, whilst there is a non-significant increase in Il6 (1.96-fold), compared 






















































Vaginal microbiome studies 
There is no difference in the diversity of bacterial species found in the 
vagina after administration of AAV HBD-3 
Vaginal lavage samples were taken pre- and post- administration of AAV HBD-3, AAV GFP and 
PBS for 16s rDNA next generation sequencing. Species diversity within the vaginal microbiome 
of each group was calculated using the Shannon’s diversity index (Figure 6.10). This diversity 
index describes the number of species within a microbial community as well as the abundance 
of those species. The post-administration groups contained pooled data from samples collected 
at 48 hours and 1 week after administration of vector or PBS. The data had to be pooled because 
the low bacterial load in the murine vagina meant that some samples had insufficient bacterial 
DNA for successful sequencing at all of the time points. 
There was no difference in the pre- and post-administration indices for each group as well as no 
difference between groups (Figure 6.10A). Looking specifically at AAV HBD3 Shannon’s entropy 
using unpooled post-administration data, we found no difference in the bacterial species 





















Figure 6.10: There is no difference in the diversity of bacterial species found in the vagina after 
administration of AAV HBD-3. (A) Shannon's entropy of the vaginal microbiome pre- and post-
administration of AAV HBD3, AAV GFP and PBS. Post-administration samples were taken at 48 
hours and 1 week, data is pooled here. (B) Shannon's entropy of vaginal microbiome before 

























































9 bacterial phyla were identified in the samples, with Firmicutes and Proteobacteria being the 
two most abundant phyla (>0.5% abundance) (Figure 6.11). There was minimal variation 
between the AAV HBD-3 and AAV GFP groups, however, there did appear to be a higher 
proportion of Proteobacteria in the PBS control group at both time points studied. Furthermore, 
there was an non-significant increase in the proportion of Proteobacteria following 
administration of vector or PBS in all groups (P=0.15, P=0.28 and P=0.23) (Figure 6.12A). The 
Gammaproteobacteria, in particular Enterobacteriales and Pseudomonadales, were responsible 
for this increase (Figure 6.12B), although the differences were not statistically significant (P=0.15 






Figure 6.11: There is no difference in the proportion of bacterial classes and phyla between 
the AAV HBD-3, AAV GFP and PBS treated. (A) Proportion of bacterial classes within each group. 
There are no obvious differences in bacterial class between the vector groups, however there is 
a larger proportion of Gammaproteobacteria in the PBS controls at both time points. There also 
appears to be a increase in the proportion of Gammaproteobacteria after administration of 
vector or PBS. (B) Proportion of bacterial phyla within each group. There are no obvious 
differences in phyla between the vector groups, however there is a larger proportion of 




















































































































































Figure 6.12: There is an increase proportion of Proteobacteria following administration of 
vector or PBS in all groups. (A) Proportion of Gammaproteobacteria pre- and post-
administration of vector or PBS. There is an increase in proportions of gammaproteobacterial 
before and after administration of vector/PBS in all groups, although this was not significant. 
(B) Proportions of classes of Gammaproteobacteria pre- and post-administration of AAV HBD-
3. There is an increase in proportions of Enterobacteriales and Pseudomonadales before and 
after administration of vector, although this was not significant. n=8, data arcsin transformed 






Lactobacillus species are not reduced following AAV HBD-3 administration 
During human pregnancy, the rise in oestrogen levels leads to a stable vaginal microbiome 
dominated by Lactobacillus species (MacIntyre et al. 2015; Romero et al. 2014). Lactobacillus 
species are thought to inhibit pathogen growth by secreting antimicrobial bacteriocins as well 
as producing lactic acid which helps to maintain a low, hostile pH (Borges et al. 2014). There is 
an association between Lactobacillus species depletion, vaginal dysbiosis and preterm birth 
(Hillier et al. 1995; DiGiulio et al. 2015; Kindinger et al. 2017). Therefore, the effect of AAV HBD3 
on the proportion of Lactobacillus species was assessed at different time points before and after 
treatment (Figure 6.13). There is no significant difference between the proportion of lactobacilli 
species before and after administration of AAV HBD-3, suggesting that AAV HBD-3 treatment 





























Figure 6.13: There is no difference in the proportion of Lactobacillus species before and after 
AAV HBD-3 administration. Proportion of Lactobacillus species pre- and post-administration of 
AAV HBD-3. n=6 pre-AAV group and n=4 both post AAV groups; data was arcsin transformed and 






This chapter shows that AAV8 HBD-3 can transduce murine cervical epithelium in vivo and 
produce peptide that is capable of inducing neutrophil influx. Furthermore, it shows that AAV8 
HBD-3 treatment does not appear to have any deleterious effects on the vaginal microbiome. 
HBD-3 detection 
The detection of HBD-3 was initially problematic due to the small peptide size (5kDa) and 
instability, but lyophilisation and the use of acetic acid for lysis, rather than standard lysis 
buffers, helped to stabilise the peptide so that protein assays were much more reliable. 
Transient transfection of the AAV HBD-3 plasmid in HEK 293-T cells resulted in overexpression 
of HBD-3 in supernatants and cell lysates (Figure 6.2). The HBD-3 in the supernatants was also 
functional leading to a dose-dependent killing of E.coli-K12 (Figure 6.4). Unexpectedly, even 
control supernatants exhibited detectable, albeit low, bactericidal activity. This could be due to 
endogenous AMP production from these cells or an antibacterial component in the cell media.  
There was also a significant reduction in E.coli K12 bioluminescence, signifying increased 
bacterial kill, in the in vitro killing assays (Figure 6.4C). A previously similar study in HBD-3 
transfected keratinocytes did not show any difference in bacterial kill although bacterial kill was 
determined by plating and counting CFUs which may be less sensitive than the change in 
bioluminescence (Hirsch et al. 2009). Furthermore, they detected approximately 3 times less 
HBD-3 in their transfected supernatants which could also explain the difference in HBD-3 killing. 
The upper vaginal and cervical epithelium expressed HBD-3 and GFP following in vivo AAV 8 
HBD-3 administration (Figure 6.5). There was obvious GFP expression on direct fluorescence at 
72 hours after intravaginal application. Interestingly, the expression seemed to be much more 
specific and localised to the cervical epithelium in the pregnant mouse on direct fluorescence, 




Integrins are known to have a role in viral vector-endocytosis, specifically with the AAV 2 
serotype and interestingly, certain integrins have been found to be upregulated in the pregnant 
mice cervix making them more susceptible to viral infection (Wickham et al. 1993; Kaminsky et 
al. 2012; Racicot et al. 2013). It is possible that the more specific cervical expression in the 
pregnant cervix may be mediated by this upregulation in integrins.  
HBD-3 expression in the upper epithelial cell layers was detected using immunofluorescence 
(Figure 6.5). It is known that the HBD-3 gene encodes a pre-HBD-3 peptide which is cleaved by 
a signal peptidase prior to secretion to release the mature HBD-3 peptide (Beckloff et al. 2008). 
Quantification of HBD-3 protein in the vaginal lavage confirmed appropriate peptide processing 
and secretion in the mouse (Figure 6.6). 
HBD-3 antimicrobial activity 
E.coli killing assays performed with vaginal lavages collected in vivo from AAV8 HBD3 transduced 
mice showed no evidence of increased bacterial kill compared with AAV8 GFP controls (Figure 
6.7). This result is unexpected and in contrast to the in vitro E.coli killing assays. It is possible that 
this is due to the lower concentrations of HBD-3 detected in lavage samples compared with 
lyophilized cell supernatants. Furthermore, lavage was performed with PBS, and although HBD-
3 is known to be the least salt sensitive it is possible that storage in PBS may modify protein 
charge and therefore have a deleterious effect on its antimicrobial function (Harder et al. 2001; 
Klüver et al. 2005).  
Immunomodulatory role of HBD-3 
Emerging evidence suggests that human beta-defensins have a much more complex role in the 
immune system than just being natural antimicrobials. Human beta-defensins have the ability 
to chemoattract numerous immune cells, such as neutrophils, macrophages and dendritic cells 




neutrophils are recruited to the upper epithelial cell layers of the cervix (Figure 6.8). Neutrophils 
are critical effector cells of the innate and acquired immune system and are part of the first line 
of defence against microorganisms. Human beta defensin-2 has been shown to attract 
neutrophils via the G-protein phospholipase C-dependent pathway (Niyonsaba et al. 2004). The 
CCR6 receptor appears to be involved in activation of this pathway; HBD-3 and mouse beta-
defensin 14 (mouse orthologue of HBD-3) are chemotactic for mouse CCR6-expression HEK 293 
cells in vitro (Röhrl et al. 2008; Wu et al. 2003). Furthermore, the cysteine residues of the three 
disulphide bridge structure of HBD-3 appear to be necessary for this chemotactic role (Wu et al. 
2003; Taylor et al. 2008). In addition to its chemotactic role, HBD-3 can prolong the lifespan of 
neutrophils at sites of infection by preventing apoptosis (Nagaoka et al. 2012; Nagaoka et al. 
2008). This mechanism may also be contributing to the increased cervical neutrophil numbers 
seen here and exert an advantageous effect on cervical mucosal defence against bacterial 
infection.  
Minimal macrophage influx into cervix was detected using CD-68 immunohistochemistry after 
vector administration in this study. This is not consistent with other studies that show HBD-3 to 
be a potent monocyte chemoattractor (García et al. 2001; Funderburg et al. 2007), although 
these studies were performed in vitro. It is possible that this time point (72 hours after vector 
administration) was too early to detect macrophage influx or alternatively, that HBD-3 
expression in the murine cervix does not induce the same macrophage chemoattractant 
function that is seen in vitro.  
HBD-3 was previously considered to be pro-inflammatory as its expression increases following 
TLR activation or IL-1β, TNF-α, IFN-ϒ release (Harder et al. 2001; García et al. 2001), however 
emerging data is recognising it more as a multifunctional effector of the immune system (Semple 
et al. 2011). It is possible that, similar to LL-37, HBD-3 may induce a strong chemoattractant and 




insult whilst at lower concentrations it has more of an anti-inflammatory, healing role (Scott et 
al. 2002). Interestingly, we show a trend towards reduced mRNA levels of Defb14 (the gene for 
mBD14, the mouse orthologue of HBD-3) in the AAV8 HBD-3 treated cervices suggesting that 
HBD-3 may be involved in a negative feedback loop suppressing Defb14 expression (Figure 6.9). 
Il1b and Tnfa also show a trend towards reduced expression in the AAV8 HBD-3 treated cervices, 
consistent with in vitro data (Semple et al. 2010; Semple et al. 2011). It would be interesting to 
determine expression of these genes following intravaginal infection as I hypothesise that the 
presence of bacteria or LPS would induce a significant pro-inflammatory cytokine response and 
possibly block this proposed negative feedback loop. In support of this, recent data has found 
that HBD-3 significantly augments the inflammatory response to bacterial DNA in human and 
mice cells via TLR-9 (McGlasson et al. 2017). 
HBD-3 and the vaginal microbiome 
Mice treated with AAV8 HBD-3 did not have an obvious effect on the vaginal microbiota 
compared with AAV8 GFP or PBS treated mice (Figure 6.10 & Figure 6.11). Furthermore, AAV8 
HBD-3 does not appear to modify Lactobacillus species abundance in the vagina (Figure 6.12). 
These results are reassuring for clinical translation as the vaginal microbiota composition 
appears to be closely associated with preterm birth outcome (Kindinger et al. 2017). Very little 
data has been published on the mouse vaginal microbiome but vaginal bacterial phyla 
abundance appears consistent with the data presented here (Barfod et al. 2013; Jašarević et al. 
2015). For further studies, it would be important to perform species-specific lactobacillus 16S 
qPCR to confirm the above findings. In support of these findings, HBD-3 does not exhibit 
antibacterial activity against lactic acid bacteria, including L.rhamnosus, suggesting that these 
bacteria may exhibit factors that protect them from host immune defence (Wang et al. 2015). 
Recent data has shown an association between an L.iners-dominant vaginal microbiome and an 




(Kindinger et al. 2017). L.crispatus promotes epithelial cell defence against Candida albicans in 
vitro by increasing human beta defensin levels, in particular HBD-3 (Rizzo et al. 2013).  This 
finding may play a role in linking the mechanism of L.crispatus dominant vaginal microbiome 
with its protective effect on preterm birth. It also importantly supports the clinical translation of 
the preventative therapy developed in this study.  
The microbiome experiments did show evidence of increased abundance of Enterobacteriaceae 
following administration of either vector or PBS. It is possible that repeated vaginal lavage may 
have a damaging effect on the mucosa allowing colonisation of Enterobacteriaceae bacteria 
(which includes E.coli). Alternatively, repeated exposure to the animal house operating room, 
where E.coli is used for other experiments, may increase the risk of E.coli colonisation.  
These experiments were limited by the fact that only small amounts of bacterial DNA were 
detected from vaginal lavage samples. This meant that, despite collecting samples at multiple 
time points, we were unable to create a sufficient library to sequence all the samples collected. 
Furthermore, these experiments were performed in non-pregnant mice resulting in a small risk 
of microbiome fluctuation due to hormonal changes in the estrous cycle.  Variations in the 
vaginal microbiome, however, have only been shown in humans as a result of the hormonal 
fluctuations during the menstrual cycle and these hormonal changes may not have an effect on 
the much shorter rodent estrous cycle (Gajer et al. 2012; MacIntyre et al. 2015). Vaginal lavage 
samples from untreated pregnant mice were also sequenced to determine if there was much 
variation in vaginal bacterial communities between pregnant and non-pregnant mice and we 
reassuringly found similar bacterial abundance in these samples meaning that the non-pregnant 
data is likely to be translatable. These experiments were not designed to infer associative links 
between the mouse and human vaginal microbiome but as a means of determining treatment 




perform in vitro experiments to determine the antimicrobial activity of HBD-3 on the 
Lactobacillus species commonly found in the pregnant human vaginal microbiome. 
In conclusion, this chapter shows that it is possible to transduce cervical and upper vaginal 
epithelium of a mouse with AAV8 HBD-3 and this produces functional HBD-3 peptide which does 





Chapter 7 Cervical gene delivery of Human 
beta-defensin 3 for the prevention of 
ascending vaginal infection in pregnancy 
Summary 
This chapter assesses the effects of a cervical gene therapy, described in the previous chapter, 
on the models of ascending vaginal infection and preterm birth developed in Results Chapter 3 
and Chapter 4. It tests the hypothesis that gene delivery of HBD-3 using an AAV8 viral vector can 
reduce bacterial ascent into the uterus and prolong gestation at delivery as well as improving 
pup survival and outcomes. This chapter focuses on pregnant mice but data from the 
experiments performed in non-pregnant mice can be found in the Appendix (10.7). 
In this chapter, I show that there is a significant reduction in bacterial ascent into the pregnant 
uterus of both non-pathogenic E.coli K12 and a pathogenic E.coli K1 strain following  AAV HBD3 
treatment. Gestation was not prolonged in the AAV HBD3 treated dams following E.coli K1 
administration but there was a statistically significant increase in the proportion of pups born 
alive. 
Pregnant mice: Experimental plan 
To assess the effect of cervical overexpression of HBD-3 on ascending vaginal infection in 
pregnant mice, AAV HBD3 was administered on embryonic day 13.5 and then 72 hours later on 






Figure 7.1: Summary of experimental plan for determining the effect of HBD-3 expression on 
intravaginal E.coli K12 or E.coli K1 infection in pregnant mice. 
Non-pathogenic E.coli K12 
HBD-3 reduces E.coli K12 bacterial ascent into the uterus of pregnant mice 
There is a smaller increase in uterine bioluminescence in the AAV HBD3 dams compared with 
the AAV GFP control dams (overall P=0.014) (Figure 7.2). This was significant at 48 hours after 
bacterial administration (P=0.03), implying less bacterial ascent into the uterine cavity in the 











Figure 7.2:  AAV HBD-3 treated dams have reduced E.coli K12 bacterial ascent into the uterus 
at 48 hours after infection. (A) Fold change in E.coli K12 bioluminescence over time (log 
transformed data shown). n=12; data log transformed and analysed with a repeated measures 
two-way ANOVA with post hoc Bonferroni test, *P˂0.05. (B) Representative images at 48 hours 
























There is no difference in gestation at delivery or litter size between the AAV 
HBD3 and AAV GFP treated E.coli K12-infected dams 
There was no difference between the gestation at the time delivery of the litter between all 
groups (P=0.23) (Figure 7.3A). Although there was an outlier in the AAV HBD3 group that 
delivered prematurely on embryonic day 17.5. This dam did not have increased bioluminescence 
(implying greater bacterial infection), compared with the other dams but did look systemically 
unwell so I suspect this was an incidental finding. The number of pups in each litter was 





























Figure 7.3: There is no difference in gestation at delivery or the number of pups in the littter 
between the AAV HBD3, AAV GFP and PBS control dams. (A) The gestation on the day of 
delivery between the groups. n=12 in AAV HBD3 and AAV GFP groups, n=8 in the PBS control 
group; data not normally distributed therefore, analysed with a Kruskal-Wallis test with post hoc 
Dunn’s test. (B) The number of pups per litter from AAV HBD3, AAV GFP and PBS control dams. 
The litter size is comparable between the groups. n=12 in AAV HBD3 and AAV GFP groups, n=8 
in the PBS control group; data not normally distributed, therefore analysed with a Kruskal-Wallis 










































There is a non-significant increase in pro-inflammatory cytokines in the 
neonatal brains of pups from AAV GFP E.coli K12-infected control dams 
Brains were harvested from pups on the day of birth of AAV HBD-3 and AAV GFP treated dams. 
These were analysed for pro-inflammatory cytokines; IL-1β, TNF-α and IL-6. There was no 
statistical difference in brain pro-inflammatory cytokine levels between the two groups, 
although there was a trend for increased inflammatory cytokine levels in AAV GFP treated dams 






















Figure 7.4: There is a non-significant increase in inflammatory cytokines in the pup brains 
from AAV GFP control dams, compared with pup brains from AAV HBD3 dams. (A) IL-1β brain 
levels in the brains from the newborn pups of AAV HBD3 and AAV GFP dams. (B) TNF-α brain 
levels in the brains from the newborn pups of AAV HBD3 and AAV GFP dams. (C) IL-6 brain levels 
in the brains from the newborn pups of AAV HBD3 and AAV GFP dams. n=12 from AAV GFP 
pups, n=18 from AAV HBD3 pups (from ≥ 3 dams); data not normally distributed therefore 
analysed by Mann Whitney rank test. 
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Pathogenic E.coli K1 
E.coli K1: High CFU dose (2x103) 
HBD-3 does not reduce high-dose E.coli K1 bacterial ascent into the uterus 
of pregnant mice 
E.coli K1 was administered intravaginally on embryonic day 16.5 and pregnant mice were imaged 
daily until delivery. The bioluminescent signal from the uterus is similar between AAV HBD3 and 
AAV GFP treated groups, implying that AAV HBD3 does not reduce bacterial ascent into the 
uterus in these mice (Figure 7.5A).  Confirming this, there is no difference in the fold change in 


















Figure 7.5: AAV HBD3 does not reduce high-dose E.coli K1 bacterial ascent into the uterus of 
pregnant mice. (A) Bioluminescence from the uterus of pregnant dams treated with AAV HBD3 
or AAV GFP after administration of intravaginal E.coli K1. (B) Fold change in uterine E.coli K1 
bioluminescence over time (log transformed data shown). There is no difference in the fold 
change in bioluminescence at 24 and 48 hours after bacterial administration between the two 
groups. n=4 in the AAV GFP group, n=5 in the AAV HBD3 group; data log transformed and 



































































AAV HBD3 treatment does not increase gestation length or increase the 
proportion of pups born alive following high dose E.coli K1 administration  
The time of delivery of the first pup was determined following bacterial administration in the 
AAV HBD3 and AAV GFP groups and following PBS administration in the uninfected control. 
There is no increase in gestation length in the AAV HBD3 infected dams compared with the AAV 
GFP infected dams (P=0.46) (Figure 7.6A). The gestation length difference between E.coli K1 
infected- AAV HBD3 or AAV GFP groups, and uninfected controls remains statistically significant 
(P=0.02 and P=0.0008 respectively). The proportions of pups born alive were determined in both 
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Figure 7.6: There is no difference in gestation at delivery or the proportion on pups born alive 
between the AAV HBD3 and AAV GFP groups. (A) Time to delivery from intravaginal E.coli K1 
administration in AAV HBD3, AAV GFP and PBS control dams. n=5; data log transformed and 
analysed with a one-way ANOVA and post-hoc Bonferroni test. (B) Proportion of pups born alive 
from AAV HBD3 and AAV GFP dams. n=5; data arcsin transformed and analysed with an 
unpaired t-test. *P˂0.05, ***P˂0.001. 
 












































E.coli K1: Low CFU dose (2x102) 
AAV HBD-3 significantly reduces low-dose E.coli K1 ascent into the uterus 
of pregnant mice 
E.coli K1 (low dose) was administered intravaginally on E16.5 and pregnant mice were imaged 
daily until delivery as described in Figure 7.1. The bioluminescent signal from the uterus is lower 
in the AAV HBD3 groups compared with the AAV GFP treated group at the 24 hour time point, 
implying that AAV HBD3 does reduce bacterial ascent into the uterus in these mice (Figure 7.7) 
Confirming this, there is a significantly increased fold change in uterine bioluminescence in the 
AAV GFP control group at 24 hours compared with the AAV HBD3 treated group which is  

















Figure 7.7: AAV HBD-3 significantly reduces low-dose E.coli K1 ascent into the uterus. (A) 
Bioluminescence from the uterus of pregnant dams treated with AAV HBD3 or AAV GFP after 
administration of intravaginal low dose E.coli K1. (B) Fold change in uterine E.coli K1 
bioluminescence over time (log transformed data shown). There is a smaller fold increase in 
uterine bioluminescence in the AAV HBD3 group, compared with AAV GFP treated dams. (C) 
Representative images at 24 hours after infection in an AAV HBD3 and AAV GFP treated dam. 
n=9 in the AAV GFP group, n=10 in the AAV HBD3 group (postpartum dams excluded); data log 

































































AAV HBD3 does not increase gestation length following low-dose E.coli K1 
administration but it does significantly increase the proportion of pups born alive 
The time of delivery of the first pup was determined following bacterial administration in the 
AAV HBD3 and AAV GFP groups and following PBS administration in the uninfected control. 
There is no increase in the gestation length in the AAV HBD3 dams compared with the AAV GFP 
dams (P=0.94) (Figure 7.8A). The gestation length difference between E.coli K1 infected-AAV 
HBD3 or AAV GFP groups, and uninfected controls remains statistically significant (P=0.01 and 
P=0.0001 respectively). The proportions of pups born alive were determined in both AAV HBD3 
and AAV GFP groups and were found to be significantly increased in the AAV HBD3 group 


















 Figure 7.8: AAV HBD3 does not increase gestation length following low-dose E.coli K1 
administration but it does significantly increase the proportion of pups born alive. (A) Time 
to delivery from intravaginal E.coli K1 administration in AAV HBD3, AAV GFP and PBS control 
dams. There is no difference in gestation at delivery between the AAV HBD3 and AAV GFP 
groups. (B) Proportion of pups born alive from AAV HBD3 and AAV GFP dams. n=9 in the AAV 
GFP group, n=10 in the AAV HBD3 group; data log transformed and analysed with a one-way 



















































There was no difference in pup survival over the first week of life 
The remaining pups were counted in the first week of life. There was no difference in the 
numbers by 7 days of life (P=0.4), although the AAV HBD3 pups have increased survival rates 
over the first 4 days of life (66% in the AAV HBD3 group versus 62% in the AAV GFP group) (Figure 
7.9A). Separating the pups into those born preterm and those born term (48 hours after bacterial 
administration was defined as the term cut-off time point) revealed a trend towards increased 
survival in the term AAV HBD-3 treated pups, compared with AAV GFP control term pups, 
although this was not significant (P=0.1) Figure 7.9B). There was no difference between pup 
survival in the preterm AAV HBD3 and preterm AAV GFP groups (P=0.8) (Figure 7.9C).  Pup 
bioluminescence, signifying E.coli K1 colonisation or infection, was assessed daily for the first 
week of life. There was no obvious difference in bioluminescence signal between AAV HBD3 and 












































Figure 7.9:  There is no difference in pup survival over the first week of life between AAV HBD3 
and AAV GFP pups, although there is a trend for increased survival in the term AAV HBD-3 pups 
compared with term AAV GFP controls pups. (A) Overall pup survival over the first week of life. 
(B) Term pup survival over the first week of life. (C) Preterm pup survival over the first week of 
life Term pups were defined as those that were delivered > 48 hours after bacterial 
administration. n=27 in AAV GFP group, n=53 in the AAV HBD3 group. Data analysed by Log-rank 





















Figure 7.10: There is no difference in whole body pup bioluminescence between AAV HBD3 
and AAV GFP pups. Whole body bioluminescence imaging data from the pups over the first 
week of life. n=5 dams; mean pup data from individual dams plotted.  
Summary of results 
Table 7.1 summarises the main findings in this chapter: 










E.coli K12  








 Non-significant  










Not assessed yet 
E.coli K1 low 
dose 
       








Not assessed yet 
Table 7.1: Summary of the main AAV HBD-3 results in this chapter. 
  













































This chapter describes the effect of a cervically-applied HBD-3 gene therapy for prevention of 
ascending vaginal infection and preterm birth. It shows that gene delivery of HBD-3 to the mouse 
cervix does appear to reduce the ascent of bacteria in pregnant models of ascending vaginal 
infection (Figure 7.2 & Figure 7.7). AAV HBD-3 treatment does not prolong gestational length in 
E.coli K1 (low dose) infected dams but it does cause an increase in pup survival at birth (Figure 
7.8). 
Preventing preterm birth 
Unfortunately AAV HBD-3 did not significantly increase the gestational length in E.coli K1 
infected dams. In both E.coli K1 dose groups (high and low), there is a slight increase in 
gestational length compared to the AAV GFP group although this is subtle and not statistically 
significant (Figure 7.6 & Figure 7.8). In order for the treatment to show effects on gestation 
length it will need to cause a drastic reduction in E.coli K1 ascent and infection for at least 48 
hours. From observation during these experiments, I hypothesise that AAV HBD3 probably 
delays infection over the first 24 hours but then the virulent strain of E.coli becomes too much 
for the “augmented” mucosal immunity of the cervix to defend. This theory is consistent with 
the reduction in bacteria seen after 24 hours in the uterus of AAV HBD3 treated dams which 
then becomes less pronounced by 48 hours with the low dose E.coli K1 (Figure 7.7). For further 
studies, I would like to try a repeated application of AAV HBD3 prior to bacterial administration. 
Increased pup survival with AAV HBD3 
This study shows that AAV HBD-3 increases the proportion of pups born alive as well as a possibly 
increasing survival for neonates born at term following low dose E.coli K1 infection (Figure 7.8 




suggesting that preterm pups are more susceptible to E.coli K1 infection than term pups (Figure 
7.9).  
Neonatal brains from AAV HBD-3 treated- E.coli K12 infected dams showed a non-significant 
reduction in inflammatory cytokine expression on the day of birth and future work would 
determine the effects of maternal AAV HBD-3 treatment on pup brain inflammation following 
E.coli K1 infection (Figure 7.4).   
Mouse versus human immune systems 
Although the mouse and human immune systems do share similarities there are some significant 
differences in immune system activation and response to challenge (Mestas & Hughes 2004). An 
important example of this includes the induction of an acute inflammatory response; mice 
require 250 times the amount of LPS endotoxin (per kg) than humans to mount the same IL-6 
inflammatory response (Copeland et al. 2005).  Therefore, we must practice caution when 
extrapolating immunological findings from mice to humans. The preterm birth model used here 
to mimic the human disease, is likely to represent a much simpler and more pathogenic process 
than what happens in the human disease. This is supported by the fact that  the types of bacteria 
associated with premature chorioamnionitis clinically are generally minimally pathogenic 
bacteria that ordinarily colonise the vagina (Jones et al. 2009). Therefore, this treatment could 
potentially provide an effective means of augmenting local mucosal immunity without having a 
drastic effect on the vaginal microbiome or maternal and fetal systemic immune response. For 
future work, it would be important to determine the effects of cervical expression of HBD-3 on 







How does AAV HBD-3 reduce bacterial ascent? 
The mechanisms by which HBD-3 in the murine cervix reduces bacterial ascent into the uterine 
cavity is intriguing. There are two ways in which HBD-3 could prevent bacterial ascent; by direct 
microbial killing action or by the recruitment of immune cells that kill the bacteria. I have shown 
that HBD-3 induces an influx of neutrophils into the cervical epithelium in vivo, but I have not 
been able to show that the vaginal lavage of AAV HBD-3 treated mice has direct E.coli killing 
activity (Figure 6.7 & Figure 6.8). Therefore, it is possible that HBD-3 mediated bacterial 
clearance is occurring solely through enhanced neutrophil action or alternatively that HBD-3 
direct killing activity is only functional in physiological conditions in vivo. Furthermore, there is 
also a possibility that HBD-3 induces an endogenous murine mbd14 response on activation by 
local bacterial DNA which helps to increase direct bacterial killing in vivo (McGlasson et al. 2017).  
A study looking at the benefits of exogenously delivered human cathelicidin LL-37 in a murine 
model of P.aeruginosa lung infection found that cathelicidin LL-37 enhanced bacterial clearance 
in vivo (Beaumont et al. 2014). Interestingly, similar to results obtained in our study, there was 
no evidence of a direct microbicidal effect in vivo and the authors concluded that the likely 
mechanism of bacterial clearance is the peptide-mediated enhanced early neutrophil influx. For 
future studies it is important to determine the exact mechanisms of bacterial killing. The use of 
a neutrophil antibody to block neutrophil activity could be used, although this would be 
inappropriate in the E.coli K1 model as the mouse is likely to become overwhelmingly septic 
without adequate neutrophil function. However, it may work in the E.coli K12 model as its non-
pathogenic nature is unlikely to lead to an overwhelming infection without neutrophil function. 
It has been shown that a HBD-3 peptide in which the six cysteine residues is replaced by alanine 
has antimicrobial function but without chemoattractant properties (Taylor et al. 2008). 
Therefore, another way to assess mechanisms would be to deliver a HBD-3 gene which produces 




Benefits of gene therapy 
The use of synthetic recombinant antimicrobial peptide therapy would potentially avoid the 
ethical and immunological implications of a gene therapy approach. However, recombinant 
HBD-3 would be very costly to produce especially as it is likely to require multiple large dose 
applications and is very unstable in bodily fluids due to peptidase degradation (Svenson et al. 
2008; Molchanova et al. 2017).  However, it would be essential to compare topically applied 
recombinant HBD-3 with cervical gene delivery of HBD-3 in future studies to determine its 
efficacy at preventing ascending infection. This would also help us to understand more about 
mechanisms of action of HBD-3 as topically applied peptide may remain intraluminal and so 
exert different or reduced microbicidal actions and immunomodulatory effects.  
Antimicrobial gene therapy 
The use of antimicrobial gene therapy has been studied before, mainly as a way of treating 
infections with antibiotic resistant bacteria and treating certain wound infections where the skin 
epithelia has been severely damaged, such as burns (Jacobsen et al. 2005; Carretero et al. 2004; 
Sawamura et al. 2005).  Gene delivery of HBD-3 to keratinocytes using adenoviral vectors has 
been performed in studies investigating novel treatments for wound infections (Hirsch et al. 
2009; Carretero et al. 2004).  They show that keratinocytes expressing HBD-3 in vitro have 
increased antimicrobial activity and interestingly found that the beta-defensins worked 
synergistically with the AMP, cathelicidin LL-37, in its antimicrobial activity against E.coli and 
S.aureus (Carretero et al. 2004). In vivo, in a model of infected diabetic wounds in pigs, 
adenoviral vectors delivering HBD-3 showed reduced bacterial load 4 days after vector 
administration and an improvement in re-epithelialization of the wound (Hirsch et al. 2009). The 
wound healing role of HBD-3 may also be of interest in women at high risk of preterm birth who 
have had previous cervical treatment for high risk precancerous cervical lesions. The expression 




wound healing in a model of combined radiation-wound injury in rats (Xia et al. 2014). In 
particular, HBD-3 and VEGF promotes skin re-epithelialization, granulation tissue formation and 
collagen I deposition. In preterm birth, premature remodelling and shortening of the cervix 
involves degradation of cervical stromal collagen, particularly collagen I and III, by matrix 
metalloproteinases (Gonzalez et al. 2011; Kirby et al. 2016; Sundtoft et al. 2017). Therefore, this 
HBD-3 gene therapy may also help to inhibit this process in women at high risk of preterm birth 
by encouraging collagen I deposition. In further studies it would be interesting to determine the 
effects of the AAV HBD-3 treatment on cervical remodelling and collagen deposition following 
E.coli ascending infection. 
In conclusion, AAV HBD3 does reduce E.coli K12 and E.coli K1 bacterial ascent into the uterine 
cavity, although it does not prevent preterm delivery in E.coli K1 infected dams. It does appear 
to have a beneficial effect on pup survival at birth whilst its effect on brain inflammation and 







Chapter 8 Conclusion 
This thesis describes the development of murine models of ascending vaginal infection and 
preterm birth as well as exploring the potential use of cervical gene therapy for the prevention 
of preterm birth in high risk women.    
The main findings of this thesis are:  
1. Bioluminescent E.coli can be used to model ascending vaginal infection and preterm 
birth in mice.  
2. There is evidence of brain inflammation in the pups exposed to intra-uterine E.coli.  
3. Viral vectors can be used to transduce the cervical epithelium.  
4. Gene delivery of human beta-defensin 3 to the murine cervix induces neutrophil influx.  
5. E.coli ascent into the uterine cavity can be reduced by AAV HBD-3 gene therapy.   
This potential preventative therapy for preterm birth adds to the plethora of other promising 
therapies currently being investigated. These substances are broadly divided into those 
targeting cytokine or cytokine signalling and those suppressing inflammation. In particular, IL-1 
receptor antagonists and statin therapies are showing promise at reducing preterm labour, 
cervical remodelling and adverse outcomes in neonates in mouse models of preterm birth  
(Nadeau-Vallée et al. 2015; Nadeau-Vallée et al. 2017; Pedroni et al. 2014; Gonzalez et al. 2014). 
A combination of these therapies may provide the key to the prevention of infection-associated 





Despite the significant differences between humans and mice, mice models of preterm birth 
have been useful for understanding the mechanisms of preterm birth and testing specific novel 
therapies. Interestingly, the pathways regulating immune responses are highly conserved 
between mice and humans indicating that mice are a useful tool for examining inflammatory 
responses in preterm birth (Riley & Nelson 2010). However, brain development is different 
between mice and humans with postnatal day 1-5 in mice corresponding to 23 to 32 weeks 
gestation in humans. In particular, oligodendrocyte development and subsequent myelination 
occurs as a postnatal event in mice as opposed to occurring in utero in humans. Therefore, it is 
important to take this into account when extrapolating findings to human brain development.  
The therapy developed in this thesis may have future clinical relevance in augmenting cervical 
immunity in women at high risk of infection-related preterm birth. The preterm birth syndrome 
is a complex multifactorial disorder and so this therapy is unlikely to be the “one size fits all” 
preventative treatment. Current research determining specific biomarkers for infection-related 
preterm birth may be helpful for identifying the women in which this type of cervical therapy 
may be beneficial. This study is limited to pre-treatment of animals with the therapy prior to 
introduction of the infectious and inflammatory agent. For this therapy to be clinically relevant 
in humans we would also ideally use this as a preventative treatment in women who are high 
risk of preterm birth before ascending infection occurs. However, we do not know when this 
infection actually occurs and although we can use cervical length and fetal fibronectin to predict 
preterm birth risk, this therapy is likely to be beneficial before any of these predictive tests 
become positive (i.e. short cervix, positive fetal fibronectin). Understanding why and when 
cervical shortening occurs is also imperative for understanding ascending infection and 
preventing preterm birth. The use and clinical benefits of this therapy would probably be guided 





The next steps in this work would be to carry out further pre-clinical experiments to determine 
the effects of AAV8 HBD-3 therapy on neonatal brain inflammation and injury as well as testing 
the efficacy of a repeated schedule of gene therapy administration. It would also be imperative 
to perform promotor and further AAV serotype studies to determine the most clinically 
translatable viral vector for this purpose. Furthermore, from a patient perspective, I plan to 
organise focus groups and interviews with patients who have experienced a preterm birth to 
determine the ethical and social acceptability of this type of maternal gene therapy.  
In conclusion, gene delivery of HBD-3 to the murine cervix reduces bacterial ascent into the non-
pregnant and pregnant uterine cavity. Whilst it does not delay premature delivery, it does 
improve neonatal survival at delivery. In the future, this type of therapy may have a potential 
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Chapter 10 Appendix  
Reagents and buffers 
E.coli culture and bacterial transformations 
Ampicillin Life Technologies, Glasgow, UK 
Erythromycin 
Kanamycin 
Life Technologies, Glasgow, UK 
Life Technologies, Glasgow, UK 
ccdB chemically competent E.coli cells Life Technologies, Glasgow, UK 
One Shot Stbl3TM  Qiagen, Manchester, UK 
Luria-Bertani agar  Life Technologies, Glasgow, UK 
Luria-Bertani Broth Life Technologies, Glasgow, UK 
Qiagen Maxi-prep kit Qiagen, Manchester, UK 
Qiagen Mini-prep kit Life Technologies, Glasgow, UK 
SOC medium Life Technologies, Glasgow, UK 
SIM medium agar Sigma Aldrich, Dorset, UK 
Immunohistochemistry and Immunofluorescence staining 
30% H2O2 Sigma Aldrich, Dorset, UK 
3,3'-Diaminobenzidine (DAB) Sigma Aldrich, Dorset, UK 
DAPI Invitrogen, California, USA 
Glacial Acetic Acid Sigma Aldrich, Dorset, UK 
Histoclear National Diagnostics, Yorkshire, UK 
Rabbit anti-mature HBD-3 antibody Abcam, Cambridge, UK  





Rat anti-Ly6g antibody Abcam, Cambridge, UK  
Rabbit anti-cytokeratin antibody Abcam, Cambridge, UK 
Hamster anti-ICAM-1 antibody Merck Millipore, Germany 
Chicken anti-GFP antibody Aves labs, Oregon, USA 
Goat anti-rat secondary antibody Vector Laboratories, Cambridge, UK 
Goat anti-mouse secondary antibody Vector Laboratories, Cambridge, UK 
Goat anti-rabbit secondary antibody Vector Laboratories, Cambridge, UK 
Goat anti-rabbit alexa fluor 488 dye Invitrogen, California, USA 
Goat anti-chicken alexa fluor 488 dye Invitrogen, California, USA 
Goat anti-rabbit alexa fluor 568 dye Invitrogen, California, USA 
Goat Serum Vector Laboratories, Cambridge, UK  
Mouse serum Vector Laboratories, Cambridge, UK 
Triton X-100 Sigma Aldrich, Dorset, UK 
ABC Vectastain Vector Laboratories, Cambridge, UK 
DPX mounting solution Thermo-fisher scientific, Glasgow 
Fluoromount-G mounting solution Southern Biotech, Birmingham, USA 
Cell culture and in vitro experiments 
0.05% Trypsin-EDTA Life Technologies, Glasgow, UK 
0.25% Trypsin-EDTA Life technologies, Glasgow, UK 
1x Phosphate buffered Saline Life Technologies, Glasgow, UK 
DMEM Life Technologies, Glasgow, UK 
Fetal Calf Serum Life Technologies, Glasgow, UK 
Keratinocyte serum free medium Life technologies, Glasgow, UK 
Bovine pituitary extract Life technologies, Glasgow, UK 





Calcium chloride Sigma Aldrich, Dorset, UK 
Penicillin-Streptomycin Life technologies, Glasgow, UK 
Viral vector production 
Isopropanol VWR, Lutterworth, UK 
10% Acrylamide gel Life Technologies, Glasgow, UK 
2x Laemlli buffer Sigma Aldrich, Dorset, UK 
4-12% Polyacrylamide gel  Life technologies, Glasgow, UK 
50KDa Polyethyleneimine (PEI) Sigma Aldrich, Dorset, UK  
PEI (AAV) Polyscience, Northampton, UK 
50x MOPS buffer Life Technologies, Glasgow, UK 
Benzonase Life Technologies, Glasgow, UK 
Ethanol VWR, Lutterworth, UK 
Gel Red Biotium, Cambridge, UK 
Glycine Sigma Aldrich, Dorset, UK 
Hyperladder 1 New England Biolabs, USA 
Magnesium Sulphate Sigma Aldrich, Dorset, UK 
Optimem Life Technologies, Glasgow, UK 
p24 assay kit Zeptometric Corporation, New York, USA 
Protein ladder broad range New England Biolabs, USA 
Sodium dexycholate VWR, Lutterworth, UK 
Tris Sigma Aldrich, Dorset, UK 






In vivo experiments 
Isoflurane  Abbott Laboratories, London, UK 
D-Luciferin (Potassium salt) (LUCK-1G-OPT2) Gold Biotechnology Inc, St Louis, USA 
Hydrochloric acid Fisher chemical, Loughborough, UK 
Lipopolysaccharide Life Technologies, Glasgow, UK 
Paraformaldehyde  Sigma Aldrich, Dorset, UK 
Sodium Azide VWR, Lutterworth, UK 
Sucrose Sigma Aldrich, Dorset, UK 
Pluronic F127 gel Sigma Aldrich, Dorset, UK 
AK12 gel PolyVivo, USA 
Western blotting 
4x laemelli buffer Sigma Aldrich, Dorset, UK 
Dithiothreitol (DTT) Sigma Aldrich, Dorset, UK 
SDS buffer BioRad, Hemel Hempstead, UK 
Mini-PROTEAN® TGX™ Precast Gels BioRad, Hemel Hempstead, UK 
Precision plus protein all blue ladder BioRad, Hemel Hempstead, UK 
PVDF membranes BioRad, Hemel Hempstead, UK 
Secondary rabbit HRP-conjugated antibody Abcam, Cambridge, UK 
Chemiluminescence kit BioRad, Hemel Hempstead, UK  






HBD-3 ELISA kit Peprotech, London, UK 
Recombinant HBD-3 protein Peprotech, London, UK 
Murine IL-1β ELISA kit R&D systems, Minneapolis, USA 
Murine TNF-α ELISA kit R&D, Minneapolis, USA 
Recombinant GFP protein Sigma Aldrich, Dorset, UK 
ABTS substrate solution Sigma Aldrich, Dorset, UK 
TMB substrate solution Sigma Aldrich, Dorset, UK 
Sulphuric acid Sigma Aldrich, Dorset, UK 
Streptavidin HRP Invitrogen, California, USA 
Monoclonal anti-GFP antibody Abcam, Cambridge, UK 
Biotinylated polyclonal anti-GFP antibody Abcam, Cambridge, UK 
 
Buffers 
LB Broth 1L: 10g NaCl, 5g Yeast extract, 10g tryptone peptone. 
Autoclave 
LB Agar 1L: 10g NaCl, 5g Yeast extract, 10g tryptone peptone, 
15g bacto agar. Autoclave. 
50 x TAE 1L: 242g Trisamine (Tris), 57.1 mL Glacial Acetic Acid, 
100mL 0.5M EDTA 
5x DNA loading dye (Orange 
G) 






TD buffer 1L: 8.18g NaCl, 372.8mg KCl, 95.26mg K2HPO4, 333.23mg 
MgCl2, 3.03g Tris; pH 7.5. Autoclave 
MOPS buffer 
 
1L: 50mL 20x MOPS buffer in 1L dH20 
Coomassie blue dye 1L: 500mL Methanol, 400mL dH20, 100mL Acetic acid, 
2.5g Coomassie Brilliant blue R-250  
Destain solution  
 
1L: 250mL Methanol, 680mL dH20, 70mL Acetic acid 
50x Alkaline Electrophoresis 
buffer 
1L: 100g NaOH, 14.62g EDTA 
Alkaline sample loading buffer 350µl: 200µl 20% Glycerol, 80µl 50x Alkaline 
electrophoresis buffer, 60µl of 20% SDS and dip pipette 
tip in Xylene Cyanol powder and mix in solution 
4x Gelred 1L: 1 gel volume solution in to 5.8g NaCl; 20mL 5M NaCl 
of dH20 
4% Paraformaldehyde (PFA) 
 
1L: 40g PFA in 1L 1x Phosphate-buffered saline (PBS) 
30% Sucrose 
 
1L: 300g Sucrose in 1L 1x PBS 
10x Tris-buffered Saline (TBS) 1L: 64g Trisamine (Tris), 88g NaCl and 34mL 
Hydrochloric acid; pH 7.6 
TBSAF 1L: 700mL 1x TBS, 3.5mL 10% Sodium Azide, 300mL 
Ethlyene Glycol and 150g Sucrose 
TBS-T 
 





TUNEL staining solution 13ml: 13µl TdT, 19.5μl biotinylated dUTP (deoxyuridine 
triphosphate), 1.3ml cacodylate buffer in 11.67ml ddH2O 
Cacodylate buffer 100ml: 3.64g Tris in 80ml dH2O, add 29.96g Cacodylate 
(pH 7.5 with HCl), add 0.24g Cobalt chloride (pH 7.2 with 
HCl) and the final volume to 100ml with ddH2O (stored at 
4°C) 
TUNEL stop solution 200ml: 300mM NaCl (1753.2mg in 100ml dH2O) + 
30mM Sodium citrate (1882.3mg in 100ml dH2O). 
DAB cobalt-nickel solution 150ml 10mM PB: 75mg DAB, 1.5ml Cobalt-nickel, 1.5ml 
CaSO4, 50.1 μl H2O2  
0.5M Phosphate buffer 1L: 20g NaOH, 71g NaH2PO4 in 1L ddH20, pH adjusted 
to 7.4 with H3PO4 
SIM medium agar 
 
3g in 100ml ddH20 
Bicarbonate buffer 
 
0.8g Na2CO3, 1.465g NaHCO3 in 500ml ddH20 
Wash buffer 
 
200μl TWEEN-20 in 400ml PBS 
Block solution 
 









Primary antibody Dilution Secondary Antibody Dilution 
Rabbit Anti-GFP 
antibody (abcam 13970) 
 
1:10000 Biotinylated Goat Anti-





antibody (abcam 9377) 
1:2000 Biotinylated Goat Anti-










Rat Anti-Ly6G antibody 
(abcam 25377) 
 
1:500 Biotinylated Goat Anti-






1:250 Biotinylated Goat Anti-





1:3000 Biotinylated Goat Anti-









Primary antibody Dilution Secondary Antibody Dilution 
Chicken Anti-GFP 
antibody (abcam 13970) 
 
1:1000 Goat anti-chicken IgY 





antibody (abcam 9377) 
1:2000 Goat anti-rabbit IgG 






1:500 Goat anti-rabbit IgG 
H&L (Alexa Fluor® 488 
abcam 150077) 
1:1000 
Rat Anti-Ly6G antibody 
(abcam 25377) 
 
1:500 Goat anti-rat IgG H&L 






1:500 Goat anti-rabbit IgG 




antibody (abcam 20034) 
1:500 Goat Anti-Mouse IgG 












Anti-mouse TNF-α capture antibody 1:40 
Biotinylated goat anti-mouse TNF- α detection antibody 1:125 
Anti-mouse IL-1β capture antibody 1:120 
Biotinylated goat anti-mouse IL-1β detection antibody 1:60 
Anti-rabbit HBD3 capture antibody  1:100 



















































































Illumina amplicon barcoded primers and custom sequencing primers 
A1   701 CGAGAGTT 501 ATCGTACG 
A2   702 ACTATGTC 501 ATCGTACG 
A3   703 ACGCTACT 501 ATCGTACG 
A4   704 ACTCACTG 501 ATCGTACG 
A5   705 TGAGTACG 501 ATCGTACG 
A6   706 CTGCGTAG 501 ATCGTACG 
A7   707 TAGTCTCC 501 ATCGTACG 
A8   708 CGAGCGAC 501 ATCGTACG 
A9   709 ACTACGAC 501 ATCGTACG 
A10   710 GTCTGCTA 501 ATCGTACG 
A11   711 GTCTATGA 501 ATCGTACG 
A12   712 TATAGCGA 501 ATCGTACG 
B1   701 CGAGAGTT 502 ACTATCTG 
B2   702 ACTATGTC 502 ACTATCTG 





B4   704 ACTCACTG 502 ACTATCTG 
B5   705 TGAGTACG 502 ACTATCTG 
B6   706 CTGCGTAG 502 ACTATCTG 
B7   707 TAGTCTCC 502 ACTATCTG 
B8   708 CGAGCGAC 502 ACTATCTG 
B9   709 ACTACGAC 502 ACTATCTG 
B10   710 GTCTGCTA 502 ACTATCTG 
B11   711 GTCTATGA 502 ACTATCTG 
B12   712 TATAGCGA 502 ACTATCTG 
C1   701 CGAGAGTT 503 TAGCGAGT 
C2   702 ACTATGTC 503 TAGCGAGT 
C3   703 ACGCTACT 503 TAGCGAGT 
C4   704 ACTCACTG 503 TAGCGAGT 
C5   705 TGAGTACG 503 TAGCGAGT 
C6   706 CTGCGTAG 503 TAGCGAGT 
C7   707 TAGTCTCC 503 TAGCGAGT 
C8   708 CGAGCGAC 503 TAGCGAGT 
C9   709 ACTACGAC 503 TAGCGAGT 
C10   710 GTCTGCTA 503 TAGCGAGT 
C11   711 GTCTATGA 503 TAGCGAGT 
C12   712 TATAGCGA 503 TAGCGAGT 
D1   701 CGAGAGTT 504 CTGCGTGT 
D2   702 ACTATGTC 504 CTGCGTGT 
D3   703 ACGCTACT 504 CTGCGTGT 
D4   704 ACTCACTG 504 CTGCGTGT 
D5   705 TGAGTACG 504 CTGCGTGT 
D6   706 CTGCGTAG 504 CTGCGTGT 
D7   707 TAGTCTCC 504 CTGCGTGT 
D8   708 CGAGCGAC 504 CTGCGTGT 
D9   709 ACTACGAC 504 CTGCGTGT 





D11   711 GTCTATGA 504 CTGCGTGT 
D12   712 TATAGCGA 504 CTGCGTGT 
E1   701 CGAGAGTT 505 TCATCGAG 
E2   702 ACTATGTC 505 TCATCGAG 
E3   703 ACGCTACT 505 TCATCGAG 
E4   704 ACTCACTG 505 TCATCGAG 
E5   705 TGAGTACG 505 TCATCGAG 
E6   706 CTGCGTAG 505 TCATCGAG 
E7   707 TAGTCTCC 505 TCATCGAG 
E8   708 CGAGCGAC 505 TCATCGAG 
E9   709 ACTACGAC 505 TCATCGAG 
E10   710 GTCTGCTA 505 TCATCGAG 
E11   711 GTCTATGA 505 TCATCGAG 
E12   712 TATAGCGA 505 TCATCGAG 
F1   701 CGAGAGTT 506 CGTGAGTG 
F2   702 ACTATGTC 506 CGTGAGTG 
F3   703 ACGCTACT 506 CGTGAGTG 
F4   704 ACTCACTG 506 CGTGAGTG 
F5   705 TGAGTACG 506 CGTGAGTG 
F6   706 CTGCGTAG 506 CGTGAGTG 
F7   707 TAGTCTCC 506 CGTGAGTG 
F8   708 CGAGCGAC 506 CGTGAGTG 
F9   709 ACTACGAC 506 CGTGAGTG 
F10   710 GTCTGCTA 506 CGTGAGTG 
F11   711 GTCTATGA 506 CGTGAGTG 
F12   712 TATAGCGA 506 CGTGAGTG 
G1   701 CGAGAGTT 507 GGATATCT 
G2   702 ACTATGTC 507 GGATATCT 
G3   703 ACGCTACT 507 GGATATCT 
G4   704 ACTCACTG 507 GGATATCT 





G6   706 CTGCGTAG 507 GGATATCT 
G7   707 TAGTCTCC 507 GGATATCT 
G8   708 CGAGCGAC 507 GGATATCT 
G9   709 ACTACGAC 507 GGATATCT 
G10   710 GTCTGCTA 507 GGATATCT 
G11   711 GTCTATGA 507 GGATATCT 
G12   712 TATAGCGA 507 GGATATCT 
H1   701 CGAGAGTT 508 GACACCGT 
H2   702 ACTATGTC 508 GACACCGT 
H3   703 ACGCTACT 508 GACACCGT 
H4   704 ACTCACTG 508 GACACCGT 
H5   705 TGAGTACG 508 GACACCGT 
H6   706 CTGCGTAG 508 GACACCGT 
H7   707 TAGTCTCC 508 GACACCGT 
H8   708 CGAGCGAC 508 GACACCGT 
H9   709 ACTACGAC 508 GACACCGT 
H10   710 GTCTGCTA 508 GACACCGT 










AAV Adeno-associated virus 
ABC Avidin–biotin conjugates 
Ad Adenovirus 
AMP Antimicrobial peptide 
bp Base pair 
BSA Bovine serum albumin 
CFU Colony forming unit 
CMV Cytomegalovirus 
Figure 10.1: Bicistronic AAV HBD3 GFP plasmid map; hDEFB103 (HBD-3 transgene) and eGFP









E.coli K1 lux-operon 
E.coli-k12 E.coli K12 lux-operon 
EDTA Ethylenediaminetetraacetic acid 







Human Embryonic Kidney 293-T cells 
Human neutrophil peptide 
HPLC High Pressure Liquid chromatography 







NF-κB nuclear factor kappa-light-chain-enhancer of activated B cell 
PBS  Phosphate buffered saline 
PCR Polymerase chain reaction 
PFA Paraformaldehyde 
RAd Recombinant adenovirus 
RT Reproductive tract 





SLPI Secretory leucocyte protease inhibitor 
TBS Tris buffered saline 
VSV-g Vesicular stomatitis virus glycoprotein G 
WT Wildtype 
 
Additional data from Chapter 5: AAV HBD-3 treatment in a non pregnant 
model of ascending infection  
HBD-3 reduces E.coli K12 vaginal infection in non-pregnant mice at 24 
hours after infection 
To assess the effect of cervical overexpression of HBD-3 on ascending vaginal infection, AAV 
HBD3 was administered and then 72 hours later intravaginal E.coli K12 was instilled (Figure 
10.2). Mice were treated with medroxy-progesterone acetate 1 week prior to these 





Figure 10.2: Summary of experimental plan for determining the effect of HBD-3 expression 
on intravaginal E.coli K12 infection in non-pregnant mice. 
Following bacterial administration, E.coli bioluminescence remains close to baseline (0h time 
point) in the HBD-3 transduced group, except for one outlier, inferring that bacterial 
clearance is likely to have occurred in most of these mice. In the control group, 
bioluminescence did not remain at baseline signifying ongoing bacterial infection (Figure 





mouse, fold change in bioluminescence signal from the whole reproductive tract was 
determined by comparing bioluminescent signal at different time points after infection to 
the bioluminescent signal prior to bacterial administration (Figure 10.4). There was no 
difference in the later time points (Figure 10.4).  
 
 
Figure 10.3: HBD-3 reduces E.coli K12 vaginal infection in non-pregnant mice at 24 hours 
after infection. Intravaginal E.coli K12 bioluminescence expression following cervical 
administration of AAV HBD3 or AAV GFP. 0h time point signifies baseline bioluminescent 
signal prior to bacterial administration. n=14 in the AAV GFP group, n=15 in the AAV HBD3 
group. 














































Figure 10.4: HBD-3 reduces E.coli K12 vaginal infection in non-pregnant mice at 24 hours 
after infection. Fold change in E.coli K12 bioluminescence over time (log transformed data 
shown here). n=14 in the AAV GFP group, n=15 in the AAV HBD3 group; data log transformed 
and analysed with repeated measures two-way ANOVA with post hoc Bonferroni test. 
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